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Diabetes mellitus is an emerging disease that is characterized by a deficiency in 
blood glucose homeostasis. Diabetes is a major health care problem with 346 
million people suffering from diabetes worldwide and an expected doubling of 
cases in 2030 (1). The disease is one of the most expensive diseases with an 
estimated global annual cost between 174 and 317 billion Euros for people aged 
20-79, potentially raising to 420 billion Euros by 2025, if the predicted increase in 
diabetes is taken into consideration (2). These numbers indicate that the direct 
diabetes-related healthcare costs are currently ranging from 2.5%-15% of the 
national annual healthcare budgets (dependent on prevalence of disease and 
availability of sophisticated treatment). Therefore, it is clear that diabetes 
represents a major healthcare and socioeconomic challenge today and the 
situation will become even worse in the future.  
In type 1 diabetes (T1D) deficiency in blood glucose control is caused by 
autoimmune destruction of the insulin producing beta cells. Insulin resistance of the 
peripheral organs are the cause of increased blood glucose levels in type 2 
diabetes (T2D), although it is proposed that fluctuations in beta cell mass occur (3). 
Although diabetes has been studied for decades, the pathogenesis of the disease 
is not well understood. Therapeutic options for both type 1 and type 2 diabetes are 
limited. Diabetes caused 4.6 million deaths in 2011 (2) and the disease is 
characterized by several complications, such as heart diseases, kidney failure, 
neuropathy and blindness. More insight in the development and progression of the 
disease could lead to better therapeutic options. Currently, beta cell function is 
generally examined by blood glucose and insulin determination, HbA1C 
measurements and glucose tolerance testing. However, these methods do not 
measure the beta cell mass and usually beta cell mass is severely decreased 
before impaired glucose and insulin response is detected. The exact role of the 
beta cell mass in the development and progression of diabetes is still unknown and 
examination of the role of the beta cell mass in the pathogenesis of the disease is 
hampered by the lack of a non-invasive method to determine the BCM. Most 
information about the BCM in diabetes is obtained from autopsy studies or in 
animal models. However, these studies do not show the dynamics of the beta cell 
mass over time and a non-invasive method to determine the BCM is still a major 
unmet need.  
An attractive approach to determine the BCM in vivo is by radionuclide imaging 
(PET/SPECT) after injection of a radiotracer. PET and SPECT offer very high 
sensitivity, i.e. low concentrations of the radiotracer can be detected (in the 
picomolar range). The development of a radiotracer for the determination of the 
BCM in vivo is challenging. First of all, the beta cells are located in the islets of 
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Langerhans scattered throughout the pancreas and constitute of 1-2% of the 
pancreatic tissue only. Most importantly, the islets of Langerhans not only consist 
of beta cells (60-80% of the total number of cells in the islet), but also alpha, delta, 
polypeptide and ghrelin cells are present. Because the spatial resolution of PET 
and SPECT (>2 mm) is not sufficient to visualize single islets, let alone single beta 
cells, a radiotracer that only binds to beta cells and not to other endocrine or 
exocrine cells is required to accurately determine the beta cell mass in vivo. 
Binding to other cell types might result in under- or overestimation of the beta cell 
mass, since in type 1 and type 2 diabetes changes in composition of the different 
cell types occur that are still not well understood. To date, there is no such 
radiotracer that can accurately detect the beta cell mass in vivo. 
 
In this thesis, we describe the development and characterization of a method to 
determine the beta cell mass in vivo. In Chapter 1, an overview is provided of the 
development of radiotracers for the determination of the beta cell mass. The rest of 
the thesis describes development and characterization of tracers for the 
determination of the beta cell mass in vivo based on radiolabeled exendin. The 
radiolabeling of the compound is a crucial step and in Chapter 2 we describe the 
improved labeling of DTPA- and DOTA-conjugated compounds, including exendin, 
with 111In using weakly coordinating buffer systems. The importance of post 
labeling purification is highlighted in Chapter 3, where various purification methods 
for purification of 68Ga-labeled exendin were compared. Once the procedures for 
radiolabeling and purification were optimized, three 111In-labeled exendin analogs, 
DTPA-exendin-3, DTPA-exendin-4 and DTPA-exendin(9-39) were evaluated for 
their in vitro and in vivo GLP-1R targeting capabilities in a mouse model with GLP-
1R expressing insulinoma tumors. The results of these studies are described in 
Chapter 4. Subsequently, 68Ga-labeled DOTA-exendin was characterized in the 
same model (Chapter 6) and since the labeling of peptides with 68Ga and in vivo 
targeting with 68Ga-labeled peptide is tedious, special attention was paid to labeling 
and in vivo targeting with 68Ga-labeled peptides with DOTA-minigastrin as a model 
peptide as described in Chapter 5. Finally, the ability of 111In-labeled DTPA-
exendin-3 to determine the beta cell mass in vivo by SPECT was examined in a rat 
model for acute beta cell loss and the results of this study are presented in 
Chapter 7. In Chapter 8 the experimental results and future perspectives are 
discussed. 
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Abstract 
 
The changes in beta cell mass (BCM) during the course of diabetes are not yet well 
characterized. A non-invasive method to measure the BCM in vivo would allow us 
to study the BCM during the onset and progression of the diseases caused by beta 
cell dysfunction. PET and SPECT imaging are attractive approaches to determine 
the BCM because of their high sensitivity and the possibility to quantitatively 
analyze the images. Several targets and their corresponding radiotracers have 
been examined for their ability to determine the BCM including radiolabeled 
antibodies, antibody fragments, peptides and small molecules. Although some of 
these tracers show promising results, there is still no reliable method to determine 
the beta cell mass in vivo. In this review, the targets and the corresponding 
radiotracers evaluated so far for the determination of the BCM in vivo in humans 
will be discussed. 
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Introduction 
 
Diabetes mellitus is characterized by a deficiency in control of glucose 
homeostasis. In type 1 diabetes (T1D), autoimmune destruction of pancreatic beta 
cells leads to an absolute deficiency of insulin secretion with hyperglycemia as a 
consequence (1). In type 2 diabetes (T2D), insulin resistance of the target cells is 
the cause of impaired glucose homeostasis as well as impaired beta cell function 
(1-3) but other factors may also play a role (4). The changes in beta cell mass 
(BCM) during diabetes are not well understood nor well characterized. Various 
animal models have been used to study the effect of the BCM on insulin secretion 
and the development of diabetes. However, most information about the BCM in 
humans are obtained from biopsy studies of diabetic patients. Biopsy studies do 
not show the dynamics of the BCM at the onset and progression of the disease. 
Previous studies showed that there is a reserve capacity of beta cells and T1D 
occurs when the BCM drops under a critical threshold (>80% loss of BCM) (5, 6). 
Moreover, a low number of insulin-producing cells (approximately 10%) is still 
present in half of all insulin-dependent T1D patients (5). A non-invasive method to 
measure the BCM in vivo would allow us to study the BCM during the onset and 
progression of diabetes. 
An attractive approach to determine the BCM is PET and SPECT imaging after 
injection of a radiotracer. The major advantage of PET and SPECT imaging over 
other imaging modalities such as MRI and CT is their high sensitivity. Moreover, 
PET and SPECT imaging can give information about biochemical changes by 
quantitative determination of the uptake of a tracer in the target tissue. Potentially 
PET and SPECT imaging would allow quantitative determination of the BCM non-
invasively. Radiotracers, based on antibodies, peptides and small molecules, have 
been successfully used for the detection of tumors and inflammation. Several 
targets and their corresponding ligands for the determination of the BCM have 
been described and examined. There are several challenges that have to be 
encountered before a non-invasive method is feasible for the detection of the BCM. 
The BCM represents only 1-2% of the total pancreatic mass and the beta cells are 
located in the islets of Langerhans scattered throughout the pancreas (7, 8). The 
tracer has to be highly beta cell specific; no or very low uptake of the tracer in the 
exocrine and the other endocrine cells is required, in order to measure significant 
changes in tracer uptake between healthy and diabetic subjects. The target has to 
be expressed on all beta cells and the expression level should not be altered 
during development and during the course of diabetes. Moreover, a highly 
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sensitive and quantitative imaging technique has to be used. Recently, an in vitro 
method to screen potential ligands for the determination of the beta cell mass has 
been described (9). The screening method is based on the binding capacity of the 
compounds to isolated islets, cell lines derived from beta cell tumors (INS-1) (10) 
and cell lines from tumors of the exocrine pancreas (PANC-1) (11). A compound is 
considered promising when it displays high binding to islets and beta cell derived 
tumor cells and low binding to tumor cells of the exocrine pancreas. Multiple tracers 
were screened in vitro and only the most promising were tested in vivo. This 
method is currently considered the standard for screening of potential agents to 
determine the beta cell mass.  
 
Here, the targets and the corresponding radiotracers will be discussed with respect 
to their ability to determine the BCM including antibodies, antibody fragments, 
peptides and small molecules. Although some of them show promising results, 
there is no reliable method to determine the beta cell mass in vivo yet. In this 
review the most promising targets and corresponding radiotracers evaluated so far 
for the determination of the BCM will be discussed. 
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Receptor imaging 
 
Peptide hormone receptor and neurotransmitter receptors are attractive targets for 
targeting of tumors and neurological and psychiatric disorders. The most 
successful example of peptide hormone receptor targeting is targeting of 
neuroendocrine tumors (NET) using radiolabeled somatostatin analogs. The 
somatostatin receptor is overexpressed on a wide variety of NET. The somatostatin 
analog DTPA-octreotide labeled with 111In (Octreoscan) is the standard procedure 
for the diagnosis of NET (12, 13). Several octreotide derivatives labeled with a 
variety of radionuclides have been successfully used for imaging and therapy of 
NET. The major advantage of peptides that are conjugated and labeled with a 
radiometal is the accumulation of the radiometal-complex in the target cells. When 
the peptide labeled with a radiometal is internalized, the radiolabeled metabolite is 
trapped in the lysosome and the radiometal will accumulate in the cell (14). 
A successful example of neurotransmitter receptor targeting is the targeting of the 
dopamine receptor. Radiolabeled dopamine derivatives are commonly used to 
target the dopamine receptor expressing tissues. These tracers are clinically used 
to diagnose dementia and Parkinsons disease (PD). The tracers are also used to 
study dementia and drug addiction. 
Here we discuss peptide hormone receptors and neurotransmitter receptor 
targeting and the corresponding tracers that can potentially be used for 
determination of the BCM. 
 
Dopamine receptor 
Dopamine is a neurotransmitter that plays an important role in neurological and 
psychiatric disorders such as dementia, Parkinson’s Disease and drug addiction 
(15). Dopamine signaling is mediated by dopamine receptors. Five receptor types 
have been described (D1 – D5), classified in two groups: dopamine D1-like (D1 
and D5) and dopamine D2-like (D2, D3 and D4) families (16, 17). Dopamine 
receptors are mainly expressed in the central and peripheral nervous system. The 
effect of dopamine on the beta cell function and insulin secretion is poorly 
understood. Recently, expression of dopamine receptor expression from both 
families have been detected by RT-PCR in beta cells (18). The expression of D2-
like receptors was confirmed by immunostaining of INS-1E cells and rodent and 
human isolated islets (18). These results suggest that targeting of the dopamine 
receptor may be a suitable approach for the determination of the beta cell mass. 
18F-DOPA PET is used to differentiate between focal and diffuse beta cell 
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hyperplasia (nesidioblastosis), a neuroendocrine condition characterized by 
hyperinsulinemia in infant age (9, 19-23). However, the high uptake in the exocrine 
pancreas (in relation to the islets) seems to limit the usefulness of 18F-DOPA PET 
for the determination of the BCM. Moreover, besides the low target-to-background 
ratio, the tracer has more disadvantages, i.e. a complex preparation procedure and 
a low radiochemical yield. 
 
VMAT2 
The vesicular monoamine transporter (VMAT) is a transport protein located on the 
presynaptic cell. Two isoforms have been identified in rodent and human tissues; 
VMAT1 and VMAT2 (24-26). VMAT2 is an integral membrane protein that acts to 
transport monoamines, particularly neurotransmitters such as dopamine, 
norepinephrine, serotonine and histamine. VMAT2 is expressed in the central and 
peripheral nervous system, the hematopoietic system and the neuroendocrine 
system (27-32). In the neuroendocrine system, VMAT2 is expressed in chromaffin 
cells of the adrenal medulla, histamine-storing enterochromaffin-like cells of the 
stomach and pancreatic islet cells (27, 30, 32-35). Isolated human islets show 
higher VMAT2 mRNA expression than cells in the exocrine pancreas (33). The 
VMAT2 receptor is expressed on rodent and human beta cells as determined 
immunohistochemically (27). These findings suggest that the VMAT2 receptor is 
suitable for targeting the pancreatic beta cells.  
Tetrabenazine (TBZ) and dihydrotetrabenazine (DTBZ) specifically inhibit vesicular 
storage of monoamine uptake by high affinity binding to the synaptic VMAT2 (36). 
Binding studies with 3H-DTBZ showed high affinity for VMAT2 (37-40). The VMAT2 
ligand (+)-11C-DTBZ was developed for VMAT2 targeting in the striatum and has 
successfully been used for PET studies in Parkinson’s Disease and other 
neurodegenerative diseases (41, 42). Recent studies showed reduced uptake of 
11C-DTBZ in the pancreas of streptozotocin-induced diabetic rats and rats that 
spontaneously develop diabetes (BB-DP rats) compared to non-diabetic rats (34, 
43). First clinical studies showed a reduction in pancreatic uptake of 11C-DTBZ in 
long-standing T1D patients compared to the uptake in the pancreas of healthy 
control subjects (44, 45). DTBZ compounds labeled with 18F were developed to 
overcome the short half-life of 11C-labeled DTBZ (T1/2 = 20 min.). Preclinical studies 
showed high pancreatic uptake of 18F-DTBZ in healthy rats with favorable 
biodistribution leading to improved target-to-background ratios (46, 47). The 
pancreas was clearly visualized in rats by PET imaging after injection of 18F-DTBZ. 
Recently, an new DTBZ derivative was developed, 18F-FP-(+)-DTBZ, with higher 
pancreatic uptake and lower uptake in the non-target tissues, especially the liver 
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(48). However, the correlation between the beta cell mass and pancreatic uptake of 
18F-DTBZ was not examined in these studies (46-48).  
A clinical study with 11C-DTBZ showed that the pancreas was visible in PET 
images and the pancreatic uptake was reduced in diabetic patients (45, 49). 
Although uptake of 11C-DTBZ in the pancreata of diabetic patients was markedly 
reduced, significant uptake was still observed (45). This residual uptake might be 
explained by VMAT2 expression in polypeptide (PP) cells in the islets (50) or 
binding of the tracer to other structures. A recent study showed VMAT2 expression 
on the sympathetic nerve endings in the pancreas (51). The nerve endings in the 
islets, but not the nerve endings in the exocrine pancreas are degraded during the 
onset of T1D in a T1D rat model (BB-DP rats) (51). It is unknown what the 
contribution of the VMAT2 expression in the nerve endings to the total VMAT2 
expression in the pancreas is and if this might contribute to the residual uptake in 
diabetic subjects. Moreover, there is heterogeneous expression of VMAT2 in islets 
(50) which makes interpretation of DTBZ binding difficult. These findings do not 
exclude the use of VMAT2 as a target for beta cell measurement, however the 
target VMAT2 and the tracer do not appear to be 100% specific for beta cells. 
 
GLP-1R 
The glucagon-like peptide 1 receptor (GLP-1R) is expressed in rat, mouse and 
human pancreatic beta cells and not in α, δ and pp cells (52). There is high 
expression of the GLP-1R in the beta cells and limited expression is found in the 
pancreatic duct and acini (53). Furthermore, there is limited expression in other 
organs (duodenum, stomach, lung, heart and brain) (54). This makes the GLP-1R 
a potential target for BCM imaging. The GLP-1R belongs to the family of the G-
protein coupled receptors, in which internalization of the receptor-ligand complex is 
triggered after binding of the agonist to the receptor (55, 56). GLP-1, the natural 
ligand of the GLP-1R, is not suitable for GLP-1R targeting due to the low stability in 
plasma resulting from rapid degradation by dipeptidyl peptidase IV (DPP IV) (57-
60). More stable agonists of the GLP-1 receptor are exendin-3 and exendin-4. (61, 
62). exendin-3 is derived from Heloderma horridum, the Beaded Mexican Lizard 
(Mexico and southern Guatemala), and exendin-4 from Heloderma Suspectum, the 
Gilamonster (a lizard living in the South West of the United States and northern 
Mexico). First preclinical studies with 123I-labeled Exendin showed high uptake in 
pancreas and in subcutaneous insulinomas (63). However, the highest uptake was 
observed 30 minutes after injection, probably due to the fast wash-out of the 
radionuclide after degradation of the internalized peptide. Introduction of a C-
terminal Lysine enabled conjugation of a chelator (eg. DTPA, DOTA) that facilitates 
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labeling with radiometals. When the peptide labeled with a radiometal is 
internalized, the radiolabeled metabolite is trapped in the lysosome and the 
radiometal will accumulate in the cell (14). 111In-labeled exendin showed a higher 
uptake and retention in the subcutaneous insulinomas compared to the 123I labeled 
compound (63). Moreover, Wild et al showed that 111In-DTPA-Lys40-Ahx-exendin-4 
showed high uptake in tumors in transgenic mice that spontaneously develop 
pancreatic insulinomas and in patients with insulinomas (64, 65). In both studies 
the insulinomas could be clearly detected by SPECT imaging. Furthermore, it has 
been shown that the uptake of 111In-DTPA-Lys40-exendin-3 correlates with the BCM 
in a linear manner in rats with alloxan-induced diabetes and that the pancreas can 
be visualized by SPECT imaging on a dedicated microSPECT scanner (66). These 
studies suggest that exendin labeled with 111In is a promising tracer for the 
determination of the BCM. However, the pancreatic uptake of the tracer in rats was 
rather low, which might limit accurate quantification of the BCM in vivo. Conjugation 
of exendin with DOTA or NOTA enables labeling with a positron emitter (eg 68Ga, 
64Cu) for PET imaging. PET imaging is superior over SPECT in terms of sensitivity 
and resolution in humans (67). However, the clinical feasibility of PET imaging with 
radiolabeled exendin has yet to be determined.  
 
SUR1 receptors 
ATP-sensitive K+ channels (KATP channels) are thought to play a critical role in the 
insulin-dependent and sulfonylurea-dependent insulin secretion. KATP channels are 
composed of a small inwardly rectifying K+ channel subunit (KIR6.1 or KIR6.2) and 
a sulfonylurea receptor (SUR1, SUR2A or SUR2B) belonging to the ATP-binding 
cassette superfamily (68). The KATP channels of pancreatic beta cells consist of a 
Kir6.2 and a SUR1 subunit. Sulfonylureas, such as glibenclamide and repaglinide 
are successfully used as blood glucose level lowering drugs in the treatment of 
T2D (69). Several studies with radiolabeled glibenclamide and repaglinide analogs 
to target the SUR1 receptor have been conducted (70, 71). 18F-labeled 
glibenclamide and repaglinide analogs have been developed as tracers for the 
determination of the BCM by PET imaging (72, 73). However, recent studies 
showed that these analogs are not suitable to determine the beta cell mass, due to 
their low uptake in the pancreas that was not SUR1 receptor mediated and high 
uptake in adjacent non-target organs (73, 74). It still has to be determined whether 
the pancreatic uptake is beta cell specific. This raises the question whether the 
SUR1 receptor is useful as a target for the non-invasive determination of the BCM. 
SUR1 is expressed all over the islet as determined by immunostaining in 
cryosection of rat pancreas and co-localizes with glucagon, somatostatin and 
  
19 
 
pancreatic polypeptide (pp) (75). These data suggest that SUR1 is expressed in α, 
β as well as the pp cells, which might render the receptor less suitable as a target 
for BCM determination.  
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Antigens 
The invention of the hybridization technology to produce monoclonal antibodies 
(mAbs) in 1975 by Georges Köhler and César Milstein largely contributed to 
immune-based therapy of cancer, but also to nuclear imaging with monoclonal 
antibodies (76). Since then, a large number of mAbs have been developed. 
Monoclonal antibodies are potential nuclear imaging agents, as they very 
selectively recognize their specific epitopes. However, due to their long circulatory 
half-life together with their slow diffusion into tissue (caused by their relatively large 
size), new approaches are applied in order to increase the target-to-background 
ratios obtained with radiolabeled mAbs in radionuclide imaging. By enzymatic 
degradation or molecular engineering, antibodies can be modified to alter their 
pharmacokinetic properties to suit specific targeting requirements. For example, 
antibody fragments have more rapid target uptake and more rapid background 
clearance. There is a wide range of radioisotopes available for labeling of 
antibodies. The potential of using antibodies or their fragments in targeting a wide 
range of molecules presented on the cells of interest is very promising. However, 
the use of antibodies for beta cell imaging is limited mainly due to unsatisfactory 
target-to-background ratios (14). Here we summarize the efforts undertaken up to 
date in antibody-based targeting strategies for radionuclide imaging of transplanted 
and native islets of Langerhans.  
 
IC2 
Anti-pancreatic autoantibodies have been found in most patients with Type I 
diabetic syndromes (77). Islet cell surface antibodies (ICSA) have been shown to 
precede the onset of diabetes in the BB rat (78). Therefore, if antipancreatic 
autoantibodies are involved in the pathogenesis of beta cell destruction, ICSA are 
considered to be potential targets for BCM imaging.  
IC2 is a beta cell-specific monoclonal antibody against an ICSA (79, 80). The IC2 
monoclonal IgM antibody is produced in a rat-rat hybridoma and reacts with both 
normal and tumor cells derived from rat islets (79). 
In 2001 Moore et al. presented promising results on the correlation between 111In 
and 125I-labeled IC2 antibody accumulation in the pancreas and the BCM (81). In 
this work 111In-labeled IC2 was characterized in vitro on isolated islets as well as in 
vivo in a diabetic mouse model. No binding to exocrine pancreas or stromal tissues 
was observed after intravenous administration of the tracer. It was also shown that 
IC2 did not react with insulin and therefore would not interfere with its secretion. 
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After chemical modification, the antibody retained its specific affinity to beta cells 
both in vitro and in vivo. 
Biodistribution of radio-iodinated IC2 revealed a higher accumulation of radiotracer 
in normal pancreas compared to uptake in the pancreas of diabetic rats. A strong 
correlation of BCM with probe accumulation was observed in both STZ-diabetic 
and control animals. The authors concluded that the accumulation of the probe in 
the islet beta cells has decreased with reduction of BCM and that it is feasible to 
detect this reduction by ex vivo nuclear imaging techniques after injection of IC2-
DTPA-111In. However, the absolute uptake of IC2 in the pancreas was rather low 
(approximately 0.5 %ID/g), which might hinder the detection of small differences in 
the BCM. Preclinical and clinical studies still have to be performed to examine the 
feasibility of IC2 to determine the BCM in vivo. 
The target of the IC2 antibody is not yet defined. Definition of the target of IC2 will 
enable the development of new tracers that bind to the IC2 antibody target, which 
might lead to higher uptake in the beta cells and in this way make it possible to 
determine small changes in BCM. 
 
R2D6 
The monoclonal antibody R2D6 recognizes a beta cell specific plasma membrane 
ganglioside antigen in rats. R2D6 is a mouse monoclonal antibody that was 
generated against a beta cell specific plasma membrane determinant that is not 
shared by other islet cell-types. R2D6 did not affect beta cell physiology, when 
incubated with islets. Unfortunately R2D6 does not cross-react with the human 
beta cell membrane antigen (82). 
In 2001 Ladriene et al., tested 125I-labelled R2D6 in a rat model using 
radioimmunoscintigraphy (83). In vitro experiments of radiolabeled R2D6 revealed 
a high specificity for beta cells, but no binding differences between normal and STZ 
rat islets. Moreover, in vivo experiments in which rats were injected with 125I-
labeled R2D6 showed neither differences between probe accumulation in 
endocrine when compared to exocrine pancreas, nor did they show differences 
between diabetic and control animals. This specificity issue will probably hinder the 
development of such beta cell specific radiolabelled mAbs (83). 
 
Single chain antibodies (SCAs) 
In order to overcome some of mAbs weaknesses as radiotracers (long circulatory 
half-life, low diffusion capacity, inadequate target-to-background ratios), single 
chain antibodies (SCAs) were developed as a promising option for immune-based 
diagnostics and therapy. It has been reported that removal of the Fc portion to 
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produce an antibody fragment reduces non-specific binding and blood clearance 
time (84). However, after testing the Fab fragment of one of beta cell specific IgM 
antibodies (K14D10) by in vitro screening it appeared that its specificity (uptake in 
endocrine vs. exocrine pancreas) is far below that required for a reasonable signal-
to-background ratio (84). 
Recently, Ueberberg et al., demonstrated a new, promising approach for beta cell 
imaging by generation of novel SCAs (85). They screened a phage-library of more 
than 1.4 x 108 different human single chain variable fragments for SCAs presented 
on the islets with two different approaches of in vivo and in vitro screening. Phages 
that specifically bound to the islet cells were selected, amplified and purified. 
Importantly, no binding to exocrine cells and several other control organs (liver, 
kidney, spleen, heart and lung) was detectable in any of the selected islet specific 
phage clones (ISPCs). Out of 6 ISPCs only two that selectively localized in the 
cytoplasm of beta and alpha cells were further evaluated (respectively: ISPC1 and 
3). ISPC1 (SCA B1) that is beta cell-specific and ISPC3 (SCA A1) that is alpha-
cell-specific were labeled with 125I. In vitro analysis of selected 125I-labeled SCAs 
was performed in order to determine the respective binding properties in beta, 
alpha and exocrine cell lines. Binding of the beta cell specific SCA B1 to INS-1 
cells was rapid and specific. Also plasma clearance kinetics of selected SCAs were 
determined in rats in vivo and revealed a very rapid elimination of both SCA B1 and 
SCA A1 from the circulation (t1/2 = 22.7 min and 19.2 min, respectively). SCA B1 
co-localized with anti-insulin antibodies in human beta cells and SCA A1 co-
localized with anti-glucagone antibodies in human alpha cells which confirmed its 
high specificity for human islets and its potential for use as a beta or alpha-cell 
marker. Also a strong positive correlation was found between probe accumulation 
in a specific cell-type and beta or alpha-cell mass (determined by quantitative 
morphometry). The specific molecular target of these SCAs remains to be 
elucidated (85). 
Low toxicity, high specificity, rapid binding and clearance kinetics and direct 
correlation of SCAs accumulation in beta cells with beta cell mass could make 
these ISPCs interesting tracers for non invasive beta cell imaging and 
quantification in vivo in rodents and humans.  
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Small molecules 
 
Dithizone 
Dithizone is a well-known agent which chelates divalent heavy metal ions, for 
example Hg2+, Pb2+, Zn2+, Pd2+ and Bi2+. Of all cells, beta cells have the highest 
zinc accumulation inside the cells. Zinc ions are involved in insulin metabolism and 
its secretion mechanisms, by creating osmotically stable hexamers of insulin within 
secretory granules of beta cells (86). Dithizone has been especially useful for zinc 
assays and therefore serves as a specific vital dye to assess the purity and viability 
of isolated pancreatic islets (87, 88). Because dithizone stains beta cells in vivo, it 
could potentially be used as a marker of islet viability (89). In the past, some 
attempts have been made to radiolabel dithizone (90), but radio iodinated 
derivatives of dithizone were extremely unstable and readily released radioactive 
iodine in biological fluids (89). Therefore a novel approach to develop a stable 
histamine conjugated dithizone has been tested and this radio-iodinated dithizone-
histamine has been evaluated in respect to preferential uptake in the pancreas (90, 
91). In a rat model of islet transplantation to the testes, specific uptake of the 
dithizone-[131I]-histamine conjugate was demonstrated (91). However, in normal 
and streptozotocin-treated rats, both the exocrine pancreas and liver showed 
significant uptake. Also in other transplantation models, the difference in uptake of 
radiolabeled dithizone-histamine between transplanted islets and an intact 
pancreas was very low (0.25% ± 0.12% vs. 0.20% ± 0.04%) (92). Moreover, 
dithizone-[131I]-histamine was described to exert toxic effects on beta cells in higher 
concentrations (93, 94), therefore for in vivo imaging of islets with radiolabelled 
dithizone-histamine may only be of limited use. 
 
Alloxan 
Alloxan (2,4,5,6-tetraoxypyrimidine) is a toxic glucose analogue. When 
administered to rodents, it selectively destroys beta cells in the pancreas. Alloxan 
also selectively inhibits glucose-induced insulin secretion through its ability to 
inhibit the beta cell glucose sensor glucokinase (95, 96). It is widely used as a 
diabetogenic agent in animal models to mimic insulin-dependent diabetes mellitus 
as it accumulates in insulin-producing cells via the GLUT2 glucose transporter. 
Alloxan is therefore highly specific for beta cells, but highly toxic at the same time. 
Autoradiography studies with 14C-2-alloxan revealed that the radioactivity in the 
pancreatic islets was higher than in any other mouse tissue after intravenous 
injections (97). In 2001 Malaisse et al., investigated the uptake of 14C-2-alloxan in 
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the pancreas in control and streptozotocin-induced diabetic (STZ) rats (98). The 
activity concentration in the pancreas of diabetic rats was lower than in the 
pancreas of control rats. Because of high toxicity very low doses have to be 
administered, thus high specific activities are needed. Moreover, alloxan is very 
unstable and light-sensitive, making the synthesis and transport of the tracer very 
cumbersome.  
 
18F-FDG 
2-18F-Fluoro-2-deoxy-glucose (18F-FDG) is a radiolabeled glucose analog that is 
transported into the cell via glucose transporters followed by phosphorylation by 
hexokinases. Once phosphorylated, no further metabolic pathway exists and 
accumulation occurs (“metabolic trapping”). 18F-FDG is a successful tool for the 
detection of tumors, since tumors have an enhanced glucose consumption. 18F-
FDG can also be used for the detection of inflammation because of the uptake of 
18F-FDG in most inflammatory cells. The onset of T1D is characterized by 
inflammation of the islets which is called insulitis. Therefore, it has been 
hypothesized that 18F-FDG PET might be useful for the non-invasive detection of 
insulitis. A study in NOD mice, mice that develop auto-immune insulin-dependent 
diabetes resembling human T1D, showed increased uptake of 18F-FDG in the 
pancreatic islets by autoradiography due to 18F-FDG uptake in islet-infiltrating 
lymphocytes (99). A clinical study showed higher uptake of 18F-FDG in patients 
with newly diagnosed T1D compared to healthy subjects and patients with long-
standing diabetes (100). After the diagnosis of diabetes, the number of insulin-
producing beta cells and islet-infiltrating lymphocytes gradually decreases leading 
to similar uptake compared to healthy subjects. However, the ratio of uptake of 18F-
FDG between pancreatic islets and exocrine cells tested in vitro is considered 
insufficient for determination of the BCM (9). Moreover, a study in streptozotocin-
induced diabetic rats showed no significantly lower uptake of 18F-FDG as 
compared to healthy rats (101). Therefore, 18F-FDG appears to be unsuitable for 
the quantification of the BCM  
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Conclusions 
 
The determination of the BCM in vivo is a major challenge, because the BCM only 
represents 1-2% of the total pancreatic mass and the islets are spread throughout 
the pancreas. Therefore, a high specific and sensitive tracer is needed. The ideal 
tracer should preferably meet the following criteria: 
1. The target of the tracer should be expressed specifically in the endocrine 
pancreas. 
2. The target should be expressed on beta cells only (and not on α, δ en PP 
cells). 
3.  High uptake in the endocrine pancreas and low uptake in the exocrine 
pancreas is needed. 
4. The uptake of the tracer should correlate with the BCM . 
5. The difference in uptake between diabetic and healthy subjects has to be 
large to enable detection of small differences in BCM. 
6. High target-to-background-ratio, in terms of endocrine versus exocrine 
pancreas and also pancreas versus adjacent organs, is needed to quantify 
the uptake in a reliable manner. 
To enable the determination of small changes in BCM, a very sensitive technique 
to determine the BCM has to be used. PET and SPECT are the most sensitive in 
vivo imaging methods available for clinical imaging at this time point, therefore they 
are promising tools for the determination of the BCM. In recent years several new 
tracers for beta cell imaging with PET and SPECT have been developed showing 
promising results in animal models. The monoclonal antibody IC2 shows beta cell 
specific uptake in the pancreas and a strong correlation between tracer uptake and 
the BCM. However, the uptake in the pancreas is relatively low which hinders the 
determination of the BCM in vivo. DTBZ, labeled with 11C and 18F, shows high 
uptake in the pancreas where 18F-FP-(+)-DTBZ shows the most promising results. 
However, the correlation with the beta cell mass is still a matter of debate. 
Moreover, the difference in uptake between diabetic and healthy subjects might be 
too low to determine minor changes in BCM. The uptake of radiolabeled exendin 
correlates with the BCM and is specific for beta cells. The uptake of exendin in the 
pancreas in rats appears to be relatively low which hampers determination of small 
differences in BCM. 
The ideal tracer has not been found yet. Antibodies usually show low uptake and 
slow clearance resulting in low target-to-background ratios. The size of an antibody 
limits tissue penetration which might hinder uptake in the beta cells. Single chain 
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antibodies and antibody fragments might overcome these problems. Peptide 
hormone receptor targeting has the advantage of internalization and metabolic 
trapping of the peptide, leading to high accumulation in the target cells. Moreover, 
there is fast clearance and fast and easy tissue penetration due to the small 
molecular size of such peptides. Small molecules (such as DTBZ) usually exhibit 
good tissue penetration and rapid clearance. The synthesis is more difficult and in 
some cases toxicity is a relevant issue. 
Several tracers are close to become clinical applicable tracers for determination of 
the BCM, but the search for improved tracers is still ongoing. The search for 
ligands of newly identified targets that might be useful to target beta cells will 
continue. 
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Abstract 
 
Background 
In SPECT, high specific activity of 111In-labeled tracers will allow administration of 
low amounts of tracer to prevent receptor saturation and/or side-effects. To 
increase the specific activity, we studied the effect of the buffer used during the 
labeling procedure: NaAc, NH4Ac, HEPES and MES-buffer. The effect of ageing of 
the 111InCl3 stock and cadmium contamination, the decay product of 111In, was also 
examined in these buffers. 
Methods 
Escalating amounts of 111InCl3 were added to 1 µg of the DTPA- and DOTA-
compound (exendin-3, octreotide and anti-CAIX antibody, cG250). Five volumes of 
MES, HEPES, NH4Ac or NaAc (0.1 M, pH 5.5) were added. After 20 min at 20 °C 
(DTPA-conjugated compounds), at 95 ⁰C (DOTA-exendin-3 and DOTA-octreotide) 
or 45 °C (DOTA-anti-CAIX antibody), the labeling efficiency was determined by 
ITLC. The effect of ageing of the 111InCl3 stock on the labeling efficiency of DTPA-
exendin-3 as well as the effect of increasing concentrations of Cd2+ were also 
examined.  
Results 
Specific activities obtained for DTPA-octreotide and DOTA-cG250 were 5 times 
higher in MES and HEPES buffer. Radiolabeling of DTPA-exendin-3, DOTA-
exendin-3 and DTPA-cG250 in MES and HEPES buffer resulted in two fold higher 
specific activities than in NaAc and NH4Ac. Labeling of DTPA-exendin-3 decreased 
with 66% and 73% for NaAc and NH4Ac, respectively at day 11 after the production 
date of 111InCl3, while for MES and HEPES the maximal decrease in specific 
activity was 10% and 4% at day 11, respectively. The presence of 1pM Cd2+ in the 
labeling mixture of DTPA-exendin-3 in NaAc and NH4Ac markedly reduced labeling 
efficiency, whereas Cd2+ concentrations up to 0.1 nM did not affect the labeling 
efficiency in MES and HEPES buffer.  
Conclusions 
We showed improved labeling of DTPA- and DOTA-conjugated compounds with 
111In in HEPES and MES buffer. The enhanced labeling efficiency appears to be 
due to the reduced competitive chelation of cadmium. The enhanced labeling 
efficiency will allow more sensitive imaging of the biomarkers with SPECT. 
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Introduction 
 
Radiolabeled peptides and antibodies are used for molecular imaging and 
radionuclide therapy of tumors. The most successful example of peptide receptor 
imaging is the somatostatin analogue octreotide, which targets the somatostatin 
subtype 2 receptor, overexpressed on neuroendocrine tumors. Tracers labeled with 
a radiometal via a chelator have the advantage that they can be labeled with high 
efficiency (>95%) without the need for post labeling purification and that the 
metabolites are trapped in the lysosomes of the cell leading to higher accumulation 
in the target cell. This phenomenon is referred to as “metabolic trapping” (1-5). 
Ideally, low peptide or protein doses are administered, because high doses may 
lead to saturation of the receptor, resulting in reduced accumulation of the 
radiotracer in the target tissue (6). In addition, higher doses may cause toxic side-
effects, especially when agonists are used. In order to administer activity doses 
sufficient for imaging (SPECT (single photon emission computed tomography) or 
planar scintigraphy), tracers with a high specific activity (SA) are required. There is 
a need to further increase the SA to improve image quality, especially in the 
preclinical setting. In general the tracer doses administered in rodent models must 
be kept low while at the same time administering relatively high activity doses (>10 
MBq/animal).  111In is a widely used radionuclide for the labeling of peptides and 
proteins used for imaging purposes. To enable labeling with a radiometal, such as 
111In, the targeting molecule has to be conjugated with a chelator. The most 
commonly used chelators are DTPA (diethylene triamine pentaacetic acid) and 
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). Labeling of 
DTPA- and DOTA-conjugated compounds is a one step reaction in which the 
conjugated compound is incubated with 111InCl3 in a slightly acidic buffer, keeping 
the pH between 4 and 5.5. Acetate buffers are commonly used as a buffer for 111In-
labeling of DTPA and DOTA-conjugated compounds. Acetate buffers readily form 
coordination complexes with metals. It is assumed that coordinating buffers are 
needed for efficient chelation of radiometals (7). However, for 68Ga-labeling of 
DOTA-conjugated compounds, HEPES (4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid ) is successfully used as a buffer. Although developed for biological 
purposes by Good et al., HEPES has beneficial characteristics in chemistry 
involving metal ions as a non-coordinating buffer (8). MES (2-(N-
morpholino)ethanesulfonic acid) was also described as a “Good buffer” (8) and has 
similar characteristics. Although HEPES and MES were described as non-
coordinating buffers, recent reports showed that HEPES forms weak complexes 
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with Cu(II) and Pb(II), but not with Zn(II) or Cd(II) (9, 10). Therefore, the term 
“weakly coordinating” buffers seems to be more appropriate. 
The fact that HEPES is successfully used for labeling of compounds with 68Ga, 
prompted us to examine the effect of the “weakly coordinating” buffers, HEPES and 
MES, on the 111In-labeling and compared this with the radiolabeling in routinely 
used acetate buffers (sodium acetate and ammonium acetate). For comparison of 
the radiolabeling in these buffers two peptides, exendin-3 and octreotide, and the 
chimeric monoclonal antibody (mAb) targeting CAIX, each conjugated with DTPA 
or DOTA, were used.  
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Experimental Procedures 
 
Peptides and antibodies and conjugation with DTPA or DOTA 
DTPA-Tyr3-octreotide, DOTA-Tyr3-octreotide, [Lys40(DTPA)]exendin-3 (DTPA-
exendin-3) and [Lys40(DOTA)]exendin-3 (DOTA-exendin-3) (11) were purchased 
from Peptide Specialty Laboratories (PSL, Heidelberg, Germany). The chimeric 
mAb anti-CAIX (cG250) was obtained from Wilex (Wilex AG, Munich, Germany). 
The conjugation of anti-CAIX with SCN-Bz-DTPA or SCN-Bz-DOTA (Macrocyclics, 
Dallas, TX, USA) with a 50-fold molar excess was performed in 0.1 M NaHCO3 
buffer, pH 8.2. After 1 h incubation, the conjugation mixture was dialyzed in a 
dialysis cell with a molecular cut-off value of 20 kD (Slide-a-lyzer, Pierce, Rockford, 
Il, USA) against 0.25 M ammonium acetate (pH 5.5) with 5 buffer changes, to 
remove the unconjugated SCN-Bz-DTPA and SCN-Bz-DOTA. After conjugation the 
protein concentration was determined spectrophotometrically (Amersham 
pharmacia biotech, Uppsala, Sweden) at 280 nm. The substitution ratio was 
determined by labeling of the conjugation mixture with 111InCl3 (Covidien, Petten, 
The Netherlands) described by Hnatowich et al. (12). After incubation at RT for 20 
min, quality control was performed on silica-gel ITLC strips (ITLC-SG Biodex, 
Shirley, NY, USA) with sodium citrate, pH 5.5 as the mobile phase (Rf 111In-labeled 
anti-CAIX mAb = 0, Rf 111In-DTPA or 111In-DOTA =1). The substitution ratio is 
represented by the percentage of activity with an Rf of 0, when the conjugation 
mixture is labeled. 
 
Buffers 
Sodium acetate (Merck, Darmstadt, Germany) was dissolved in distilled water 
(Versol, Lyon, France) to a final concentration of 0.1 M and the pH was adjusted to 
5.5 by titration with 1 M HCl (Merck, Darmstadt, Germany). Ammonium acetate 
buffer was prepared by mixing equal volumes of 0.2 M acetic acid (Merck, 
Darmstadt, Germany) and 0.2 M ammonia (Merck, Darmstadt, Germany) and the 
pH was adjusted to 5.5 by adding 0.2 M acetic acid or 0.2 M ammonia. MES and 
HEPES (Sigma Aldrich, St. Louis, MO, USA) was dissolved in distilled water to a 
final concentration of 0.1 M and the pH was adjusted to 5.5 with 1 M NaOH (Merck, 
Darmstadt, Germany).  
 
111In-labeling of peptides and antibodies 
The labeling of the six compounds with 111In was performed at 9 days after 111In 
production (The calibration date of 111InCl3 is 10 days after the production of 
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111InCl3 and the expiry date of 111InCl3 is 11 days after the production of 111InCl3). 
The peptides and antibodies were dissolved in metal-free water to a final 
concentration of 0.1 µg/µl and 5 µl was added to 0.1 M NaAc, NH4Ac, MES or 
HEPES buffer. Five volumes of buffer and one volume of 111InCl3 (Covidien, Petten, 
the Netherlands) were added. The reaction mixtures were incubated for 20 min at 
RT for DTPA-conjugated compounds, at 95 ⁰C for DOTA-exendin and DOTA-
octreotide or 45 ⁰C for the DOTA-conjugated anti-CAIX antibody. After incubation, 
Tween80 (Sigma Aldrich, St. Louis, MO, USA) was added to a final concentration 
of 0.1% and EDTA (Sigma Aldrich, St. Louis, MO, USA) in 0.25 M NH4Ac, pH 5.5, 
was added to a final concentration of 5 mM to complex unincorporated 111In. 
Quality control was performed on silica-gel ITLC strips with 0.1 M EDTA in 0.1 M 
NH4Ac as a mobile phase (Rf 111In-labeled compounds = 0, Rf 111In-EDTA = 1). The 
maximum specific activity was determined by correcting the initial specific activity 
for the radiochemical purity. 
 
Effect of ageing of the 111InCl3 stock on the labeling efficiency of DTPA-
exendin-3 
DTPA-exendin-3 (0.5 µg) was labeled in triplicate (except for t = 14, in duplicate) 
with 111In (75 MBq) in 0.1 M NaAc, NH4Ac, MES and HEPES, pH 5.5 as described 
above, from 4 days after the production date (delivery of 111InCl3) until 14 days after 
the production date of 111InCl3. Quality control was performed as described above. 
 
Effect of the presence of cadmium on the labeling efficiency of DTPA-
exendin-3 
The effect of the cadmium, the decay product of 111In, on the radiolabeling was 
examined by adding increasing amounts of Cd2+ to the labeling mixture of DTPA-
exendin-3. CdCl2 (Sigma Aldrich, St. Louis, MO, USA) was dissolved in 0.1 M 
Ultrapure HCl (J.T. Baker, Deventer, The Netherlands) and serial dilutions ranging 
from 10-1 to 10-7 M CdCl2 in 0.02 M HCl were prepared. DTPA-exendin-3 (0.5 µg) 
was labeled with 1.85 MBq 111InCl3 (at day 9 after 111InCl3 production) in 0.1 M 
NaAc, NH4Ac, MES and HEPES, pH 5.5 as described above and various amounts 
of CdCl2 were added simultaneously with 111InCl3 to amounts ranging from 1 x 10-3 
to 9 x 104 nmol (resulting in final concentrations of Cd2+ ranging from 1 pM to 8.3 
µM). The amount of buffer was adjusted for the amount of CdCl2 in 0.02 M HCl 
added (final pH 5.5.). The experiment was performed in triplicate for all CdCl2 
concentrations and all buffers. Quality control was performed as described above. 
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Results 
 
Substitution ratio of DTPA- and DOTA-anti-CAIX 
The substitution ratio of DTPA- and DOTA-anti-CAIX was 3 DTPA and 7 DOTA 
molecules per antibody molecule, respectively. 
 
Effect of the buffer on the labeling efficiency of DTPA-conjugates 
The labeling efficiency at different specific activities of DTPA-exendin-3, DTPA-
octreotide and DTPA-anti-CAIX in 0.1 M NaAc, NH4Ac, MES and HEPES are 
summarized in Figure 1. The maximum specific activities of the compounds in 
different buffers were calculated and are shown in Figure 2 and Table 1. Labeling 
of DTPA-exendin-3 in NaAc buffer resulted in a maximal SA of 379 ± 16 MBq/nmol. 
The SA was somewhat lower when DTPA-exendin-3 was labeled in NH4Ac: 207 ± 
20 MBq/nmol. Two- to four-fold higher specific activities were observed when 
DTPA-exendin-3 was labeled in MES or HEPES (717 ± 29 and 837.3 ± 6 
MBq/nmol, respectively). Similar results were observed for labeling of DTPA-
octreotide and DTPA-anti-CAIX (Figure 1 and 2, Table 1). 
When DTPA-exendin-3 was labeled in MES the SA was 42 ± 2% of the maximum 
theoretical SA (Figure 3). Labeling of DTPA-exendin-3 in HEPES resulted in a SA 
that was 49 ± 1% of the maximum theoretical SA and was higher than the SA in 
acetate buffers (NaAc: 22 ± 1% and NH4Ac: 12 ± 1%). Similar results were 
obtained for the labeling of the anti-CAIX antibody, whereas the overall 
complexation of 111In by DTPA-octreotide was somewhat lower for all buffers. 
 
Effect of the buffer on the labeling efficiency of DOTA-conjugates 
The SA for 111In-DOTA-exendin-3 were lower than that of 111In-DTPA-exendin-3 
(Figure 2 and Table 1). However, the same trend was observed: Labeling in MES 
and HEPES resulted in higher SA (56 ± 4 and 38 ± 16 MBq/nmol) compared to the 
acetate buffers (NaAc: 23. ± 8 MBq/nmol and NH4Ac: 22 ± 1 MBq/nmol), with the 
exception that MES performed better than HEPES in these experiments (Figure 1 
and 2, Table 1). Also for DOTA-anti-CAIX higher SA were observed in MES and 
HEPES buffer: 947 ± 44 and 1018 ± 7 MBq/nmol, respectively versus 330 ± 87 
MBq/nmol for NaAc and 254 ± 2 for NH4Ac (Figure 1 and 2, Table 1). No difference 
in specific activities were observed for DOTA-octreotide (Figure 1 and 2, Table 1). 
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Figure 1: 111In-labeling of DTPA-exendin-3, DOTA-exendin-3, DTPA-octreotide, DOTA-octreotide, 
DTPA-anti-CAIX and DOTA-anti-CAIX in 0.1 M NaAc, NH4Ac, MES and HEPES buffer.  
 
The complexation of 111In by DOTA-conjugated compounds was less efficient than 
DTPA-conjugated compounds (Figure 3). The most efficient complexation of 111In 
was achieved by labeling of DOTA-anti-CAIX in HEPES buffer: 8.2 ± 0.1% of the 
DOTA-chelates complexed an 111In-atom. Labeling in HEPES buffer resulted in a 
similar complexation efficiency (7.6 ± 0.4%), whereas labeling in acetate buffers 
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resulted in a 3-5 fold reduction in the percentage of DOTA-molecules complexed 
(NaAc: 2.7 ± 0.7 and NH4Ac: 1.6 ± 0.4). Incorporation of 111In was also more 
efficient in HEPES and MES buffer for DOTA-exendin-3, but no differences in 
complexation efficiency was observed when DOTA-octreotide was labeled.  
 
NaAc 
(MBq/nmol) 
NH4Ac
(MBq/nmol) 
MES
(MBq/nmol) 
HEPES
(MBq/nmol) 
Maximum 
theoretical 
specific activity 
(GBq/nmol) 
DTPA-
exendin-3 
379 ± 16 207 ± 20 717 ± 29 837 ± 6 1.7 
DTPA-
octreotide 
95 ± 5 52 ± 4 248 ± 24 650 ± 10 1.7 
DTPA-
cG250 
338 ± 60 246 ± 37 835 ± 46 939 ± 50 5.2 
DOTA-
exendin-3 
23 ± 8 22 ± 1 56 ± 4 38 ± 16 1.7 
DOTA-
octreotide 
38 ± 0 39 ± 0 39 ± 0 39 ± 0 1.7 
DOTA-
cG250 
330 ± 87 254 ± 2 947 ± 44 1018 ± 7 12.4 
Table 1: Maximal specific activities (in MBq/nmol) and the maximum theoretical specific activity (in 
GBq/nmol) for DTPA-exendin-3, DOTA-exendin-3, DTPA-octreotide, DOTA-octreotide, DTPA-anti-CAIX 
and DOTA-anti-CAIX in 0.1 M NaAc, NH4Ac, MES and HEPES buffer. Maximum theoretical specific 
activity is calculated, assuming that 1 nmol DTPA or DOTA can complex 1 nmol 111In. 
 
Effect of ageing of the 111InCl3 stock on the labeling efficiency of DTPA-
exendin-3 
The effect of ageing of the 111InCl3 stock on the labeling efficiency of DTPA-
exendin-3 in 0.1 M NaAc, NH4Ac, MES and HEPES was investigated and the 
results are summarized in Figure 4 and 5. Four days after the production of 111InCl3 
(arrival of 111InCl3 stock), DTPA-exendin-3 could be labeled with 111In with similar 
labeling efficiency, resulting in similar SA, for all buffers. In NaAc and NH4Ac a 
reduced labeling efficiency was observed as soon as 7 days after production of 
111InCl3 decreasing to a labeling efficiency of 34 ± 8% and 27 ± 3% for NaAc and 
NH4Ac, respectively at day 11. Only a minimal decrease in labeling efficiency was 
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observed when the labeling was performed in MES buffer: 92.6 ± 5.2% at day 4 to 
78.3 ± 3.0 at day 14. A decrease in labeling efficiency was not observed up to day 
9. The time point of radiolabeling did not have any significant effect on the labeling 
efficiency or SA when HEPES was used for the radiolabeling. Labeling in HEPES 
at day 4 resulted in a labeling efficiency of 87 ± 7 % with a SA 627 ± 54 MBq/nmol. 
A labeling efficiency of 92 ± 6% and a SA of 625 ± 54 MBq/nmol) was obtained at 
day 14 after production date of 111InCl3.  These results were not significantly 
different from the results obtained 4 days after the production date. 
 
Figure 2: Maximal specific activities (in 
MBq/nmol) for DTPA-exendin-3, DOTA-
exendin-3, DTPA-octreotide, DOTA-octreotide, 
DTPA-anti-CAIX and DOTA-anti-CAIX in 0.1 M 
NaAc, NH4Ac, MES and HEPES buffer. 
Figure 3: Percentage of the maximum 
theoretical specific activity of DTPA-exendin-3, 
DOTA-exendin-3, DTPA-octreotide, DOTA-
octreotide, DTPA-anti-CAIX and DOTA-anti-
CAIX in 0.1 M NaAc, NH4Ac, MES and HEPES 
buffer. 
 
 
Effect of the presence of cadmium on the labeling efficiency of DTPA-
exendin-3 
In Figure 6 and Table 2 the effect of the Cd2+ concentration in the labeling mixture 
on the labeling efficiency of DTPA-exendin-3 is summarized. A decrease in labeling 
efficiency was observed when 1 pM CdCl2 was added to the labeling of DTPA-
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exendin-3 with 111In in NaAc and NH4Ac, whereas up to 0.1 nM Cd2+ did not affect 
the labeling efficiency when DTPA-exendin-3 was labeled in MES or HEPES. 
The Cd2+ concentration that lead to a 50% reduction in labeling efficiency was 
lower in NaAc (0.011 nM, 95% confidence interval: 0.007 – 0.019 nM) and NH4Ac 
(0.013 nM, 95% confidence interval: 0.010 – 0.019 nM) than in MES (2.5 nM, 95% 
confidence interval: 1.5 – 4.1 nM) and HEPES (2.7, 95% confidence interval: 2.2 – 
3.3 nM), indicating that the labeling efficiency was not affected by Cd2+ 
contamination in MES and HEPES buffer. 
 
 
 
Figure 4: Radiolabeling of DTPA-exendin-3 with 
111In at different time points from the production 
(day 0) of 111InCl3 for 0.1 M NaAc, NH4Ac, MES 
and HEPES. 
*= labeling performed in duplicate 
**= single labeling performed 
 
Figure 5: Maximal specific activity of 111In-
DTPA-exendin-3 at several time points 
after production of 111InCl3 (t=1 days). The 
specific activity was calculated by the 
initial specific activity (712 MBq/nmol) 
corrected by the labeling efficiency.  
*= labeling performed in duplicate 
**= single labeling performed 
 
 
*
*
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Figure 6: Effect of Cadmium on the labeling of 111In-DTPA-exendin-3 in 0.1 M NaAc, NH4Ac, 
MES and HEPES. 
 
Buffer 50% inhibitory concentration of Cd2+ (nM) 
NaAc 0.011 (0.007 – 0.019) 
NH4Ac 0.013 (0.010 – 0.019) 
MES 2.5 (1.5 – 4.1) 
HEPES 2.7 (2.2 – 3.3) 
Table 2: Cadmium concentrations that lead to a 50% reduction in labeling efficiency of DTPA-
exendin-3 in 0.1 M NaAc, NH4Ac, MES and HEPES. The 95% confidence interval is indicated in 
parenthesis. 
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Discussion 
 
High SA of 111In-labeled peptides and antibodies are required to administer a tracer 
dose of peptide or protein, preventing target saturation and/or side effects, while 
administering high activity doses are required for imaging. Acetate buffers are 
routinely used for the labeling of DTPA and DOTA-conjugated compounds with 
111In. Here, we examined the effect of the buffer used during the radiolabeling: 
HEPES and MES and compared this with the most commonly used acetate 
buffers: sodium acetate and ammonium acetate and showed an increased SA 
could be obtained when DTPA and DOTA-conjugated compounds were labeled in 
MES or HEPES buffer. Moreover, the labeling efficiency was not affected by Cd2+ 
concentrations up to 0.1 nM when the labeling was performed in MES and HEPES, 
whereas a drastic effect was observed when the labeling was performed in acetate 
buffers. In line with these results, the ageing of the 111InCl3 stock had only a minor 
effect on the labeling efficiency 14 days after production of 111InCl3 when 
compounds were labeled in MES and HEPES.  
The use of MES as a buffer for radiolabeling resulted in a SA of all DTPA-
conjugated compounds that was approximately 2 to 3 times higher when compared 
to radiolabeling in ammonium acetate and sodium acetate, respectively. When 
HEPES was used, an even higher SA of the DTPA-conjugated compounds was 
observed: four times higher than labeling performed in ammonium acetate. The 
effect was less pronounced when the DOTA-conjugated compounds were labeled 
with 111In. Overall, radiolabeling in HEPES and MES was more efficient than in 
acetate buffers in most cases and at least as efficient in the case of DOTA-
octreotide. Labeling of DOTA-conjugated compounds resulted in 5- to 20-times 
lower SA than DTPA-conjugated compounds. Most likely this is due to the 
interference of contaminating metals with DOTA-chelation, which might play a role 
to a lesser extent when labeling DTPA-conjugated compounds. 
The decay product of 111In, 111Cd, can also be chelated by DTPA or DOTA and it is 
therefore expected that the complexation of 111In is less efficient over time due to 
increasing amounts of Cd2+. Indeed, this phenomenon was observed when sodium 
acetate and ammonium acetate were used for the 111In-labeling of DTPA-exendin. 
Lower labeling efficiencies were observed as early as 7 days after production of 
111InCl3 and 3-fold lower SA were obtained when the labeling was performed with 
111InCl3 11 days after the production date. This effect was not observed for labeling 
of DTPA-exendin-3 in MES and HEPES with a maximal decrease in SA of 10% 
and 4% at day 11, respectively. Even the decrease in SA 14 days after the 
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calibration date of 111InCl3 was not more than 18% for 111In-labeling in MES and 5% 
for HEPES. These latter results could explain the differences in SA of the six 
compounds used in this study, since the labeling of these compounds was 
performed with 111In 9 days after production. Generally, 111InCl3 is used from 7 to 
11 days after the production day, which could lead to reduced specific activities at 
later time points when acetate buffers are used. To overcome this problem, HEPES 
or MES buffer could be used for radiolabeling, with high specific activities at time-
points up to 14 days after 111InCl3 production. This could have impact on 
experiment planning, since experiments which require high SA labeled compounds 
are only available early after 111In production when acetate buffers are used, 
whereas the time point is not relevant when MES or HEPES are used. These 
results suggest that increasing amounts of Cd2+ contamination, due to ageing of 
the 111InCl3 stock, do not influence the labeling of DTPA-conjugated compounds 
when MES and HEPES are used as a buffer for radiolabeling. 
The suggested effect of cadmium on the 111In-labeling of DTPA-conjugated 
compounds was confirmed when increasing amounts of Cd2+ were added to the 
111In-labeling mixture of DTPA-exendin. In HEPES and MES buffer a 100-fold 
higher amount of cadmium could be added to the labeling mixture without reducing 
the labeling efficiency, than in acetate buffer. The decreased labeling efficiency at 
low concentrations of cadmium might be due to efficient formation of coordination 
complexes of Cd2+ with acetate allowing efficient “transchelation” of Cd2+, whereas 
no coordination complex with HEPES or MES is formed (9) and “transchelation” of 
Cd2+ to DTPA or DOTA is less efficient.  
It has been postulated that coordination complex formation of 111In with acetate 
buffers is necessary for efficient labeling of DTPA and DOTA-conjugated 
compounds (13), since it is assumed that the coordination complex formation 
prevent the formation of insoluble 111In-hydroxide. This study suggest that 
coordination complex formation of the buffer with 111In is less important for efficient 
labeling of DTPA- and DOTA-conjugated compounds, since the labeling in the 
“weakly coordinating” buffers MES and HEPES was more efficient than in acetate 
buffers in most cases or at least equivocal in the case of DOTA-octreotide. 
Breeman et al. described the effect of contaminants on the labeling of DOTA-
octreotide with 111In, 177Lu and 90Y and found a similar effect of cadmium 
contamination on the radiolabeling (14). The labeling procedures described in the 
latter study were performed in sodium acetate and these findings are in line with 
the findings in our study, where a pronounced effect of Cd2+ on the labeling of 
DTPA-exendin-3 is observed when sodium acetate is used as buffer for 
radiolabeling. 
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The purification of 111InCl3 by an anion exchange method was described to improve 
the labeling of DTPA- and DOTA-conjugated compounds caused by the removal of 
contaminants, mainly Cd2+, present in the 111InCl3 solution (15). By using HEPES or 
MES buffer for the labeling of the compounds this could omit time consuming 
purification methods. 
In conclusion, we showed improved labeling of DTPA- and DOTA-conjugated 
peptides, proteins and antibodies with 111In when HEPES or MES buffer was used 
for radiolabeling. The enhanced labeling efficiency could be due to the reduced 
competitive chelation of cadmium, the decay product of 111In. When 111In-labeling of 
DTPA- and DOTA-conjugated compounds is performed in MES or HEPES, 111In-
labeled compounds can be produced with high specific activities regardless from 
the time-point after 111In production. 
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Abstract 
 
Background 
68Ga-labeled radiotracers are increasingly used for PET imaging since 68Ga is a 
readily available generator-derived PET radionuclide. Chelate-conjugated 
compounds can be labeled with 68Ga in a one-step procedure. During the labeling 
procedure formation of 68Ga-hydroxide (Ga(OH)3) and other insoluble 68Ga3+ 
species, generally referred to as 68Ga-colloid, may occur. Upon iv injection 68Ga-
colloid will accumulate rapidly in the liver, spleen and bone marrow, resulting in 
reduced target-to-background ratios. Here, we studied the effect of the purification 
method on the in vivo characteristics of 68Ga-labeled DOTA-exendin-3.  
Methods 
DOTA-exendin-3 was labeled with 68Ga by incubation in 2.5 M HEPES buffer, for 
20 min at 95 ⁰C at a final pH of 3.5-4. After labeling, EDTA was added to chelate 
unincorporated 68Ga3+. Quality control was performed with ITLC-SG with two 
mobile phases to determine the content of 68Ga-EDTA and 68Ga-colloid. The 68Ga-
labeled compound was purified by gel filtration on a 5 ml G25M column, by RP-
HPLC using a C8 column or by solid-phase extraction (SPE) on an HLB cartridge. 
The in vivo characteristics of the preparations were determined in BALB/c nude 
mice and PET images were acquired 1 h p.i. using a microPET scanner. In these 
studies unpurified 68Ga-DOTA-exendin-3 and 111In-DOTA-exendin-3 were used as 
a reference.  
Results 
The 111In/68Ga-colloid content of 111In-DOTA-exendin-3 and unpurified, gel filtration, 
RP-HPLC and SPE-purified 68Ga-DOTA-exendin-3 was < 3%, 7%, 9%, < 3% and < 
3%, respectively. The amount of unincorporated 68Ga was < 3% for all 
preparations. Unpurified 68Ga-DOTA-exendin-3 showed high liver and spleen 
uptake: 6.1 ± 1.0 and 4.5 ± 0.7 %ID, respectively. Gel filtration partly removed 
68Ga-colloid from the preparation, resulting in moderate liver and spleen uptake 
(3.0 ± 0.3 and 1.4 ± 0.3 %ID/g). SPE-purified 68Ga-DOTA-exendin-3 showed very 
low liver (0.8 ± 0.1 %ID/g) and spleen (0.5 ± 0.1 %ID/g) uptake, that was similar to 
that of RP-HPLC purified 68Ga-DOTA-exendin-3 (0.6 ± 0.1 and 0.4 ± 0.1 %ID/g, 
respectively). The uptake of SPE- and RP-HPLC-purified 68Ga-DOTA-exendin-3 in 
liver and spleen was similar to those of 111In-DOTA-exendin-3: 0.7 ± 0.1 and 0.3 ± 
0.1 %ID/g, respectively. On the PET images liver uptake was clearly visible after 
injection of unpurified 68Ga-DOTA-exendin-3. Liver uptake after injection of gel 
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filtration purified 68Ga-DOTA-exendin-3 was reduced, whereas it was absent in the 
PET images after injection of the HPLC and SPE-purified preparations. 
Conclusions 
Solid-phase extraction is a fast and simple method to completely remove 68Ga-
colloid from 68Ga-labeled tracer preparations. The uptake in liver and spleen of the 
SPE-purified product was similar to 111In-DOTA-exendin-3 or HPLC purified 68Ga-
DOTA-exendin-3, indicating complete removal of 68Ga-hydroxide from the 
preparation. 
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Introduction 
 
68Ga-labeled peptides are increasingly used for positron emission tomography 
(PET), since 68Ga is a readily available PET-radionuclide. Because 68Ga is a 
generator-produced positron emitter, it is widely available and relatively cheap. 
PET imaging is advantageous over conventional scintigraphy and SPECT, 
because of its excellent sensitivity in combination with its superior spatial 
resolution. A recent study in patients with neuro-endocrine tumors (NET) showed 
that PET imaging with the somatostatin analog 68Ga-DOTA-TOC was more 
sensitive for detecting NET lesions than conventional somatostatin receptor 
scintigraphy with 111In-octreotide (1). Moreover, 68Ga-labeling of peptides 
conjugated with a chelator (eg. DOTA, NOTA, a.o.) is a fast and efficient one-step 
reaction. Because of all these characteristics, there is an increasing interest in the 
application of 68Ga-labeled peptides. 
It has been shown that for efficient receptor targeting low peptide doses should be 
administered, since higher peptide doses could lead to receptor saturation and 
reduced uptake in the target tissue (2-4). In rodents, relatively high activity doses 
(3-10 MBq) have to be administered to acquire PET images with adequate image 
quality. Therefore, 68Ga-labeled peptides with a high specific activity should be 
produced to administer high activity doses at a low peptide/tracer dose. However, 
when producing 68Ga-labeled compounds with a high specific activity, the formation 
of insoluble 68Ga-species, such as 68Ga(OH)3 may occur. These insoluble 68Ga-
species, generally referred to as ‘68Ga-colloid’ will accumulate in the liver, spleen 
and bone marrow. Indeed, previous studies showed enhanced uptake in liver and 
spleen of 68Ga-labeled tracers as compared to the 111In-labeled compounds (3, 5, 
6). This enhanced tracer uptake in liver and spleen might result in decreased 
target-to-background ratios. We previously showed that insoluble 68Ga-species can 
be removed from the labeling reaction of 68Ga-labeled DOTA-exendin-3, a tracer 
targeting the GLP-1R, using (preparative) RP-HPLC (3). However, this purification 
method is time consuming and the purified 68Ga-labeled peptide is diluted, making 
post-purification concentration necessary. Due to the short half-life of 68Ga (68 
minutes) this method is not convenient in clinical practice. Moreover, purification 
with RP-HPLC requires expensive equipment. Therefore, there is a need for a fast, 
simple and cheap purification method. 
In this study we examined the effect of the purification methods on the in vivo 
characteristics of 68Ga-DOTA-exendin-3 in BALB/c nude mice. 68Ga-DOTA-
exendin-3 was purified by RP-HPLC, gel filtration or solid-phase extraction. 
  
59 
 
Unpurified 68Ga-DOTA-exendin-3 and 111In-DOTA-exendin-3 were used as a 
reference in this study. Finally, we describe a quality control method, based on thin 
layer chromatography (TLC), to determine the colloid content of the 68Ga-labeled 
tracer (7). 
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Materials and Methods 
 
Peptides and radionuclides 
[Lys40(DOTA)]exendin-3 (DOTA-exendin-3) was purchased from Peptide Specialty 
Laboratories (Heidelberg, Germany). DOTA (1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid) was conjugated to the ε-amino group of the Lysine at 
position 40 (K40) and the C-terminal carboxyl group was amidated (3). 68GaCl3 was 
eluted from a TiO2-based 1,110 MBq 68Ge/68Ga generator (IGG100, Eckert and 
Ziegler, Berlin, Germany) with 0.1 N Ultrapure HCl (J.T. Baker, Deventer, The 
Netherlands). 111InCl3 was obtained from Covidien (Petten, The Netherlands). 
 
Radiolabeling 
DOTA-exendin-3 was labeled with 68Ga and 111In as previously described (3). 
Briefly, 120 MBq 68Ga in 1000 µl Ultrapure 0.1 N HCl was added to 10 µg DOTA-
exendin-3 in 120 µl 2.5 M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid, Sigma Aldrich, St Louis, MO, USA). After 20 min incubation at 95°C, EDTA 
was added to a final concentration of 5 mM and the reaction mixture was incubated 
at room temperature for another 5 min. Subsequently, 10% Tween-80 (Sigma 
Aldrich, St Louis, MO, USA) was added to a final concentration of 0.1% to prevent 
sticking of the radiolabeled peptide to the vessel wall and quality control was 
performed as described below. 
DOTA-exendin-3 was labeled with 111In by adding 10 MBq 111InCl3 to 1 µg peptide 
in 0.1 M MES, pH 5.5 under similar conditions as described above.  
 
Quality control 
Quality control was performed using reversed-phase high performance liquid 
chromatography (RP-HPLC) on a C18 reversed-phase column (Zorbax Rx-C18; 4.6 
mm x 25 cm; Agilent Technologies) and Instant Thin Layer Chromatography 
(ITLC). The column was eluted with water containing 0.1% TFA with a linear 
gradient from 3% to 100% acetonitril in 10 min (flow rate: 1 ml/min). ITLC was 
performed on silica gel ITLC (Pall Corporation Life Sciences, New York, NY, USA). 
Two mobile phases were used: 0.1 M EDTA in 0.25 M NH4Ac, pH 5.5 (Rf =0: 68Ga-
labeled exendin and 68Ga-colloid, Rf =1: 68Ga-EDTA) and 1.25 M NH4Ac, pH 5.5: 
dimethylformamide (DMF) (1:1) (Rf = 0: 68Ga-colloid, Rf =1: 68Ga-DOTA-exendin-3 
and 68Ga-EDTA). 
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Validation of the quality control by TLC for the detection of 68Ga-colloid.  
68Ga-colloid was prepared by adding 1250 µl 2.5M HEPES to 500 µl 68GaCl3 in 0.1 
M HCl. The final pH of this mixture was approximately 6. The mixture was 
incubated at 95°C for 15 min and EDTA was added to a final concentration of 5 
mM. The amount of 68Ga-colloid was determined by TLC with 0.1 M EDTA in 0.25 
M NH4Ac, pH 5.5 as a mobile phase (Rf = 0: 68Ga-colloid, Rf =1 68Ga-EDTA) and 
1.25 M NH4Ac, pH 5.5: dimethylformamide (DMF) (1:1) as a mobile phase (Rf = 0: 
68Ga-colloid, Rf =1: 68Ga-DOTA-exendin-3 and 68Ga-EDTA). The reaction mixture 
was applied on a disposable PD-10 desalting column, containing SephadexTM G-25 
medium (GE Life Sciences, Diegem, Belgium) and was eluted with 6 ml PBS 
containing 5 mM EDTA. The fraction containing the majority of the radioactivity was 
collected (from 3-4 ml), representing 68Ga-colloid and quality control was performed 
by TLC as described above.  
68Ga-DOTA-exendin-3 was purified by RP-HPLC as described below and various 
amounts of the 68Ga-colloid were added to final 68Ga-colloid fractions of 1, 2, 3, 4, 
5, 10, 20, 40 and 80% (n=4). The amount of 68Ga-colloid was determined by TLC 
with 1.25 M NH4Ac, pH 5.5: dimethylformamide (DMF) (1:1) as the mobile phase 
(Rf = 0: 68Ga-colloid, Rf = 1: 68Ga-DOTA-exendin-3 and 68Ga-EDTA). RP-HPLC 
purified 68Ga-DOTA-exendin-3, 68Ga-EDTA and 68Ga-colloid were used as controls. 
TLC strips were exposed to an imaging plate (Fuji Film BAS-SR 2025, Raytest, 
Straubenhardt, Germany) for 1 min. Images were acquired with a 
radioluminography laser imager (Fuji Film BAS 1800 II system, Raytest, 
Straubenhardt, Germany) and analyzed with Aida Image Analyzer software 
(Raytest, Straubenhardt, Germany). Correlation between the measured 68Ga-
colloid fraction and the added 68Ga-colloid content was determined by linear 
regression using GraphPad Prism 5. The detection limit of the TLC method was 
defined by the Y-intercept as determined by linear regression analysis.  
 
RP-HPLC purification of 68Ga-DOTA-exendin-3 
After radiolabeling, the reaction mixture was purified by HPLC, using a C8 
reversed-phase column (Zorbax eclipse XDB C8 4.6 x 150 mm, 5 µm, Agilent 
Technologies). The column was eluted with water containing 0.1% TFA (0-5 min), 
40% ethanol (5-10 min) followed by a linear gradient from 40% to 90% ethanol in 5 
min (flow rate: 1 ml/min). The fractions containing 68Ga-DOTA-exendin-3 were 
collected (retention time: 14-15 min.) and diluted with PBS containing 0.5% bovine 
serum albumin (BSA) to a final ethanol concentration of less than 10% before 
injection into mice (injection volume: 0.2 ml). The radiochemical purity of the 
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purified 68Ga-labeled DOTA-exendin-3 preparations was determined using ITLC as 
described above. 
 
Purification of 68Ga-DOTA-exendin-3 by gel filtration 
Purification by gel filtration was performed on disposable PD-10 desalting columns, 
containing SephadexTM G-25 medium. The column was preconditioned by eluting 
with 10 ml PBS containing 0.5% (v/w) BSA and the reaction mixture was loaded 
onto the column. The reaction mixture was eluted with PBS-BSA (0.5%) and 0.5 ml 
fractions were collected. The majority of the radioactivity, representing 68Ga-DOTA-
exendin-3, was collected in fraction 5 and 6. The radiochemical purity of the tracer 
in the fractions was analyzed by RP-HPLC and ITLC as described above.  
 
Purification of 68Ga-DOTA-exendin-3 by solid-phase extraction 
Solid-phase extraction was performed using a HLB (hydrophilic-lipophilic balance 
reversed-phase sorbent) cartridge (Waters Oasis©, Milford, MA, USA). The 
cartridge was activated with 1 ml ethanol, the excess of ethanol was removed with 
1 ml water (Versol, and the column was conditioned with 1 ml 0.1 N HCl : 2.5 M 
HEPES (8:1, similar to the reaction mixture). The reaction mixture was loaded and 
68Ga-EDTA was washed from the column with 2 ml 0.1 N HCl : 2.5 M HEPES (8:1). 
After removal of the HCl-HEPES mixture with 1 ml water, 68Ga-DOTA-exendin-3 
was eluted with 200 µl ethanol. The radiochemical purity of the tracer in the 
fractions was analyzed by RP-HPLC and ITLC as described above. Before 
injection into mice 68Ga-DOTA-exendin-3 was diluted with PBS containing 0.5% 
BSA to a final ethanol concentration of less than 10%. 
 
Biodistribution studies 
The biodistribution of unpurified, gel filtration, RP-HPLC and SPE-purified 68Ga-
DOTA-exendin-3 was determined in BALB/c nude mice. Mice (n=5) were injected 
intravenously with 3 MBq 68Ga-labelled exendin-3 at a peptide dose of 0.3 µg (60 
pmol). As a control another group of mice received 370 kBq 111In-DTPA-exendin-3 
(60 pmol). The mice were euthanized 1 hour post-injection by CO2/O2 suffocation, 
a blood sample was taken and samples of relevant tissues were dissected, 
weighed and counted. 
 
MicroPET 
PET images were acquired 1 h after injection of the mice using a small-animal 
PET/CT scanner (Inveon™; Preclinical Solutions, Siemens Medical Solutions USA, 
Inc., Knoxville, TN, USA). The mice were injected intravenously with 3 MBq (0.3 
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µg) unpurified, gel filtratrion, RP-HPLC or SPE-purified 68Ga-DOTA-exendin-3. 
Mice were euthanized 1 h p.i. by CO2/O2 suffocation and PET images were 
acquired during 45 min. Images were reconstructed by OSEM3D/MAP 
reconstruction with the following parameters: 256 x 256 matrix, 2 OSEM3D 
iterations, 18 MAP iterations and a resolution of 0.075 mm uniform variance. CT 
images were acquired for anatomical correlation directly after PET imaging (spatial 
resolution 113 µm, 80 kV, 500 µA, exposure time 300 msec). 
 
Statistical analysis 
All mean values are expressed as mean ± standard deviation (SD). Statistical 
analysis was performed using unpaired two-tailed unpaired t test using GraphPad 
Prism (version 5). The level of significance was set at p < 0.05.
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Results 
 
Radiolabeling 
DOTA-exendin-3 could be labeled with 68Ga with a specific activity of 110 
GBq/µmol with a radiochemical purity >95% after purification. The colloid content of 
111In-DOTA-exendin-3 and unpurified, gel filtration, RP-HPLC and SPE-purified 
68Ga-DOTA-exendin-3 was < 3%, 7%, 9%, < 3% and < 3%, respectively (Table 1). 
After purification the amount of unincorporated 68Ga was < 3% for all preparations. 
 
Validation of TLC method 
The results of the validation of the TLC method to determine the colloid content in 
preparations of 68Ga-DOTA-exendin-3 are shown in Figure 1. The colloid content 
measured by TLC correlated linearly with the amount of colloid present in the 
reaction mixtures (R2 = 0.98). The detection limit of the TLC method was a 68Ga-
colloid content of 3.2 ± 0.9 %, as determined by the Y-intercept of the trend line.  
 
Figure 1: TLC method for the determination of the 68Ga-colloid content. A: TLC images and profiles of 
68Ga-DOTA-exendin-3 with various amounts of 68Ga-colloid (typical examples). B: Correlation between 
the amount of 68Ga-colloid added and the measured colloid content as determined by TLC. 
 
Biodistribution studies 
The results of the biodistribution studies are summarized in Figure 2. 111In-DOTA-
exendin-3 showed very low accumulation in liver and spleen: 0.7 ± 0.1 and 0.3 ± 
0.1 %ID/g, respectively, representing the liver and spleen uptake of a preparation 
without colloid. High uptake in liver and spleen (6.1 ± 1.0 and 4.5 ± 0.7 %ID, 
respectively) was observed when unpurified 68Ga-DOTA-exendin-3 was injected. 
Gel filtration partially removed 68Ga-hydroxide, resulting in intermediate uptake in 
liver and spleen: 3.0 ± 0.3 and 1.4 ± 0.3 %ID/g, respectively). Uptake in liver and 
spleen of SPE (0.8 ± 0.0 %ID/g and 0.5 ± 0.1 %ID/g, respectively) and RP-HPLC-
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purified tracer (0.6 ± 0.1 and 0.4 ± 0.1 %ID/g, respectively) was very low and 
similar to liver and spleen uptake of 111In-DOTA-exendin-3, indicating complete 
removal of 68Ga-colloid with these purification methods. 
The pancreatic uptake was similar for all compounds, except of RP-HPLC purified 
68Ga-DOTA-exendin-3, that had a significantly higher pancreatic uptake (10.2 ± 2.5 
%ID/g, p<0.05) 
 
 68Ga-colloid content 
(%) 
Liver uptake
(%ID/g) 
Spleen uptake 
(%ID/g) 
111In-DOTA-exendin-3 < 3 0.7 ± 0.1 0.3 ± 0.1 
68Ga-DOTA-exendin-3 7 6.1 ± 1.0 4.5 ± 0.7 
Gel filtration purified 
68Ga-DOTA-exendin-3 
9 3.0 ± 0.3 1.4 ± 0.3 
HLB-purified 
68Ga-DOTA-exendin-3 
< 3 0.8 ± 0.0 0.5 ± 0.1 
RP-HPLC purified 
68Ga-DOTA-exendin-3 
< 3 0.6 ± 0.1 0.4 ± 0.1 
Table 1: The colloid content determined by TLC, liver and spleen uptake of unpurified, gel filtratrion, 
RP-HPLC and SPE purified 68Ga-DOTA-exendin-3 and 111In-DOTA-exendin-3 
 
MicroPET 
PET images of BALB/c nude mice after injection of unpurified, gel filtration, RP-
HPLC or SPE-purified 68Ga-DOTA-exendin-3 are shown in Figure 3. When 
unpurified 68Ga-DOTA-exendin-3 was injected, the liver was clearly visualized in 
the PET images. Liver visualization was less pronounced when 68Ga-DOTA-
exendin-3 was purified by gel filtration. No uptake in the liver was visible when 
68Ga-DOTA-exendin-3 was purified with SPE or RP-HPLC.  
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Figure 2: Biodistribution of unpurified, gel filtration, RP-HPLC and SPE-purified 
68Ga-DOTA-exendin-3 in BALB/c nude mice (n=5 per group). 111In-DOTA-
exendin-3 was used as a reference. Values are expressed as %ID/g ± SD. Mice 
were dissected 1 h p.i. 
 
 
Figure 3: PET images of BALB/c nude mice after injection of 68Ga-
DOTA-exendin-3. High liver uptake is seen when the unpurified 
tracer is injected (A). Gel filtration partially removed the 68Ga-colloid 
(B), whereas no liver uptake was observed when 68Ga-DOTA-
exendin-3 was purified by RP-HPLC (C) or SPE (D). 
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Discussion 
 
During the radiolabeling procedure of DOTA-conjugated compounds with 68Ga, in 
most cases insoluble 68Ga colloidal species are formed, especially when 
compounds are labeled at a high specific activity. This insoluble 68Ga-colloid results 
in enhanced accumulation in liver and spleen when injected in laboratory animals 
or patients, resulting in reduced image quality. Therefore, prevention of formation 
or removal of 68Ga-colloid is required. We characterized three purification methods 
for the removal of 68Ga-colloid: solid-phase extraction (SPE), preparative HPLC en 
gel filtration. Solid-phase extraction was a fast and simple method that effectively 
removed all 68Ga-colloid from a labeling mixture of 68Ga-DOTA-exendin-3, resulting 
in liver and spleen accumulation that was similar to that of 111In-DOTA-exendin-3. 
The major advantage of this technique is that purification of the labeling mixture 
can be performed within 5 minutes. Purification by preparative RP-HPLC resulted 
in similar spleen and liver accumulation. However, this technique is more time-
consuming and less suited for purification of 68Ga-labeled tracers, due to the short 
half-life of 68Ga. Gel filtration removed 68Ga-colloid less efficiently, resulting in 
higher liver and spleen uptake than SPE and RP-HPLC purification.  
High specific activities of 68Ga-labeled tracers are required to administer high 
activity doses in combination with low tracer peptide doses. It was shown that high 
tracer peptide doses lead to reduced uptake in the target tissues due to (partly) 
saturation of the receptors (2-4). Moreover, high tracer doses can lead to (toxic) 
side effects, especially when biologically active compounds are used as a tracer. 
The need of a high specific activity generally enhances 68Ga-colloid formation, 
since incorporation of 68Ga present in the labeling mixture at high specific activity 
might be incomplete. Since 68Ga(OH)3 could be formed at pH 3 in the absence of 
chelating agents (such as DOTA, DTPA and EDTA) (8), 68Ga(OH)3 is readily 
formed in a labeling mixtures at a pH between 3.5 and 4 when 68Ga-incorporation 
is incomplete. 
Enhanced liver and spleen uptake will hamper the detection of lesions in the upper 
abdomen. Radiolabeled exendin was successfully used for the detection of 
insulinomas (9) and could potentially be used for the detection of the pancreatic 
beta cell mass. Enhanced liver and spleen uptake might reduce the sensitivity of 
these methods. In conclusion, solid-phase extraction using HLB is a fast and 
simple method to remove 68Ga-colloid. The uptake in liver and spleen of the SPE-
purified product was similar to 111In-DOTA-exendin-3 or HPLC purified 68Ga-DOTA-
exendin-3, indicating complete removal of insoluble 68Ga-colloid.  
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Abstract 
 
Background 
For peptide receptor targeting usually internalizing agonists are selected. There is 
increasing evidence that non-internalizing receptor antagonists can be used for this 
purpose. We investigated whether the glucagon-like peptide-1 receptor (GLP-1R) 
antagonist exendin(9-39) can be used for in vivo targeting of GLP-1R expressing 
tumors and compared the in vitro and in vivo characteristics to the GLP-1R 
agonists exendin-3 and exendin-4. 
Methods 
The binding and internalization kinetics of labeled [Lys40(DTPA)]exendin-3, 
[Lys40(DTPA)]exendin-4 and [Lys40(DTPA)]exendin(9-39) were determined in vitro 
using INS-1 cells. The in vivo targeting properties of [Lys40(111In-DTPA)]exendin-3, 
[Lys40(111In-DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39) were examined 
in BALB/c nude mice with subcutaneous INS-1 tumors.  
Results 
natIn-labeled [Lys40(DTPA)]exendin-3, [Lys40(DTPA)]exendin-4 and 
[Lys40(DTPA)]exendin(9-39) exhibited similar IC50 values (13.5, 14.4 and 13.4 nM, 
respectively) and bound to 26 x 103, 41 x 103 and 37 x 103 receptors/cell, 
respectively. [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-DTPA)]exendin-4 
showed rapid in vitro binding and internalization kinetics, whereas [Lys40(111In-
DTPA)]exendin(9-39) showed lower binding and minimal internalization in vitro. In 
mice, high specific uptake of [Lys40(111In-DTPA)]exendin-3 (25.0 ± 6.0 %ID/g) in the 
tumor was observed at 0.5 h p.i. with similar uptake up to 4 h p.i.. [Lys40(111In-
DTPA)]exendin-4 showed higher tumor uptake at 1 and 4 h p.i. (40.8 ± 7.0 and 
41.9 ± 7.2 %ID/g, respectively). Remarkably, [Lys40(111In-DTPA)]exendin(9-39) 
showed only low specific uptake in the tumor at 0.5 h p.i. (3.2 ± 0.7 %ID/g), rapidly 
decreasing over time. 
Conclusion 
The GLP-1R agonists [Lys40(DTPA)]exendin-3 and [Lys40(DTPA)]exendin-4 labeled 
with 111In could be useful for in vivo GLP-1R targeting, whereas 
[Lys40(DTPA)]exendin(9-39) is not suited for in vivo targeting of the GLP-1R. 
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Introduction 
 
Peptide receptor targeting is a successful method for the diagnosis and therapy of 
neuroendocrine tumors (NET) (1) with somatostatin receptor targeting as the most 
successful example. In general, agonists are selected for receptor targeting, 
because agonists usually trigger the internalization of the ligand-receptor complex 
(2). Internalization of the ligand-receptor complex is the basis for increasing target-
to-background ratios, due to retention of the radiolabeled tracer in the target tissue 
through metabolic trapping (1, 3-6). Therefore, internalization is considered to be a 
crucial step for in vivo peptide receptor targeting (5, 6). A correlation between 
internalization rate and in vivo accumulation of radiolabeled somatostatin 
analogues in somatostatin receptor subtype 2 (sstr2) has been found in rats with 
AR42J tumors (7).  
Most peptide receptor antagonist do not internalize, while they do bind to the same 
receptor with high affinity. Antagonists were considered not be suitable for in vivo 
imaging of tumors due to the lack of internalization. This has been supported by 
several studies, for example a study showing that a bombesin agonist displayed 
superior in vivo targeting characteristics in comparison to the antagonist (8). 
However, recent studies showed favourable in vivo targeting of radiolabeled 
bombesin antagonists with higher tumor uptake and longer washout compared to 
bombesin agonists (9-11). Moreover, a recent study with somatostatin receptor 
type 2 (sstr 2) and type 3 (sstr 3) ligands showed a remarkably higher uptake in the 
tumor of the antagonists than the agonists (12). Therefore, there is increasing 
evidence that peptide receptor antagonists may be useful for the in vivo targeting 
of receptor expressing tissues.  
Insulinomas are NET derived from pancreatic beta cells. Although somatostatin 
receptor scintigraphy is highly efficient in detecting NET and their metastases (13), 
the sensitivity for the detection of insulinomas is only 40-60% caused by a relatively 
low incidence of sstr2 and sstr5 receptor subtype expression in insulinomas (13-
15). In comparison, the glucacon-like peptide-1 receptor (GLP-1R) is expressed on 
more than 90% of insulinomas and at a mean density that is two times higher than 
that of the sst2r (16). Exendin is a GLP-1 (glucagon-like peptide-1) analogue that 
targets the GLP-1R. For the detection of insulinomas, radiolabeled exendin has 
been developed recently, with promising preclinical as well as clinical results (17-
20). Therefore, exendin analogues should be considered for insulinoma targeting 
(17-21). 
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For the targeting of the GLP-1R, only agonists (exendin-3 and exendin-4) labeled 
with 111In via DTPA conjugated to a C-terminal lysine residue have been examined 
(17, 18, 20-22). The GLP-1R antagonist exendin(9-39) is an amino-terminally 
truncated variant prepared by enzymatic degradation of exendin (Table 1). We 
aimed to investigate whether exendin(9-39) may also be suitable or – in analogy to 
the sstr2, sstr3 and bombesin antagonists (9-12) – may even be superior for 
insulinoma imaging as compared to exendin 3 and 4. Therefore, we investigated 
the in vitro and in vivo GLP-1R targeting characteristics of the GLP-1R antagonist 
exendin(9-39) conjugated with DTPA at a C-terminal Lysine: 
[Lys40(DTPA)]exendin(9-39) and compared these with these of agonists 
[Lys40(DTPA)]exendin-3 and [Lys40(DTPA)]exendin-4. 
 
Peptide Amino acid sequence 
GLP-1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 
exendin-3 HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 
exendin-4 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 
exendin(9-39)                      DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 
Table 1: Amino acid sequence of GLP-1, exendin-3, exendin-4 and exendin(9-39). The homologous 
amino acids compared to GLP-1 are underlined. 
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Materials and Methods 
 
Radiolabeling of exendin  
[Lys40(DTPA)]exendin-3, [Lys40(DTPA)]exendin-4 and [Lys40(DTPA)]exendin(9-39) 
were purchased from Peptide Specialty Laboratories (Heidelberg, Germany). 
Labeling of DTPA-conjugated [Lys40]exendin-3, [Lys40]exendin-4 or 
[Lys40]exendin(9-39) was performed under identical conditions. 150 MBq 111InCl3 
was added to 1 μg of exendin in 5 volumes of 0.1 M MES buffer, pH 5.5. After 30 
min of incubation at room temperature, EDTA was added to a final concentration of 
5 mM and incubated at room temperature for 5 min. Tween80 was added to a final 
concentration of 0.1% and quality control was performed using reversed-phase 
high performance liquid chromatography (RP-HPLC) on a C18 reversed-phase 
column (Zorbax Rx-C18; 4.6 mm x 25 cm; Agilent Technologies). The column was 
eluted with 10 mM NH4Ac, pH 5.5 with a linear gradient to 100% acetonitrile over 
10 min with a flow rate of 1 ml/min. 
ITLC was performed on silica gel ITLC strips (Pall Corporation Life Sciences, New 
York, NY, USA). Two mobile phases were used: 0.1 M EDTA in 0.1 M NH4Ac, pH 
5.5 (Rf 111In-labeled exendin = 0, Rf 111In-EDTA = 1) and 0.25 M NH4Ac, pH 
5.5:methanol (1:1) (Rf colloidal residues = 0, Rf 111In-labeled [Lys40(DTPA)]exendin 
= 0.2-0.8: and Rf 111In-EDTA = 1). 
 
Cell culture  
The rat insulinoma cell line INS-1 (23) was maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 mM HEPES, 50 
µM β-mercaptoethanol, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 
µg/ml streptomycin, in a humidified 5% CO2 atmosphere at 37 °C. The cells were 
harvested by trypsinization with trypsin/EDTA. 
 
Receptor binding assays 
The 50% inhibitory concentration (IC50) was determined for [Lys40(natIn-
DTPA)]exendin-3, [Lys40(natIn-DTPA)]exendin-4 and [Lys40(natIn-DTPA)]exendin(9-
39) using suspensions of INS-1 cells. [Lys40(DTPA)]exendin-3 and 
[Lys40(DTPA)]exendin-4 were labeled with natIn by adding 21 µl natInCl3 (0.5 mM in 
0.02 M HCl) to 105 µl 0.1 M MES buffer, pH 5.5 containing 10 µg peptide, 
representing equimolar conditions. [Lys40(DTPA)]exendin(9-39) was labeled by 
adding 25 µl natInCl3 (0.5 mM in 0.02 M HCl) to 125 µl 0.1 M MES buffer, pH 5.5 
containing 10 µg peptide. The reaction mixtures were incubated at room 
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temperature for 20 min and 64 µl 1% Tween80 in PBS was added. Serial dilutions 
of [Lys40(natIn-DTPA)]exendin-3, [Lys40(natIn-DTPA)]exendin-4 and [Lys40(natIn-
DTPA)]exendin(9-39) were prepared in binding buffer (RPMI 1640 medium 
containing 1% BSA). INS-1 cells were resuspended in binding buffer to a 
concentration of 3 million cells/0.5 ml. After 10 min incubation on ice, [Lys40(natIn-
DTPA)]exendin-3, [Lys40(natIn-DTPA)]exendin-4 and [Lys40(natIn-DTPA)]exendin(9-
39) were added at final concentrations ranging from 0.10-350 nM along with 
radiolabeled [Lys40(111In-DTPA)]exendin-3 (1,000 Bq). To prevent internalization, 
cells were incubated on ice for 4 h. The cell suspension was centrifuged at 3,000 g 
for 5 min and the supernatant was discarded. The cell pellet was washed with 500 
µl ice-cold PBS, centrifuged at 3,000 g for 5 min and the supernatant was 
discarded. The radioactivity in the cell pellet was determined in a gamma counter 
(Wizard, Wallac-Oy, Uppsala, Sweden) and the bound fraction was determined.  
Saturation binding assays were performed for [Lys40(111In-DTPA)]exendin-3, 
[Lys40(111In-DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39) in suspensions 
of INS-1 cells. Serial dilutions of the radiolabeled peptides, ranging from 0.1-125 
nM, were added to 7 x 106 INS-1 cells in 600 µl binding buffer. The cells were 
incubated on ice, to prevent internalization, for 4 h. After incubation the cells were 
centrifuged at 3,000 g for 5 min, the supernatant was discarded and the cells were 
washed with 500 µl ice-cold PBS. The radioactivity in the cell pellet was 
determined in a  counter. The bound fraction (in receptors/cell) was plotted against 
the tracer concentration added. In the scatchard plot the bound/free was plotted 
against the bound fraction and the dissociation constant (Kd) and the maximum 
number of binding sites was calculated by nonlinear regression using GraphPad 
Prism (version 4). 
 
Internalization assay 
The kinetics of internalization of [Lys40(111In-DTPA)]exendin-3, [Lys40(111In-
DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39) were determined using 
suspensions of INS-1 cells as described above. Approximately 1,000 Bq of 111In-
labeled peptide (55 fmol) was added and incubated for 0.5, 1, 2 or 4 h at 37 ºC. 
After incubation, the cells were centrifuged and the supernatant was discarded. 
The cells were washed twice with 0.5 ml ice-cold PBS and subsequently 0.5 ml 
acid buffer (0.1 M acetic acid, 154 mM NaCl, pH 2.5) was added. After 10 min 
incubation at 4 ºC, cells were spun down and the pellet was washed twice with ice-
cold PBS. The radioactivity associated with the cell pellet (internalized fraction) and 
the supernatants (receptor-bound fraction) was determined. 
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Biodistribution studies 
Animal experiments were performed after approval of the local ethical committee 
(RUDEC) for animal experiments (RUDEC). Six to eight weeks old female BALB/c 
nude mice were injected subcutaneously with 0.2 ml of a 1 x 107 cells/ml 
suspension of INS-1 cells. When the tumors were 2-5 mm in diameter, mice were 
randomly divided in groups of 5 mice. Mice were intravenously injected with 370 
kBq (peptide dose: 20 pmol) of 111In-labeled [Lys40(DTPA)]exendin-3, 
[Lys40(DTPA)]exendin-4 or [Lys40(DTPA)]exendin(9-39) via a tail vein. At various 
time points (0.5, 1, 2 and 4 hours) after injection, mice were euthanized by CO2 
suffocation and blood, tumor and relevant tissues (muscle, heart, lung, spleen, 
pancreas, kidney, liver, stomach and duodenum) were dissected, weighed and 
counted in a gamma counter. The percentage injected dose per gram tissue 
(%ID/g) was determined for each tissue. To determine whether the exendin uptake 
is GLP-1 receptor-mediated, a 100-fold excess (2 nmol) of unlabeled 
[Lys40]exendin-3 was co-injected in a separate group of mice (n=5). 
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Results 
 
Radiolabeling 
All peptides could be labeled with 111In with a specific activity of up to 700 
GBq/μmol. Radiochemical purity was >99% as determined by HPLC and ITLC. 
111In-EDTA eluted from the column after 3 min whereas 111In-labeled 
[Lys40(DTPA)]exendin-3, [Lys40(DTPA)]exendin-4 and [Lys40(DTPA)]exendin(9-39) 
had a retention time of ~13 min. 
 
Receptor binding assays 
The results of the IC50 determination are shown in Figure 1 and Table 2. The IC50 
of natIn-labeled [Lys40(DTPA)]exendin-3, [Lys40(DTPA)]exendin-4 and 
[Lys40(DTPA)]exendin(9-39) were 13.5 nM, 13.4 nM and 14.4 nM, respectively.  
The results of the saturation binding assay are summarized in Figure 2 and Table 
2. [Lys40(111In-DTPA)]exendin-3 bound 26,000 receptors/cell, [Lys40(111In-
DTPA)]exendin-4 bound 41,000 receptors/cell and [Lys40(111In-DTPA)]exendin(9-
39) bound 37,000 receptors/cell. The Kd for [Lys40(111In-DTPA)]exendin-3, 
[Lys40(111In-DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39) was 8.7 nM, 
17.6 nM and 15.1 nM, respectively. 
The large standard deviation for the Kd and Bmax for [Lys40(111In-DTPA)]exendin(9-
39) is due to the lower in vitro binding of this tracer, resulting in a low signal in this 
assay. This finding is in line with the results reported by Waser et al., which also 
showed lower in vitro binding of exendin(9-39) (24). 
 
Internalization assay 
The internalization kinetics of [Lys40(111In-DTPA)]exendin-3, [Lys40(111In-
DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39) are shown in Figure 3. 
After 0.5 hour 1.1 ± 0.1 fmol [Lys40(111In-DTPA)]exendin-3 was bound to the 
receptor and 1.1 ± 0.2 fmol was internalized, increasing to 3.3 ± 0.2 fmol cell bound 
and 1.6 ± 0.1 fmol internalized after 4 hours. The binding kinetics of [Lys40(111In-
DTPA)]exendin-4 were similar to that of [Lys40(111In-DTPA)]exendin-3, with 
maximum binding and internalization after 4 hours: 4.2 ± 0.2 fmol and 2.1 ± 0.2 
fmol, respectively. Membrane bound [Lys40(111In-DTPA)]exendin(9-39) after 0.5 h 
was 0.9 ± 0.3 fmol and decreased to 0.4 ±0.1 fmol after 4 h. Minimal internalization 
of [Lys40(111In-DTPA)]exendin(9-39) was observed 
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Figure 1: Competition binding assay (IC50) of [Lys40(natIn-DTPA)]exendin-3, [Lys40(natIn-
DTPA)]exendin-4 and [Lys40(natIn-DTPA)]exendin(9-39). [Lys40(111In-DTPA)]exendin-3 was 
used as tracer.  
 
 
Figure 2: Saturation binding assay and Scatchard plot (insert) of [Lys40(111In-
DTPA)]exendin-3, [Lys40(111In-DTPA)]exendin-4 and [Lys40(111In-DTPA)]exendin(9-39). 
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Compound IC50 (nM) Kd (nM) 
Bmax
(receptors/cell) 
[Lys40(DTPA)]exendin-3 
13.5 
(9.9 – 18.5) 
8.7 
(7.6 – 10.1) 
26,000 
(24 x 103 – 29 x 103) 
[Lys40(DTPA)]exendin-4 
13.4 
(10.5 – 17.0) 
17.6 
(14.2 – 23.3) 
41,000 
(35 x 103 – 50 x 103) 
[Lys40(DTPA)]exendin(9-39) 
14.4 
(4.8 – 43.2) 
15.1 
(6.9 – 80.7) 
37,000 
(13 x 103 – 60 x 103) 
Table 2: IC50 values (with the 95% confidence interval in parenthesis) of [Lys40(natIn-DTPA)]exendin-3, 
[Lys40(natIn-DTPA)]exendin-4 and [Lys40(natIn-DTPA)]exendin(9-39) determined in a competition binding 
assay in INS-1 cells. The dissociation constant (Kd) and the Bmax (with the 95% confidence interval in 
parenthesis) of [Lys40(111In-DTPA)]exendin-3, [Lys40(111In-DTPA)]exendin-4 and [Lys40(111In-
DTPA)]exendin(9-39) determined by a binding saturation experiment in INS-1 cells. 
 
Figure 3: Internalization kinetics of [Lys40(111In-DTPA)]exendin-3, [Lys40(111In-DTPA)]exendin-4 and 
[Lys40(111In-DTPA)]exendin(9-39). Specifically internalized (solid bars) and specifically cell surface 
bound (hatched bars) tracer are expressed in fmol. 
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Biodistribution studies 
The results of the biodistribution studies are summarized in Figure 4. [Lys40(111In-
DTPA)]exendin-3 showed high uptake in the tumor as soon as 30 min after 
injection (25.0 ± 6.0 %ID/g) and a similar uptake was observed up to 4 h p.i. (26.5 
± 8.9 %ID/g). There was no significant difference in tumor uptake between any time 
points. Co-administration of an excess unlabeled exendin resulted in much lower 
uptake: 2.4 ± 0.5 %ID/g, indicating that the uptake was GLP-1R-mediated. Specific 
uptake of [Lys40(111In-DTPA)]exendin-3 was also seen in pancreas, lung and 
stomach. [Lys40(111In-DTPA)]exendin-4 showed a higher tumor uptake : 30.7 ± 6.1 
%ID/g at 0.5 h p.i. increasing to 41.9 ± 7.2 %ID/g at 4 h p.i. and was statistically 
higher than tumor uptake of [Lys40(111In-DTPA)]exendin-3 at 1 and 4 h p.i. (p = 0.04 
and 0.02, respectively). There was no significant difference in pancreas, stomach 
and lung uptake between [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-
DTPA)]exendin-4.  
In contrast, [Lys40(111In-DTPA)]exendin(9-39) showed much lower uptake in the 
tumor at 0.5 h p.i.: 3.2 ± 0.7 %ID/g and there was a rapid wash-out of [Lys40(111In-
DTPA)]exendin(9-39) from the tumor. The same phenomenon was found in all 
GLP-1R positive organs (pancreas, lung, stomach and duodenum). 
Renal uptake was significantly higher with [Lys40(111In-DTPA)]exendin-3 and 
[Lys40(111In-DTPA)]exendin-4 compared to renal uptake of [Lys40(111In-
DTPA)]exendin(9-39) (p=0.0003 and p=0.0002 respectively). 
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Figure 4: Biodistribution study of [Lys40(111In-DTPA)]exendin-3 (A), 
[Lys40(111In-DTPA)]exendin-4 (B) and [Lys40(111In-DTPA)]exendin(9-39) 
(C) in BALB/c nude mice bearing a subcutaneous INS-1 tumor. Values 
are expressed as percentage injected dose per gram tissue (%ID/g). 
Blocking was performed by co-injection of a 100-fold molar excess of 
unlabeled [Lys40]exendin-3. Mice were dissected 4 hours after injection. 
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Discussion 
 
In this study, the tumor targeting characteristics of the GLP-1 receptor (GLP-1R) 
antagonist exendin(9-39) and the agonists exendin-3 and exendin-4 were 
evaluated in vitro and in vivo. We found that [Lys40(natIn-DTPA)]exendin(9-39) had 
a similar affinity for the GLP-1R as the agonists [Lys40(natIn-DTPA)]exendin-3 and 
[Lys40(natIn-DTPA)]exendin-4, as determined in the IC50 assay. [Lys40(111In-
DTPA)]exendin(9-39) bound to a similar number of receptors per cell in vitro as 
compared to the 111In-labeled agonists. The results of the IC50 determination and 
the Scatchard analysis of exendin-3 were paradoxal: the IC50 of exendin-3 (13.5 
nM) was significantly higher than the Kd as derived from the Scatchard analysis 
(8.7 nM). This could be due to the fact that in the Scatchard analysis 111In-labeled 
exendin-3 was used, while in the IC50 nonradioactive exendin-3 was used. 
Despite the high affinity, [Lys40(111In-DTPA)]exendin(9-39) showed lower in vitro 
binding compared to the agonists and minimal internalization as compared to the 
agonists. The biodistribution study showed high uptake of the agonists in the tumor 
and in GLP-1R positive organs (pancreas, lung and stomach). In contrast, 
[Lys40(111In-DTPA)]exendin(9-39) showed much lower uptake in GLP-1R 
expressing tissues at 0.5 h p.i. and the uptake rapidly decreased at later time 
points. These results suggest that internalization is a prerequisite for specific 
accumulation of the ligand in GLP-1R expressing tissues in vitro and in vivo. 
Previous studies showed tumor targeting of antagonists compared to agonists, that 
could be explained by the fact that the antagonists bound to more receptors than 
the agonists (9, 12, 25, 26). In our study there was no significant difference 
between the number of receptors bound by [Lys40(111In-DTPA)]exendin(9-39) and 
agonists [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-DTPA)]exendin-4. 
Our study showed that [Lys40(111In-DTPA)]exendin(9-39) is not suitable for the 
targeting of the GLP-1R in vivo. A recent study evaluated the potency of 125I-
exendin(9-39) for pancreatic beta cell imaging and showed high uptake in the 
pancreas (approximately 20% ID/g) of ddY mice (27). A difference between the two 
studies is the peptide dose injected. We have previously shown that the optimal 
peptide dose for the GLP-1R agonist [Lys40(111In-DTPA)]exendin-3 in BALB/c nude 
mice with a subcutaneous tumor model is < 0.1µg (28). The peptide dose of 125I-
exendin(9-39) was 60-fold lower than the peptide dose in our study (0.0017 µg vs. 
0.1 µg), which might explain the enhanced pancreatic uptake of 125I-exendin(9-39). 
A straight comparison between the two tracers is needed to clarify the cause of the 
paradoxal results in the two studies. Although high pancreatic uptake was 
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observed of 125I-exendin(9-39), the feasibility for beta-cell imaging remains to be 
determined, because for imaging purposes higher activity doses and thus higher 
peptide doses will be required. 
By in vitro autoradiography Waser et al. found that 125I-exendin(9-39) had a high 
affinity for the GLP-1R in murine pancreatic tissue (2.6 ± 0.4 nM), whereas the 
affinity for the human GLP-1R is much lower (63 ± 47 nM) (29). It should be noted 
that this study does not provide data to show that GLP-1R antagonists are superior 
or inferior to GLP-1R agonists. 
Our biodistribution study showed high uptake for all peptides in the kidney, which 
was not GLP-1R-mediated. The renal uptake of the radiolabeled tracer is caused 
by tubular reabsorbtion after glomerular filtration. The renal uptake of [Lys40(111In-
DTPA)]exendin(9-39) was significantly lower than that of [Lys40(111In-
DTPA)]exendin-3 and [Lys40(111In-DTPA)]exendin-4, indicating that the 8 N-terminal 
amino acid sequence caused more efficient tubular reabsorption. Another 
explanation might be a different uptake mechanism of [Lys40(111In-
DTPA)]exendin(9-39) and [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-
DTPA)]exendin-4 in the proximal tubules of the kidney.  
In conclusion, the GLP-1R agonists exendin-3 and exendin-4 show high receptor 
affinity and efficient in vitro binding and internalization kinetics. [Lys40(111In-
DTPA)]exendin-3 and [Lys40(111In-DTPA)]exendin-4 accumulated efficiently in INS-
1 tumors and GLP-1R positive organs and could therefore be useful for detection 
and therapy of insulinomas. [Lys40(DTPA)]exendin(9-39) exhibited high affinity for 
the GLP-1R, but did not show internalization and low uptake in INS-1 tumors and 
GLP-1R positive organs and therefore is not suited for targeting the GLP-1R in 
vivo. This study indicates that internalization is crucial for efficient accumulation 
and retention in GLP-1R positive tissues.  
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Abstract 
 
Background 
In comparison to somatostatin receptor scintigraphy, gastrin receptor scintigraphy 
using 111In-DTPA-Minigastrin (MG0) showed added value in diagnosing 
neuroendocrine tumors. We investigated whether the 68Ga-labeled gastrin 
analogue DOTA-MG0 is suited for positron emission tomography (PET) which 
could improve image quality. 
Methods 
Targeting of CCK2/gastrin receptor positive tumor cells with DOTA-MG0 labeled 
with either 111In or 68Ga in vitro was investigated using the AR42J rat tumor cell 
line. Biodistribution was examined in BALB/c nude mice with a subcutaneous 
AR42J tumor. In vivo PET imaging was performed using a preclinical PET/CT 
scanner. 
Results 
DOTA-MG0 showed high receptor affinity in vitro. Biodistribution studies revealed 
high tumor uptake of 68Ga-DOTA-MG0: 4.4 ± 1.3 %ID/g at 1 h p.i. Co-
administration of an excess unlabeled peptide blocked the tumor uptake (0.7 ± 0.1 
%ID/g), indicating CCK2/gastrin receptor mediated uptake (p=0.0005).The 
biodistribution of 68Ga-DOTA-MG0 was similar to that of 111In-DOTA-MG0. 
Subcutaneous and intraperitoneal tumors were clearly visualized by small animal 
PET imaging with 5 MBq 68Ga-DOTA-MG0. 
 
Conclusion 
111In and 68Ga-labeled DOTA-MG0 specifically accumulate in CCK2/gastrin receptor 
positive AR42J tumors with similar biodistribution apart from the kidneys. AR42J 
tumors were clearly visualized by microPET. Therefore, 68Ga-DOTA-MG0 is a 
promising tracer for PET imaging of CCK2/gastrin receptor positive tumors in 
humans. 
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Introduction 
 
Somatostatin receptor scintigraphy (SRS) is the standard procedure for the 
detection of neuroendocrine tumors (NET) and their metastases.(1, 2) The method 
is based on the specific binding of radiopeptides to mainly the somatostatin 
subtype 2 receptor (sstr2) that is overexpressed on these tumors.(3) However, for 
some tumor types the sensitivity of SRS is limited. For example, the detection rate 
of medullary thyroid carcinoma (MTC) with SRS is only 40%.(4) However, a tumor 
detection rate of 94% was observed with gastrin receptor scintigraphy with 111In-
DGlu1-minigastrin in patients with MTC and when gastrin receptor scintigraphy was 
combined with CT even 97% of the known tumor sites were detected.(4) Gotthardt 
et al. showed that gastrin receptor scintigraphy also had added value in patients 
with gastroenteropancreatic neuroendocrine tumors (GEP-NET), especially when 
no or low uptake of 111In-labeled octreotide was observed.(5) The principle of 
gastrin receptor scintigraphy is based on binding of radiolabeled minigastrin to the 
cholecystokinin-2 (CCK2)/gastrin receptor which is expressed on the majority of 
NET and MTC.(6) 
PET imaging is advantageous over conventional scintigraphy and SPECT, 
because of its excellent sensitivity in combination with its improved spatial 
resolution. A recent study in patients with NET showed that PET imaging with the 
somatostatin analog 68Ga-DOTA-TOC had a higher detection rate compared to 
conventional somatostatin receptor scintigraphy.(7) Based on these findings it 
might be possible to further improve image quality and sensitivity of gastrin 
receptor scintigraphy by radiolabeling of MG0 with 68Ga for PET imaging. Because 
68Ga is a generator-produced positron emitter, it is readily available - also in 
centers without a cyclotron - and relatively cheap. 
In this study we investigated the potential of 68Ga-labeled DOTA-DGlu-(Glu)5-
Minigastrin (DOTA-MG0) for detection of CCK2/gastrin receptor positive tumors in 
vitro using CCK2/gastrin receptor-positive AR42J cells and in vivo in a BALB/c 
nude mouse model with subcutaneous or intraperitoneal AR42J tumors. 111In-
DOTA-MG0 was used as a reference in this study. 
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Materials and Methods 
 
Peptides and radionuclides 
DOTA-Minigastrin (DOTA-MG0) was obtained from Peptide Specialty Laboratories 
(PSL GmbH, Heidelberg, Germany). The gastrin analogue DOTA-(His)2-
Minigastrin(8) was obtained from PiChem (piCHEM GmbH, Graz, Austria). The 
amino acid sequences of DOTA-MG0 and DOTA-(His)2-Minigastrin are depicted in 
Table 1. 111InCl3 was obtained from Covidien (Petten, The Netherlands). 68GaCl3 
was eluted from a TiO2-based 1,110 MBq 68Ge/68Ga generator (Obninsk, Russia) 
with 5 ml 0.1 N Ultrapure HCl (J.T. Baker, Deventer, The Netherlands). The 
68GaCl3 was collected in 5 fractions of 1 ml, the second fraction containing the 
majority of 68GaCl3 was used for radiolabeling. 
 
Peptide Amino acid sequence Molecular weight 
DOTA-Minigastrin 
(DOTA-MG0) 
DOTA-Dglu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2112.5 Da 
DOTA-(His)2-Minigastrin DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 1677.8 Da 
Table 1: Structure of DOTA-Minigastrin and DOTA-(His)2-Minigastrin. DOTA = 1,4,7,10-tetraacetic acid. 
 
Radiolabeling of DOTA-MG0 with 111In 
DOTA-MG0 was dissolved in 0.25 M ammonium acetate buffer, pH 5.5 and 11 
MBq 111InCl3 was added to 1 µg (0.5 nmol) peptide and 5 volumes of 0.25 M 
ammonium acetate buffer, pH 5.5, was added containing 35 mM DL-methionine 
(Sigma Chemicals, St. Louis, MO, USA) to prevent oxidation of the methionine 
residue. After 30 min incubation at 95 ⁰C, 10 mM EDTA was added to a final 
concentration of 1 mM. Quality control was performed using reversed-phase high 
performance liquid chromatography (RP-HPLC) with a C18 reversed-phase column 
(Zorbax Rx-C18; 4.6 x 250 mm; Agilent Technologies). The column was eluted with 
0.1% trifluoroacetic acid (TFA) (Lab-scan, Analytical sciences, Brussels, Belgium) 
in H2O with a linear gradient to 100% acetonitril containing 0.1% TFA over 10 
minutes with a flow of 1 ml/min. ITLC was performed on silica gel ITLC (ITLC-SG, 
Pall Corporation Life Sciences, New York, NY, USA). Two mobile phases were 
used: 0.1 M EDTA in 0.1 M NH4Ac, pH 5.5 (Rf 111In-DOTA-MG0 = 0, Rf 111In-EDTA 
= 1) and 0.25 M NH4Ac, pH 5.5:methanol (1:1) (Rf colloidal compounds = 0, Rf 
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111In-DOTA-MG0 ≥ 0.2 and Rf 111In-EDTA = 1). 111In-DOTA-MG0 was used for in 
vitro and in vivo experiments without further purification. 
 
Radiolabeling of DOTA-MG0 with 68Ga 
Radiolabeling of DOTA-MG0 was performed in 2.5 M HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) buffer (Sigma Chemicals, St. Louis, MO, USA). 
68GaCl3 (300 MBq in 1 ml) was added to 120 µl HEPES buffer containing 13 µg 
(6.2 nmol) DOTA-MG0. The final pH of the reaction mixture was 3.0. After 
incubation at 95 ⁰C for 20 min 10 mM EDTA was added to a final concentration of 
1 mM. The reaction mixture was purified by RP-HPLC as described above, except 
ethanol was used instead of acetonitril containing 0.1% TFA. The peak containing 
68Ga-DOTA-MG0 (including the oxidized fraction) was collected and diluted with 
PBS containing 0.5% w/v bovine serum albumin (BSA) to a final ethanol 
concentration of less than 5% before injection into mice (injection volume: 0.2 ml). 
The unincorporated 68Ga and the 68Ga-colloid content in the purified 68Ga-labeled 
DOTA-MG0 preparations were determined using ITLC as described above. 
 
Cell culture 
The AR42J rat pancreatic tumor cell line (9, 10) was used in these studies. Cells 
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L D-
glucose (Gibco, Invitrogen, Breda, The Netherlands) supplemented with 10% fetal 
calf serum and 1% penicillin/streptomycin in a humidified 5% CO2 atmosphere at 
37 ⁰C. The cells were harvested by trypsinization with trypsin/EDTA. 
 
IC50 determination 
The apparent 50% inhibitory concentration (IC50) of DOTA-MG0, natIn-DOTA-MG0 
and natGa-DOTA-MG0 was determined using AR42J cells grown in 6-well plates 
(approximately 106 cells/well). 
DOTA-MG0 was labeled with natIn by adding 23.7 nmol InCl3 (Merck, Darmstadt, 
Germany) in 26.2 µl 0.02 M HCl to 73.8 µl 0.25 M ammonium acetate pH 5.5 
containing 4.7 nmol DOTA-MG0. The labeling mixture was incubated at 95 ⁰C for 
30 min. Labeling with natGa was carried out by adding 23.7 nmol Ga(NO3)3 (Sigma 
Chemicals, St. Louis, MO, USA) in 6 µl 0.02 M HCl to 44 µl 0.25 M ammonium 
acetate pH 5.5 containing 4.7 nmol DOTA-MG0. The reaction mixture was 
incubated overnight at room temperature. 
The cells were washed twice with PBS and incubated with 2 ml binding buffer 
(DMEM with 4.5 g/L D-glucose with 0.5% w/v BSA) at 37 ⁰C for 60 min. 111In-
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labeled DOTA-MG0 (60,000 dpm, 5-10 pmol in 100 µl binding buffer ) was added 
to the cells after addition of various amounts of unlabeled peptide ranging from 0.1 
to 300 nM. After incubation at room temperature for 2 h the medium was removed 
and the cells were washed twice with PBS. The cells were harvested with a cotton 
swab and the radioactivity associated with the cells was measured in a well-type 
gamma-counter (Wallac 1480-Wizard, Perkin-Elmer, Boston, MA, USA). Under 
these conditions internalization may occur. We therefore describe the results of this 
competitive binding assay as “apparent IC50” values rather than IC50. 
 
Peptide dose escalation study 
Six to eight week old male BALB/c nude mice (Taconic, Hudson, NY, USA) were 
injected subcutaneously in the right flank with 1 x 107 AR42J cells. When the tumor 
had a diameter of 2-5 mm, mice were randomly divided in groups of 5 mice each. 
To determine the optimal peptide dose of DOTA-MG0 for targeting AR42J tumors 
in this model, mice were injected intravenously with 370 kBq 111In-DOTA-MG0 and 
were co-injected with escalating amounts of unlabeled DOTA-MG0, resulting in 
final peptide doses ranging from 0.1 to 100 µg/mouse. One hour after injection the 
mice were euthanized, tumor and relevant tissues were dissected, weighed and the 
radioactivity was measured in a gamma-counter. 
 
Biodistribution studies of 68Ga-DOTA-MG0 and 111In-DOTA-MG0 
BALB/c nude mice with a subcutaneous AR42J tumor were injected intravenously 
with 370 kBq (0.25 µg) 68Ga-labeled DOTA-MG0 or 185 kBq (0.25 µg) 111In-labeled 
DOTA-MG0. A separate group of 3 mice was co-injected with an excess (25 µg) 
unlabeled DOTA-(His)2-Minigastrin (a CCK2/gastrin receptor ligand that was 
available in relatively high amounts) to determine receptor-mediated uptake. The 
mice were euthanized 1 h after injection by CO2/O2 suffocation. Tumor and relevant 
tissues were dissected, weighed and counted in a gamma-counter. The injected 
dose per gram (%ID/g) was determined for each tissue. 
 
PET/CT imaging of mice with subcutaneous tumors 
PET images were acquired of BALB/c nude mice with a subcutaneous AR42J 
tumor on the shoulder using a small-animal PET/CT scanner (Inveon™; Preclinical 
Solutions, Siemens Medical Solutions USA, Inc., Knoxville, TN, USA). The scanner 
has an axial field of view of 12.7 cm and a 1.4 mm FWHM spatial resolution in 
images reconstructed using Fourier rebinning and filtered back projection.(11) 
When the tumor had a diameter of 2-5 mm, the mice were injected intravenously 
with 5 MBq (1 µg) 68Ga-DOTA-MG0. Mice were euthanized by CO2/O2 suffocation 
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and PET images were acquired during 30 min and images were reconstructed by 
OSEM3D/MAP reconstruction with the following parameters: 256 x 256 matrix, 2 
OSEM3D iterations, 18 MAP iterations and a resolution of 0.075 mm uniform 
variance. CT images were acquired for anatomical correlation directly after PET 
imaging (spatial resolution 113 µm, 80 kV, 500 µA, exposure time 300 msec). 
 
PET imaging of mice with intraperitoneal tumors 
Intraperitoneal tumors were induced by intraperitoneal injection of 1 x 106 AR42J 
cells (injection volume 50 µl) under isoflurane inhalation anesthesia. PET scans 
were acquired weekly, after injection of 5 MBq 68Ga-DOTA-MG0 (peptide dose 1 
µg) starting two weeks after injection of the cells. PET/CT images were acquired as 
described above. For CT contrast, mice were injected intraperitoneally with 250 µl 
non-ionic contrast medium (Optiray 300, Covidien, Petten, The Netherlands). When 
tumors were clearly visible on PET scans, mice were euthanized by CO2/O2 
suffocation and the abdomen was examined macroscopically for tumor growth. 
Tumor and relevant tissues were dissected, weighed and counted in a gamma-
counter. The injected dose per gram (%ID/g) was determined for each tissue. 
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Results 
 
Radiolabeling 
Radiolabeling of DOTA-MG0 with 68Ga resulted in a specific activity up to 30 
GBq/µmol with a radiochemical purity >99% after HPLC purification. Before HPLC 
purification the fraction of unincorporated of 68Ga was <5% and the labeling mixture 
contained approximately 3% 68Ga-colloid, as determined by ITLC. The fraction 
oxidized 68Ga-DOTA-MG0 was always less than 2% as determined by HPLC. 
Unbound 68Ga had a retention time of 3 min, whereas the oxidized peptide and 
radiolabeled native peptide had a retention time of 13.2 and 13.5 min, respectively 
(Figure 1). 
For 111In-DOTA-MG0, specific activities up to 45 GBq/µmol were obtained with a 
radiochemical purity >95%. The fraction of oxidized 111In-DOTA-MG0 was always 
less than 2% as determined by HPLC. 
 
 
Figure 1: HPLC profile of 68Ga-DOTA-MG0, the first peak 
represents the unbound 68Ga, the second peak represents 
radiolabeled oxidized peptide (retention time 13.2 min) and the third 
peak the radiolabeled peptide (retention time 13.5 min). 
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IC50 determination 
Results of the IC50 determination are summarized in Figure 2. The apparent IC50 of 
DOTA-MG0, natIn-DOTA-MG0 and natGa-DOTA-MG0 of CCK2/gastrin receptor on 
AR42J cells was 2.4 nM (95% confidence interval: 1.6 to 3.4), 3.2 nM (95% 
confidence interval: 2.6 to 3.9) and 1.8 nM (95% confidence interval: 1.7 to 2.0), 
respectively.  
 
Figure 2: Competition binding assay (IC50) of DOTA-MG0, natIn-DOTA-MG0 and 
natGa-DOTA-MG0 in AR42J cells. 111In-DOTA-MG0 was used as a tracer
 
Peptide dose escalation study 
The effect of the peptide dose on tumor targeting was studied in BALB/c nude mice 
with s.c. AR42J tumors. The results are summarized in Figure 3. The MG0 peptide 
dose had a pronounced effect on uptake in the AR42J tumor: uptake decreased at 
higher peptide doses. Highest tumor uptake of DOTA-MG0 was observed when 0.1 
µg peptide was administered: 7.0 ± 0.6 %ID/g at 1 h p.i.. Administration of 0.3 µg 
DOTA-MG0 resulted in a significantly reduced tumor uptake: 4.7 ± 0.8 %ID/g 
(p<0.001). At the 1 µg peptide dose there is still specific uptake of MG0 in the 
tumor (4.2 ± 0.5 %ID/g), while non-specific uptake was as low as 0.23 ± 0.01 
%ID/g. Besides tumor uptake, high kidney uptake of 111In-DOTA-MG0 was 
observed. This kidney uptake decreased at higher doses of DOTA-MG0. 
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Figure 3: Peptide dose escalation study of 111In-DOTA-MG0 in BALB/c nude mice with s.c. AR42J 
tumors. Mice were injected intravenously with 370 kBq 111In-DOTA-MG0 and were co-injected with 
various amounts of unlabeled DOTA-MG0 resulting in final peptide doses ranging from 0.1 to 100.0 
µg. Values are expressed as percentage injected dose per gram tissue (n=5 mice). Mice were 
dissected 1 hour after injection. 
 
Biodistribution of 68Ga-DOTA-MG0 and 111In-DOTA-MG0 
The biodistribution of 68Ga-DOTA-MG0 and 111In-DOTA-MG0 in BALB/c nude mice 
with s.c. AR42J tumors is summarized in Figure 4. High tumor uptake of 68Ga-
DOTA-MG0 was observed 1 h p.i. (4.4 ± 1.3 ID/g). Co-administration of an excess 
of unlabeled peptide (DOTA-(His)2-Minigastrin) blocked the tumor uptake (0.7 ± 0.1 
%ID/g, p=0.0005), indicating CCK2/gastrin-mediated tumor uptake. Specific uptake 
was also observed in the stomach (p<0.0001). High uptake was observed in the 
kidneys for both 111In and 68Ga-labeled DOTA-MG0, which could not be blocked by 
an excess unlabeled DOTA-(His)2-Minigastrin. 
The biodistribution of 111In-DOTA-MG0 in BALB/c nude mice with a s.c. AR42J 
tumor was highly similar to that of 68Ga-DOTA-MG0, although kidney retention was 
two times higher for 68Ga-labeled MG0 (Fig. 4). The explanation for this remarkable 
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finding is unknown. There was no significant difference in uptake in the tumor or 
relevant organs between 68Ga-labeled and 111In-labeled DOTA-MG0. 
RP-HPLC purification of 68Ga-DOTA-MG0 was necessary because elevated uptake 
in liver and spleen was observed (1.1 ± 0.4 and 2.9 ± 0.3 %ID/g, respectively) 
when unpurified 68Ga-DOTA-MG0, containing minor amounts of 68Ga-colloid, was 
injected. 
 
 
Figure 4: Biodistribution of 111In-DOTA-MG0 and 68Ga-DOTA-MG0 in BALB/c nude mice with 
subcutaneous AR42J tumors. Values are expressed as percentage injected dose per gram tissue 
(n=5 mice). Blocking was performed by co-injection of a 100-fold excess of unlabeled DOTA-
(His)2-Minigastrin (n=3). Mice were dissected 1 h after injection. 
 
PET imaging of subcutaneous tumors 
Subcutaneous AR42J tumors, with a diameter of approximately 5 mm, were clearly 
visualized on PET images as early as 1 h after intravenous injection of 68Ga-DOTA-
MG0 (Figure 5). Besides tumor uptake, pronounced uptake was also seen in the 
kidneys. The PET images were fused with CT for anatomical correlation. 
 
PET imaging of intraperitoneal tumors 
Intraperitoneal tumor growth was observed on the PET images 28-35 days after 
tumor cell inoculation. The weight of the visualized lesions ranged from 0.044 to 
0.499 gram (median weight: 0.057 gram). The tumor of 0.044 gram (approximately 
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1 mm in diameter) was clearly visible (Figure 6A-C). A larger tumor (0.45 gram, 
approximately 10 mm in diameter) adjacent to the left kidney was visualized 
despite of the high kidney uptake (Figure 6D-F). In one mouse an abscess 
adjacent to the tumor was observed macroscopically and by CT. There was no 
uptake of 68Ga-DOTA-MG0 in the abscess and the tumor adjacent to the abscess 
was clearly visualized (Figure 6G-I). 
 
 
Figure 5: Ventral (A) and lateral (B) view of 
a maximum intensity projection (MIP) of a 
BALB/c nude mouse with a subcutaneous 
AR42J tumor,1 h after injection of 68Ga-
DOTA-MG0. Tumor (arrow) and kidneys (K) 
are clearly visible. The PET image was 
fused with CT for anatomical correlation. 
 
Figure 6: Coronal slices of PET images (B, 
E, H) of 3 mice with intraperitoneal tumors 
after injection with 68Ga-DOTA-MG0. PET 
images were acquired 1 h pi. CT images (A, 
D, G) were acquired (after i.p. injection of 
optiray 300) and fused with the PET images 
(C, F, I) for anatomical correlation. Tumors 
are clearly visible (white arrow), also the 
kidneys (K) exhibit high uptake of 68Ga-
DOTA-MG0. The abscess (green arrow) 
present in the abdomen of one mouse (G-I) 
showed no uptake of 68Ga-labeled MG0. 
Images were acquired 28-35 days after 
tumor inoculation. 
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Discussion 
 
Gastrin receptor scintigraphy was shown to have an excellent detection rate in 
patients with medullary thyroid carcinoma (MTC).(4) Moreover, gastrin receptor 
scintigraphy had an additional value in patients with gastroenteropancreatic 
neuroendocrine tumors (GEP-NET) and additional lesions were detected with 
gastrin receptor scintigraphy when no or low uptake was observed with 
somatostatin receptor scintigraphy (SRS).(5) Due to its excellent sensitivity and 
higher resolution PET is advantageous over conventional scintigraphy and SPECT. 
It was previously shown that PET imaging with 68Ga-DOTA-TOC is a very sensitive 
method for the detection of NET.(7) Since the sensitivity and spatial resolution of 
PET is higher as compared to SPECT, it is expected that PET imaging with 68Ga-
labeled DOTA-MG0 could improve the detection rate of NET and MTC. In patients 
with MTC 68Ga-DOTA-MG0 PET might be the first choice over 68Ga-DOTA-TOC 
PET whereas in patients with NET 68Ga-DOTA-MG0 PET could have added value 
when 68Ga-DOTA-TOC PET is equivocal or negative. In this study, 68Ga-DOTA-
MG0 for detection of CCK2/gastrin-positive tumors with PET was evaluated in 
comparison to 111In-DOTA-MG0. 
DOTA-MG0 could be labeled with 68Ga with high efficiency, in a one-step reaction, 
reaching specific activities as high as 30 GBq/µmol. The labeling mixture was 
purified by RP-HPLC to remove 68Ga-colloid as well as unincorporated 68Ga. After 
purification a radiochemical purity of >99% was obtained. By RP-HPLC purification, 
the colloid contamination could be removed completely. As a result, this 
preparation had the same very low level of uptake in liver and spleen as the 111In-
labeled preparation. 
Biodistribution studies in BALB/c nude mice with a subcutaneous AR42J tumor 
showed high tumor uptake of 68Ga-DOTA-MG0 that was CCK2/gastrin receptor 
mediated. 68Ga-DOTA-MG0 showed biodistribution characteristics as favorable as 
those of 111In-DOTA-MG0. Recently, it has been shown that 68Ga-labeled DOTA-
TATE had a higher affinity for the somatostatin receptor subtype 2 than 111In-
DOTA-TATE.(12) In contrast to this study, there was no difference in affinity or 
tumor uptake between natIn-DOTA-MG0 and natGa-DOTA-MG0. Remarkably, the 
kidney retention of 68Ga-DOTA-MG0 is two times higher compared to 111In-DOTA-
MG0. The explanation for this higher kidney retention of the 68Ga-labeled 
compounds remains unclear. 
In this mouse model, a DOTA-MG0 dose of 0.1 µg resulted in maximal tumor 
accumulation. Administration of higher peptide doses resulted in partial saturation 
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of the CCK2/gastrin receptor leading to lower accumulation of the tracer in the 
tumor. Thus, high specific activities of the tracer are required in order to administer 
a sufficient activity dose for imaging. These results are in line with previous studies 
showing the importance of high specific activities of radiolabeled peptides and the 
influence of the peptide dose on tracer characterization in vitro(13) and in vivo.(14-
16) Subcutaneous AR42J tumors in BALB/c nude mice were clearly visualized by 
PET imaging after intravenous injection of 68Ga-labeled DOTA-MG0. Peritoneal 
tumors were visualized despite high kidney uptake of the tracers and even tumors 
that were in close proximity of the kidneys were visible on PET images. The high 
positron range of 68Ga causes some blurring of the PET images especially around 
the kidneys were high uptake is observed. In a clinical setting, the positron range 
will be of less importance because under these circumstances the resolution of the 
scanner will be the limiting factor. Inflammation observed macroscopically in one 
mouse was not visualized in the PET images. These data suggest that 68Ga-
DOTA-MG0 is specific for imaging CCK2/gastrin receptor expressing tumors. 
However, this issue should be examined in more detail. 
Radiolabeled DOTA-MG0 (DOTA-DGlu-(Glu)5-minigastrin) showed relatively high 
kidney uptake. A previous study showed only limited CCK2/gastrin receptor mRNA 
expression in murine kidneys as determined by RT-PCR.(17) The biodistribution 
study showed that the renal uptake of radiolabeled MG0 could not be blocked with 
an excess unlabeled DOTA-(His)2-Minigastrin, indicating that the uptake is not 
CCK2/gastrin receptor mediated. Most likely, the high activity levels in the kidneys 
are due to tubular reabsorption of the peptide via scavenger receptors.(18, 19) 
However, the renal uptake could be reduced by administration of a high dose of 
unlabeled DOTA-MG0 as observed in the peptide dose escalation study. A 
previous study showed that the uptake of 111In-DTPA-MG0 in the kidneys can be 
reduced by co-administration of polyglutamic acids.(18) The present data suggest 
that the 6 glutamic acid sequence in the N-terminus of MG0 is responsible for 
inhibition of renal uptake in the peptide dose escalation study. Apparently high 
doses can mimic the effect of polyglutamic acids. DOTA-(His)2-Minigastrin does not 
contain this penta-glutamic acid sequence and would therefore only inhibit 
CCK2/gastrin receptor-mediated uptake. The blocking of kidney uptake by DOTA-
DGlu-(Glu)5-minigastrin (DOTA-MG0) appears to be not CCK2/gastrin receptor 
mediated. 
Several minigastrin analogs have been developed and characterized.(20) 
Reduction of the number of glutamic acids in the amino acid sequence of MG0 
resulted in an increased tumor-to-kidney ratio.(20) However, reduction of the 
number of glutamic acids also reduced the receptor affinity and/or the metabolic 
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stability. Characterization of these minigastrin analogues labeled with 68Ga might 
be needed to select the optimal minigastrin analogue for PET imaging. 
 
In conclusion, 68Ga-DOTA-MG0 is a suitable PET tracer for the detection of 
CCK2/gastrin receptor-positive tumors. 68Ga-DOTA-MG0 showed high uptake in 
subcutaneous AR42J tumors. Moreover, subcutaneous and peritoneal AR42J 
tumors were clearly visualized with a dedicated microPET after injection of 68Ga-
DOTA-MG0. Clinical studies should be conducted to elucidate the potential of 
68Ga-DOTA-MG0 for PET imaging of MTC and NET. 
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Abstract 
 
Background 
Insulinomas are neuroendocrine tumors derived from pancreatic beta cells. The 
Glucagon-like peptide 1 receptor (GLP-1R) is expressed at a high incidence 
(>90%) and high density in insulinomas. Glucagon-like peptide 1 (GLP-1), the 
natural ligand of the GLP-1R, is rapidly degraded in vivo. A more stable agonist of 
the GLP-1R is exendin-3. We investigated imaging of insulinomas with DOTA 
conjugated exendin-3 labeled with 68Ga.  
Methods 
Targeting of insulinomas with [Lys40(DOTA)]exendin-3 labeled with either 111In or 
68Ga was investigated in vitro using insulinoma tumor cells (INS-1). [Lys40(111In-
DTPA)]exendin-3 was used as a reference in this study. In vivo targeting was 
investigated in BALB/c nude mice with subcutaneous (s.c.) INS-1 tumors. PET 
imaging was performed using a preclinical PET/CT scanner. 
Results 
In vitro exendin-3 specifically bound and was internalized by the GLP-1R positive 
cells. In BALB/c nude mice with s.c. INS-1 tumors a high uptake of 111In-
[Lys40(DOTA)]exendin-3 in the tumor was observed: 33.5 ± 11.6 %ID/g at 4h p.i. 
Uptake was specific as determined by co-injection of an excess of unlabeled 
[Lys40]exendin-3 (1.8 ± 0.1 %ID/g). The pancreas also exhibited high and specific 
uptake: 11.3 ± 1.0 %ID/g. High uptake was also found in the kidneys: 144 ± 24 
%ID/g and this uptake was not receptor-mediated. In this murine tumor model 
optimal targeting of the GLP-1R expressing tumor was obtained at exendin doses ≤ 
0.1 µg. Remarkably, tumor uptake of 68Ga-labeled [Lys40(DOTA)]exendin-3 was 
lower (8.9 ± 3.1 %ID/g) compared to tumor uptake of 111In-labeled 
[Lys40(DTPA)]exendin-3 (25.4 ± 7.2 %ID/g). The subcutaneous tumors were clearly 
visualized by small animal PET imaging after injection of 3 MBq of [Lys40(68Ga-
DOTA)]exendin-3. 
Conclusion 
[Lys40(68Ga-DOTA)]exendin-3 specifically accumulates in insulinomas, although the 
uptake is lower than [Lys40(111In-DTPA)]exendin-3. Therefore, [Lys40(68Ga-
DOTA)]exendin-3 is a promising tracer to visualize insulinomas with PET. 
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Introduction 
 
Insulinomas are neuroendocrine tumors (NET) derived from pancreatic beta-cells. 
The diagnosis is based on clinical symptoms (such as neuroglycopenic symptoms) 
and biochemical parameters (endogenous hyperinsulinism confirmed by 
hypoglycaemia). The standard treatment of insulinomas is surgical resection, 
requiring exact localization of the tumor lesions. Therefore, patients usually 
undergo computed tomography (CT) and magnetic resonance imaging (MRI) to 
precisely localize the primary tumor and potential metastases in case of malignant 
insulinoma. Somatostatin receptor scintigraphy (SRS) is considered the most 
sensitive method for detection of NET (1). In contrast to other neuroendocrine 
tumors, the sensitivity of SRS for detecting insulinomas is only 40-60% due to 
relatively low incidence of somatostatin subtype receptor (sstr) 2 and sstr5 
expression in insulinomas (1-3). Therefore, SRS is not suitable to localize 
insulinomas. Recent studies showed a high detection rate of insulinomas with 
endoscopic ultrasonography (4). However, the high detection rate is limited to 
tumors that are located in the head and the body of the pancreas. Moreover, this 
technique requires specialized expertise and is observer dependent. Angiography 
showed reasonable localization of insulinomas of approximately 70% of the cases. 
However, the localization varies from 43% to 94% due to the observer dependency 
(5). Arterial stimulation and venous sampling (ASVS) is a sensitive method, it 
localizes over 90% of the insulinomas (5). The major drawback is that the 
procedure is invasive. Thus, there is a need for new non-invasive strategies for 
localization of insulinomas. 
The Glucagon-like peptide 1 receptor (GLP-1R) is expressed in >90% of the 
insulinomas at a mean density that is two times higher than that of the sstr2 (6). 
First preclinical studies showed that 123I-GLP-1 and 123I-exendin-3 accumulated in 
rat insulinomas (RINm5F) subcutaneously implanted in NEDH rats and that these 
tumors could be detected scintigraphically (7). However, the radioiodinated 
peptides have a relatively low uptake in vivo, due to wash-out of the radionuclide 
after internalization (8-11). Recent studies showed high uptake of DTPA-
conjugated [Lys40]exendin-4 labeled with 111In in the Rip1Tag2 spontaneous 
insulinoma mouse model (12, 13). Moreover, administration of a therapeutic dose 
of 111In-labeled [Lys40(DTPA)]exendin-4 markedly inhibited the growth of 
insulinomas in Rip1Tag2 mice (14). Based on these promising results, 111In-labeled 
exendin-4 has been used for detection of insulinomas in humans by single photon 
emission computed tomography (SPECT) (15). Previous studies used exendin-3 
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and exendin-4, which share 95% homology (Table 1). Exendin-3 and exendin-4 
differ in two amino acids (position 2 and 3) located in the region of the peptide that 
is involved in internalization of the receptor-ligand complex, which might lead to 
differences in biodistribution of these peptides. In this study we therefore compared 
the biodistribution of [Lys40(DTPA)]exendin-3 and [Lys40(DTPA)]exendin-4 labeled 
with 111In. 
Because insulinomas may already induce clinical symptoms at a small size, 
imaging methods for the detection of these tumors should be highly sensitive. 
Positron emission tomography (PET) may therefore offer an advantage over 
SPECT, because of its excellent sensitivity in combination with its improved spatial 
resolution. As radionuclide for PET imaging of GLP-1 receptors with exendin, 68Ga 
seems to be the optimal candidate: DOTA-conjugated probes can be rapidly and 
efficiently labeled with 68Ga and, because 68Ga is a generator-produced positron 
emitter, it is widely available and relatively cheap. The conjugation of exendin-3 
with DOTA could change the pharmacokinetics of the peptide. Therefore we 
compared the biodistribution of [Lys40(DTPA)]exendin-3 and [Lys40(DOTA)]exendin-
3 labeled with 111In. 
In this study, we have determined the potential of 68Ga-labeled 
[Lys40(DOTA)]exendin-3 for insulinoma imaging. [Lys40(111In-DTPA)]exendin-4 was 
successfully used for this application (12, 14, 15). Here, biodistributions of 
[Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-DTPA)]exendin-4 were compared. 
The effect of the chelator (DOTA or DTPA) was examined by comparing the 
biodistributions of [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-DOTA)]exendin-3. 
The biodistributions of 68Ga and 111In-labeled exendin-3 were compared. Finally, 
microPET images were acquired of insulinoma-bearing BALB/c nude mice after 
injection of [Lys40(68Ga-DOTA)]exendin-3. 
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Materials and Methods 
 
Peptides and radionuclides 
[Lys40(DOTA)]exendin-3, [Lys40(DTPA)]exendin-3 and [Lys40(DTPA)]exendin-4 
were purchased from Peptide Specialty Laboratories (Heidelberg, Germany). The 
DTPA or DOTA was conjugated to the ε-amino group of the Lysine (K40) and the 
C-terminal carboxyl group was amidated. The structures of [Lys40(DTPA)]exendin 
and Lys40(DOTA)]exendin are shown in Figure 1. 111InCl3 was obtained from 
Covidien (Petten, The Netherlands). 68GaCl3 was eluted from a TiO2-based 1,110 
MBq 68Ge/68Ga generator (Obninsk, Russia) with 0.1 N Ultrapure HCl (J.T. Baker, 
Deventer, The Netherlands). 
 
Peptide Amino acid sequence
Exendin-3 HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 
Exendin-4 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 
Table 1: Amino acid structure of exendin-3 and exendin-4. Homologous amino acids are 
underlined. 
 
 
 
Figure 1: Structure of [Lys40(DTPA)]exendin-3 (A) and [Lys40(DOTA)]exendin-3 (B).  
 
Radiolabeling 
[Lys40(DTPA)]exendin-3 was dissolved in 0.1 M MES (2-(N-
morpholino)ethanesulfonic acid) buffer, pH 5.5 and 150 MBq 111In was added to 1 
µg peptide and five volumes of 0.1 M MES buffer, pH 5.5 were added, resulting in 
a total volume of the reaction mixture ranging from 800 µl to 2345 µl. After 
Mw=4816.3 g/mol Mw=4715.3 g/mol 
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incubation at room temperature for 30 min, quality control was performed using 
reversed-phase high performance liquid chromatography (RP-HPLC) on a C18 
reversed-phase column (Zorbax Rx-C18; 4.6 mm x 25 cm; Agilent Technologies) 
and Instant Thin Layer Chromatography (ITLC). The column was eluted with 10 
mM ammonium acetate, pH 5.5 with a linear gradient from 3% to 100% acetonitrile 
in 10 min (flow rate: 1 ml/min). ITLC was performed on silica gel ITLC (Pall 
Corporation Life Sciences, New York, NY, USA). Two mobile phases were used: 
0.1 M EDTA in 0.1 M NH4Ac, pH 5.5 (Rf 111In-labeled exendin = 0, Rf unbound 111In 
= 1) and 0.25 M NH4Ac, pH 5.5:methanol (1:1) (Rf = 0: colloidal residues, Rf = 1: 
111In-labeled exendin and unbound 111In).  
Radiolabeling of [Lys40(DOTA)]exendin-3 with 111In was carried out by adding five 
volumes of 0.25 M ammonium acetate buffer, pH 5.5 containing 5 µg peptide and 
55 MBq 111In, resulting in a total volume of the reaction mixture ranging from 359 µl 
to 1043 µl. After 20 min incubation at 95 ⁰C, quality control was performed using 
RP-HPLC and ITLC as described above.  
For labeling [Lys40(DOTA)]exendin-3 with 68Ga, 185 MBq of 68Ga in 350 µl 0.1 N 
Ultrapure HCl was added to 42 µl 2.5 M HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer, pH 7, containing 8 µg [Lys40(DOTA)]exendin-
3. The final pH of the reaction mixture was 3.0. The mixture was incubated at 95 ⁰C 
for 15 min, EDTA was added to a final concentration of 5 mM and incubated at 
room temperature for 5 min. The reaction mixture was purified by HPLC, using a C8 
reversed-phase column (Zorbax eclipse XDB C8 4.6 x 150 mm, 5 µm, Agilent 
Technologies). The column was eluted with 10 mM ammonium acetate, pH 5.5 (0-5 
min), 40% ethanol (5-10 min) followed by a linear gradient from 40% to 90% 
ethanol in 5 min (flow rate: 1 ml/min). The fractions containing [Lys40(68Ga-
DOTA)]exendin-3 were collected and diluted with PBS containing 0.5% BSA to a 
final ethanol concentration of less than 10% before injection into mice (injection 
volume: 0.2 ml). The unincorporated 68Ga and the 68Ga colloid content in the 
purified 68Ga-labeled [Lys40(DOTA)]exendin-3 preparations was determined using 
ITLC as described above.  
 
Cell Culture 
The rat insulinoma cell line INS-1 (16) was maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 mM HEPES, 50 
µM β-mercaptoethanol, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 
µg/ml streptomycin, in a humidified 5% CO2 atmosphere at 37 °C. The cells were 
harvested by trypsinisation with trypsin/EDTA. 
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IC50 determination 
The 50% inhibitory concentration (IC50) of [Lys40(natIn-DTPA)]exendin-3, [Lys40(natIn-
DOTA)]exendin-3 and [Lys40(natGa-DOTA)]exendin-3 was determined using 
suspensions of INS-1 cells. [Lys40(DTPA)]exendin-3 was labeled with stable natIn by 
adding 10.6 nmol natInCl3 (Merck, Darmstadt, Germany) to 2.12 nmol 
[Lys40(DTPA)]exendin-3 (0.21 nmol/µl) in 30 µl 0.1 M MES buffer pH 5.5 and 
incubated at RT for 30 min. natIn labeling of [Lys40(DOTA)]exendin-3 was performed 
in 0.25 M NH4Ac pH 5.5 containing 2.12 nmol [Lys40(DOTA)]exendin-3. 10.6 nmol 
natIn was added and the reaction mixture was incubated at 95 ⁰C for 30 min. 
Labeling of [Lys40(DOTA)]exendin-3 with stable natGa was performed by adding 
10.6 nmol natGa(NO)3 (Sigma Aldrich, St Louis, MO, USA) to 2.12 nmol 
[Lys40(DOTA)]exendin-3 in 30 µl 0.25M NH4Ac pH 5.5 and incubated at RT for 3 h. 
INS-1 cells were resuspended in binding buffer (HEPES-buffered RPMI containing 
1% BSA) to a concentration of 3 million cells/0.5 ml. After 10 min incubation at 0 
ºC, natIn or natGa-labeled peptide was added at a final concentration ranging from 
0.10-350 nM along with radiolabeled [Lys40(111In-DTPA)]exendin-3 (60,000 dpm). 
To prevent internalization, cells were incubated on ice for 4 h. The cell suspension 
was centrifuged at 3,000 g for 5 min and the supernatant was discarded. The cells 
were washed twice with ice-cold PBS, centrifuged and the radioactivity in the cell 
pellet was determined in a γ-counter (Wizard, Wallac-Oy, Uppsala, Sweden) and 
the bound fraction was determined.  
 
In vitro internalization  
The kinetics of internalization of [Lys40(111In-DTPA)]exendin-3 were determined as 
described previously (17). INS-1 cells were seeded at a density of 500,000 
cells/well in 6-well plates and incubated overnight at 37 °C. The cells were washed 
twice with binding buffer and subsequently incubated at 37 ºC for 10 min in 1.0 ml 
binding buffer. Approximately 60,000 dpm of 111In-labeled peptide (55 fmol) were 
added and incubated for 0.5, 1, 2 or 4 h at 37 ºC. To determine a-specific binding, 
1 µg unlabeled [Lys40]exendin-3 was added together with the 111In-labeled peptide 
to 3 wells per time point. After incubation, the cells were washed twice with binding 
buffer. To determine the surface-bound radiolabeled peptide, ice-cold acid buffer 
(0.1 M acetic acid, 154 mM NaCl, pH 2.5) was added and cells were incubated for 
10 min at 4 ºC. After washing the cells twice with binding buffer, cells were 
harvested with a cotton stick and the cell-associated activity was measured in a 
gamma-counter. The internalized fraction (cell-associated activity after acid wash) 
and receptor bound fraction (activity removed by acid wash) was determined. The 
values of the internalized and receptor bound fraction were corrected for non-
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specific binding as determined by co-incubation with an excess unlabeled 
[Lys40]exendin-3 (1 µg/well). 
 
Biodistribution studies of [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-
DTPA)]exendin-4 
The biodistribution of [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-DTPA)]exendin-
4 were compared. Six to eight weeks old female BALB/c nude mice were injected 
subcutaneously in the right flank with 0.2 ml of a 5 x 107 cells/ml suspension of 
INS-1 cells. When the tumors were 2-5 millimetres in diameter, mice were 
randomly divided in groups of 5 mice. Mice were injected intravenously with 370 
kBq (peptide dose: 0.1 µg) of 111In-labeled [Lys40(DTPA)]exendin-3 (n=5) or 111In-
labeled [Lys40(DTPA)]exendin-4 (n=5) via the tail vein. Four hours after injection, 
mice were euthanized by CO2/O2 suffocation and blood, tumor and relevant tissues 
(muscle, heart, lung, spleen, pancreas, kidney, liver, stomach and duodenum) were 
dissected, weighed and counted in a gamma-counter. The percentage injected 
dose per gram (%ID/g) was determined for each tissue. To determine whether the 
exendin uptake is GLP-1 receptor-mediated, a 100-fold excess (10 μg) of 
unlabeled [Lys40]exendin was co-injected in a separate group of mice (n=2). 
 
Biodistribution studies of [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-
DOTA)]exendin-3 
In order to determine the effect of the chelator, the biodistribution of [Lys40(111In-
DTPA)]exendin-3 and [Lys40(111In-DOTA)]exendin-3 was examined in BALB/c nude 
mice with a s.c. tumor. Mice were injected intravenously with 370 kBq 111In-labeled 
[Lys40(DTPA)]exendin-3 (n=5) or [Lys40(DOTA)]exendin-3 (n=5). To determine the 
GLP-1R-mediated uptake, a separate group of mice was co-injected with an 
excess unlabeled [Lys40]exendin (n=2). Mice were euthanized 4 h p.i. by CO2/O2 
suffocation and blood, tumor and major organs were dissected, weighed and 
counted. 
 
Biodistribution studies of [Lys40(111In-DTPA)]exendin-3 and [Lys40(68Ga-
DOTA)]exendin-3 
The biodistribution of [Lys40(111In-DTPA)]exendin-3 and [Lys40(68Ga-
DOTA)]exendin-3 was determined in BALB/c nude mice with subcutaneous INS 
tumors. Mice were injected intravenously with 370 kBq 111In (n=5) or 1 MBq 68Ga-
labeled exendin-3 (n=5) at a peptide dose of 0.1 µg. To determine the GLP-1R-
mediated uptake, a separate group of mice was co-injected with an excess 
unlabeled [Lys40]exendin (n=2). Another group of mice (n=2) was injected with 
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[Lys40(68Ga-DOTA)]exendin-3 that was purified on a disposable PD10 column 
instead of by RP-HPLC. The mice were euthanized 1 hour post injection by CO2/O2 
suffocation and blood, tumor and major organs were dissected, weighed and 
counted. 
 
Peptide dose escalation study 
To determine the optimal peptide dose of exendin-3 in this model for tumor 
imaging, BALB/c nude mice with a subcutaneous INS-1 tumor were injected 
intravenously with 370 kBq [Lys40(111In-DTPA)]exendin-3 (peptide dose 0.003 µg) 
and were co-injected with various amounts of unlabeled [Lys40]exendin-3 to final 
peptide doses ranging from 0.003 to 10.0 µg (n=5 mice per peptide dose). Four 
hours after injection the mice were killed by CO2/O2 suffocation and the 
radioactivity in the blood, tumor and relevant tissues was measured in a gamma 
counter. 
 
PET imaging  
PET images were acquired of BALB/c nude mice (n=3) with a s.c. INS-1 tumor on 
the hind limb using a small-animal PET/CT scanner (Inveon™ , Siemens Medical 
Solutions, Knoxville, TN, USA). The scanner has an axial field of view of 12.7 cm 
and a 1.4 mm FWHM spatial resolution in images reconstructed using Fourier 
rebinning and filtered back projection. When the tumors had a diameter of 2-5 mm, 
mice were injected intravenously via the tail vein with 3 MBq HPLC purified 
[Lys40(68Ga-DOTA)]exendin-3 (Specific activity 110 GBq at completion of the 
labeling, 50 GBq/µmol at time of injection) corresponding with an exendin dose of 
0.3 µg. One hour post injection PET images were acquired under 
isoflurane/O2/N2O inhalation anesthesia. The PET image was acquired during 45 
minutes for the emission scan and the images were reconstructed by 
OSEM3D/MAP reconstruction. 
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Results 
 
Radiolabeling 
Specific activities up to 700 GBq/μmol for [Lys40(111In-DTPA)]exendin-3 could be 
obtained with a radiochemical purity exceeding 95%. [Lys40(DOTA)]exendin-3 
could be labeled efficiently with 111In and 68Ga. Specific activities of 20 GBq/µmol 
with a radiochemical purity >95% as determined by HPLC were obtained for 
[Lys40(111In-DOTA)]exendin-3. [Lys40(DOTA)]exendin-3 could be labeled with 68Ga 
with a specific activity of 110 GBq/µmol with a radiochemical purity >99% after 
HPLC purification. Without HPLC purification a specific activity of 17 GBq/µmol 
could be obtained. 
Unbound 111In and 68Ga eluted from the column after 3 min whereas 111In and 
68Ga-labeled exendin had a retention time of ~13 min.  
 
IC50 determination  
The results of the IC50 determination are shown in Figure 2. The IC50 for natIn-
DTPA-[Lys40]exendin-3, [Lys40(natIn-DOTA)]exendin-3 and [Lys40(natGa-
DOTA)]exendin-3 for binding INS-1 cells were 8.5 (95% Confidence Interval: 4.30 
to 16.8), 5.3 (95% Confidence Interval: 2.75 to 11.1), and 5.7 nM (95% Confidence 
Interval: 2.91 to 11.3), respectively. There was no significant difference between 
the IC50 value of [Lys40(natIn-DTPA)]exendin-3, [Lys40(natIn-DOTA)]exendin-3 and 
[Lys40(natGa-DOTA)]exendin-3 (p=0.5038 for Log(IC50) differences determined by F-
test). 
 
Internalization kinetics 
Fig. 3 summarizes the internalization kinetics of [Lys40(111In-DTPA)]exendin-3 in 
INS-1 cells as determined in vitro. After 0.5 hour, 0.1 ± 0.03 fmol [Lys40(111In-
DTPA)]exendin-3 was bound to the receptor and 0.4 ± 0.01 fmol was internalized. 
After 4 h these values had increased to 2.6 ± 0.04 and 3.9 ± 0.06 fmol, 
respectively. 
 
Biodistribution studies of [Lys40(111In-DTPA)]exendin-3, [Lys40(111In-
DTPA)]exendin-4, and of [Lys40(111In-DOTA)]exendin-3 
Fig. 4. summarizes the biodistribution of [Lys40(111In-DTPA)]exendin-3 and 
[Lys40(111In-DTPA)]exendin-4. Both 111In-labeled exendin-3 and exendin-4 showed 
high tumor uptake: 36.0 ± 5.4 %ID/g and 36.3 ± 8.0 %ID/g. Co-administration of an 
excess unlabeled [Lys40]exendin-3 blocked the tumor uptake indicating that the 
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uptake is GLP-1R-mediated (p<0.01) for [Lys40(111In-DTPA)]exendin-3 and 
[Lys40(111In-DOTA)]exendin-3 compared to the uptake co-administered with an 
excess unlabeled [Lys40]exendin-3: 1.2 ± 0.3 %ID/g and 1.0 ± 0.4 %ID/g, 
respectively. Specific uptake of [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-
DTPA)]exendin-4 was also seen in pancreas (p<0.01), lung (p<0.01) and stomach 
(p<0.01). There was no significant difference in uptake in tumor, pancreas, lung 
and stomach of [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In–DTPA)]exendin-4. 
The renal uptake of [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In–DTPA)]exendin-
4 was 146.1 ± 21.0 and 140.5 ± 17.7 %ID/g, which could not be blocked by an 
excess of unlabeled exendin-3, indicating that the uptake is not GLP-1R-mediated. 
The chelator did not affect the biodistribution of [Lys40]exendin-3 as evidenced by 
the almost identical concentrations of [Lys40(111In-DOTA)]exendin-3 and 
[Lys40(111In-DTPA)]exendin-3 in all tissues examined (Fig. 5).  
 
Figure 2: Competition binding assay (IC50) of [Lys40(natIn-DTPA)]exendin-3, [Lys40(natIn-
DOTA)]exendin-3 and [Lys40(natGa-DOTA)]exendin-3 in INS-1 cells. [Lys40(111In-DTPA)]exendin-3 was 
used as tracer. 
 
Biodistribution of [Lys40(68Ga-DOTA)]exendin-3 
The biodistribution of [Lys40(68Ga-DOTA)]exendin-3 was determined 1 h post-
injection in BALB/c nude mice with a subcutaneous INS-1 tumor using [Lys40(111In-
DTPA)]exendin-3 as a reference (Fig. 6). Specific uptake of [Lys40(68Ga-
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DOTA)]exendin-3 was observed in tumor (p<0.05) and pancreas (p<0.05). Uptake 
of [Lys40(68Ga-DOTA)]exendin-3 was significantly lower than that of [Lys40(111In-
DTPA)]exendin-3 in the tumor (25.4 ± 7.2 %ID/g and 8.9 ± 3.1 ID/g, p<0.01) and 
pancreas (17.5 ± 2.8 %ID/g and 6.7 ± 1.8. %ID/g, p<0.001).  
In contrast to the RP-HPLC-purified preparation [Lys40(68Ga-DOTA)]exendin-3 
purified by gel filtration on a Sephadex™ G-25 column showed enhanced uptake in 
spleen and liver: 16.8 ± 0.9 %ID/g and 20.9 ± 1.6 %ID/g respectively. This 
enhanced hepatic and splenic uptake was not receptor-mediated as it could not be 
blocked by co-injection of an excess unlabeled [Lys40]exendin (data not 
shown).Very low uptake in liver and spleen was observed when RP-HPLC-purified 
[Lys40(68Ga-DOTA)]exendin-3 was injected: 0.44 ± 0.05 %ID/g and 0.25 ± 0.02 
%ID/g respectively. Again, no specific uptake was observed in liver and spleen as 
determined by co-administration of an excess unlabeled exendin (0.31 ± 0.02 
%ID/g and 0.20 ± 0.01 %ID/g respectively). 
 
Figure 3: In vitro internalization kinetics of [Lys40(111In-DTPA)]exendin-3 in INS-1 cells. The cell 
bound and internalized fraction is corrected for a-specific binding and uptake, determined by co-
incubation with an excess unlabeled [Lys40]exendin-3. 
 
117 
 
 
Figure 4: Biodistribution of [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-DTPA)]exendin-4 in BALB/c 
nude mice bearing a subcutaneous INS-1 tumor. Values are expressed as percentage injected dose 
per gram tissue (n=5 mice). Blocking was performed by co-injection of a 100-fold molar excess of 
unlabeled [Lys40]exendin-3. Mice were dissected 4 hours after injection. 
 
 
Figure 5: Biodistribution of [Lys40(111In-DTPA)]exendin-3 and [Lys40(111In-DOTA)]exendin-3 in BALB/c 
nude mice bearing a subcutaneous INS-1 tumor. Values are expressed as percentage injected dose 
per gram tissue (n=5 mice). Blocking was performed by co-injection of a 100-fold molar excess of 
unlabeled [Lys40]exendin-3. Mice were dissected 4 hours after injection. 
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Peptide dose escalation study 
The effect of the exendin-3 dose on the biodistribution in mice with subcutaneous 
INS-1 tumors was studied in a peptide dose escalation study. The results of this 
study are summarized in Fig. 7. Highest uptake of 111In-labeled 
[Lys40(DTPA)]exendin-3 was observed when doses ≤ 0.1 µg of peptide were 
administered. Administration of 0.3 µg [Lys40(DTPA)]exendin-3 resulted in a 
significantly reduced uptake of [Lys40(111In-DTPA)]exendin-3 in the tumor and the 
pancreas (p<0.0005 and p=0.001, respectively). Further escalation of the peptide 
dose resulted in a further decrease of tumor and pancreatic uptake of [Lys40(111In-
DTPA)]exendin-3.  
 
Figure 6: Biodistribution of [Lys40(111In-DTPA)]exendin-3 and [Lys40(68Ga-DOTA)]exendin-3 in 
BALB/c nude mice bearing a subcutaneous INS-1 tumor. Values are expressed as percentage 
injected dose per gram tissue (n=5 mice). Blocking was performed by co-injection of a 100-fold 
molar excess of unlabeled [Lys40]exendin-3. Mice were dissected 1 hour after injection. 
 
 
119 
 
 
Figure 7: Peptide dose escalation study of [Lys40]exendin-3 in BALB/c nude mice with a 
subcutaneous INS-1 tumor. Mice were injected intravenously with 0.37 MBq [Lys40(111In-
DTPA)]exendin-3 and were co-injected with various amounts of unlabeled [Lys40]exendin 3 ranging 
from 0.003 to 10.0 µg. Values are expressed as percentage injected dose per gram tissue (n=5 
mice). Mice were dissected 4 hours after injection. 
 
PET imaging 
Subcutaneous INS-1 tumors on the hind limb were clearly visualized on the PET 
images as early as 1 hour post injection (Fig. 8 and 9). The PET images were 
fused with CT images. Besides high tumor uptake, also uptake was seen in the 
kidneys. The PET image of a mouse injected with unpurified [Lys40(68Ga-
DOTA)]exendin-3 showed high uptake in the liver (Figure 7C). Despite the high 
liver uptake the tumor was still clearly visible. 
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Figure 8: Maximum Intensity Projection (MIP) of PET images of different BALB/c nude mice with a 
subcutaneous INS-1 tumor on the right limb. Image A and B represent PET images of mice injected with 
HPLC-purified [Lys40(68Ga-DOTA)]exendin-3. Tumor (arrow) and kidneys are clearly visible. Image C 
represents a mouse that was injected with unpurified [Lys40(68Ga-DOTA)]exendin-3. Although high 
uptake in liver is seen, the tumor is still clearly visible. 
 
 
 
Figure 9: Maximum Intensity 
Projection (MIP) of a PET/CT image 
after injection of 3 MBq HPLC 
purified [Lys40(68Ga-DOTA)]exendin-
3 of a BALB/c nude mouse with a 
subcutaneous INS-1 tumor on the 
right limb. Tumor (arrow) and 
kidneys are clearly visible. Due to 
the low background activity, the 
additional anatomical information 
given by the CT images helps to 
localize the tumor. 
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Discussion 
 
Somatostatin receptor scintigraphy (SRS), the standard method for imaging of 
NET, only detects around 50% of insulinomas (1, 2, 12). Clinical studies with 18F-
DOPA PET for the detection of insulinomas showed promising results (18). 
However, physiological uptake of 18F-DOPA in the pancreas and duodenum may 
cause false-positive results or mask small lesions. An exendin-based imaging 
method targeting the GLP-1 receptor specifically expressed on insulinomas might 
therefore improve the visualisation of insulinomas. 
Preclinical studies with [Lys40(111In-DTPA)]exendin-4 in different animal models 
showed high accumulation of 111In-labeled exendin in insulinomas (12, 13). Wild 
and co-workers demonstrated that in vivo imaging of insulinomas by SPECT with 
radiolabeled exendin is feasible in patients (15). In animals, they detected 
insulinomas of less than 1 mm in diameter in a transgenic mouse model using 
[Lys40(111In-DTPA)]exendin-4 as tracer. Although SPECT has a higher resolution in 
small animal imaging, for clinical imaging PET offers a higher spatial resolution, a 
higher sensitivity and the possibility to accurately quantify uptake, which makes it 
preferable to SPECT. Recent studies showed that PET of neuroendocrine tumors 
with 68Ga-labeled octreotide is superior compared to SPECT with 111In-labeled 
octreotide (19, 20). 
In this study we, therefore investigated the potential of [Lys40(68Ga-DOTA)]exendin-
3 for the detection of insulinomas by PET in a mouse model. Conjugation of 
[Lys40]exendin-3 with DOTA instead of DTPA allows radiolabeling of the tracer with 
a broad range of radionuclides including the positron emitter 68Ga. We selected 
68Ga as positron emitter because it is a generator-derived radionuclide (and 
therefore readily available), the labeling strategy is fast and relatively simple and 
the half-life matches the pharmacokinetics of the tracer (exendin) (13). A potential 
disadvantage of 68Ga for animal imaging may be the high energy of the emitted β+ 
particles limiting the spatial resolution of the images to 3 mm while the intrinsic 
resolution of the scanner is 1.5 mm (21). This is only a relevant issue in preclinical 
scanners, as in clinical scanners the intrinsic resolution of the scanner rather than 
the β+ energy will limit the resolution of the images. 
Biodistribution studies in BALB/c nude mice with subcutaneous INS-1 tumors 
showed high and specific uptake of [Lys40(68Ga-DOTA)]exendin-3 in the tumor and 
pancreas. Subcutaneous INS-1 tumors on the hind limb of BALB/c nude mice were 
clearly visualized by microPET imaging. Therefore, our data show that imaging of 
insulinomas with 68Ga-labeled exendin is feasible. 
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[Lys40(111In-DTPA)]exendin-3 was used as a reference in all experiments. 
Biodistribution studies with [Lys40(111In-DTPA)]exendin-3 showed specific uptake in 
GLP-1R expressing tissues as described previously (13). The peptide dose 
escalation study revealed that in this murine model a peptide dose of ≤ 0.1 µg 
results in maximum accumulation of radiolabeled exendin in the tumor and in GLP-
1R positive organs. Apparently, at higher doses in vivo receptor saturation occurs. 
The biodistribution of [Lys40(111In-DTPA)]exendin-3 was identical to the 
biodistribution of [Lys40(111In-DTPA)]exendin-4. Also, there was no measurable 
effect of the chelator on receptor targeting as the biodistribution of 111In-labeled 
[Lys40(DTPA)]exendin-3 and [Lys40(DOTA)]exendin-3 were identical.  
The uptake of [Lys40(68Ga-DOTA)]exendin-3 in the tumor and the pancreas was 
significantly lower than that of 111In-labeled [Lys40(DTPA)]exendin-3. It has been 
demonstrated that the affinity of a peptide can be influenced by the chelator as well 
as by the radionuclide. Reubi et al. showed that 68Ga-labeled DOTA-TATE had a 
higher affinity for the somatostatin receptor subtype 2 than 111In-DOTA-TATE (22). 
However, there was no significant difference between the IC50 values of Lys40(natIn-
DTPA)]exendin-3, [Lys40(natIn-DOTA)]exendin-3 and [Lys40(natGa-DOTA)]exendin-3. 
The differences in tumor and pancreatic uptake between [Lys40(68Ga-
DOTA)]exendin-3 and 111In-labeled [Lys40(DTPA)]exendin-3 could not be attributed 
to the substitution of DTPA by DOTA, because in our mouse model, the uptake of 
111In-labeled [Lys40(DTPA)]exendin-3 and [Lys40(DOTA)]exendin-3 in the tumor and 
other receptor-positive organs were identical.  
Enhanced uptake of [Lys40(68Ga-DOTA)]exendin-3 was seen in liver and spleen 
when the preparation was only purified by gel filtration, probably because this 
preparation still contained some colloidal 68Ga. Colloidal 68Ga will accumulate in the 
liver and spleen. RP-HPLC purification removed the colloidal contamination, since 
this preparation had the same very low uptake in liver and spleen as the 111In-
labeled preparation. Previous studies with 68Ga-labeled DOTA-conjugated 
compounds not purified by RP-HPLC also showed enhanced liver and spleen 
uptake (23, 24). It is still a matter of debate whether the enhanced uptake in liver 
and spleen is caused by colloidal 68Ga or by instability of the 68Ga-DOTA complex. 
In the present study, uptake of HPLC purified [Lys40(68Ga-DOTA)]exendin-3 in liver 
and spleen was identical to that of 111In-labeled exendin-3. Our data suggest that 
the enhanced uptake in liver and spleen of 68Ga-labeled compounds described in 
previous studies is not caused by instability of the 68Ga-DOTA-complex but by 
minor amounts of colloid.  
To obtain high-quality PET images a 68Ga activity of 3 MBq was required. This 
necessitated us to administer an exendin dose of 0.3 µg, and although this resulted 
 
123 
 
in suboptimal uptake (as demonstrated in the peptide dose escalation study), the 
tumors could exactly be visualized.  
The GLP-1R is also expressed on the native pancreatic beta-cells. Radiolabeled 
exendin can potentially be used to target beta-cells. This is an attractive approach 
for the determination of the beta-cell mass, a key issue in diabetes mellitus. 
[Lys40(111In-DTPA)]exendin and [Lys40(68Ga-DOTA)]exendin-potentially can be 
used to non-invasively determine the beta-cell mass in the pancreas by SPECT or 
PET. A previous study showed a correlation between the uptake of 111In-labeled 
exendin and the beta-cell mass (25), which makes this approach promising for the 
in vivo determination of the beta-cell mass. 
 
In conclusion, 68Ga-labeled [Lys40(DOTA)]exendin-3 is a suitable tracer for PET 
imaging of GLP-1R expressing insulinomas. 68Ga-labeled [Lys40(DOTA)]exendin-3 
showed high uptake in subcutaneous INS-1 tumors in BALB/c mice. Subcutaneous 
INS-1 tumors were clearly visualized with a micro PET/CT scanner after injection 
with 68Ga-labeled [Lys40(DOTA)]exendin-3. Therefore, clinical studies should be 
conducted to elucidate the potential of [Lys40(68Ga-DOTA)]exendin-3 for insulinoma 
imaging in humans. 
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Abstract 
 
A reliable, non-invasive method that could quantitatively determine the pancreatic 
beta cell mass (BCM) in vivo would allow studies that would give further insight in 
the development of type 1 and 2 diabetes. Therefore, we investigated the potential 
of SPECT imaging with 111In-exendin-3 to determine the BCM in vivo in Brown 
Norway rats. 111In-exendin-3 accumulated efficiently and specifically in the 
pancreas of healthy rats (0.29 ± 0.04 %ID/g) and the pancreas was clearly visible 
in SPECT images. Severely diabetic rats showed an 80% reduction of pancreatic 
uptake (0.06 ± 0.01 %ID/g) and the pancreas was hardly detectable by SPECT. 
There was a significant correlation between 111In-exendin-3 uptake determined by 
ex vivo counting and BCM (Pearson r=0.89) and between 111In-exendin-3 uptake 
determined by in vivo SPECT and BCM (Pearson r=0.83). These studies in rats 
indicate that 111In-exendin-3 can be used to determine the pancreatic beta cell 
mass non-invasively with SPECT.  
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Introduction 
 
Diabetes mellitus is characterized by a deficiency in control of glucose 
homeostasis. In type 1 diabetes (T1D), autoimmune destruction of pancreatic beta 
cells leads to an absolute deficiency of insulin secretion with hyperglycemia as a 
consequence (1). It has been shown that there is a reserve capacity of beta cells 
and T1D becomes clinically apparent when the beta cell mass (BCM) drops under 
a critical threshold (>70-80% loss of BCM) (2, 3). A low number of insulin-
producing cells (approximately 10%) is still present in half of all insulin-dependent 
T1D patients (2). In type 2 diabetes (T2D), failure of the beta cells to adapt to the 
increased insulin demand posed by insulin resistance in target tissues leads to 
impaired glucose homeostasis (1, 4-7). BCM changes during the development and 
course of T2D (8), but this process is neither well understood nor well 
characterized (6). It also appears that the beta cell mass and the beta cell function 
do not always correlate in the course of the disease (6, 9).  
Various animal models have been used to study the effect of the BCM on insulin 
secretion and the development of diabetes. Most information about the BCM in 
humans is obtained from studies on autopsies of diabetic patients (6). However, 
autopsies cannot show the dynamics of the BCM at the onset and progression of 
the disease. Therefore, a non-invasive in vivo imaging method to measure the 
BCM would allow us to gain a better insight into the pathophysiology of diabetes 
during progression of the disease. 
There are, however, several challenges to be overcome in order to develop a 
reliable BCM imaging method. The BCM represents only 1-2% of the total 
pancreatic mass and the beta cells are located in the islets of Langerhans that are 
scattered throughout the pancreas (10, 11). In order to visualize these small islets, 
an imaging modality with a high spatial resolution is needed. Although offering the 
highest resolution of currently available human imaging technology, neither 
resolution and contrast to the surrounding tissue of magnetic resonance imaging 
(MRI) nor that of computed tomography (CT) suffices to visualize single pancreatic 
islets in humans in vivo. As an alternative, nuclear medicine imaging modalities 
such as SPECT (Single Photon Emission Computed Tomography) or PET 
(Positron Emission Tomography) offer a very high sensitivity which may be 
sufficient for the detection of the relatively low number of cells with a radiolabeled 
tracer molecule. This tracer should be highly specific and accumulate efficiently in 
the beta cells, while at the same time having a low uptake in the exocrine (and the 
other endocrine) cells of the pancreas. Highly specific accumulation of the tracer in 
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the target cell combined with the high sensitivity offered by SPECT and PET may 
allow the measurement of small differences in BCM between healthy and diabetic 
subjects.  
In recent years, several radiotracers, such as the monoclonal antibody IC2 (12), 
11C- or 18F-labeled dihydrotetrabenazine (DTBZ) (13, 14), 6-[18F]fluoro-L-3,4-
dihydroxy-phenylalanine (18F-DOPA)  (15-18), dithizone, glibenclamide, 
nicotinamide and FDG (19), have been evaluated for the determination of the BCM. 
Of these tracers DTBZ appears to be the most promising one, but the maximal 
difference in tracer uptake between healthy and diabetic subjects is approximately 
50%, possibly due to limited specificity, which may hamper the detection of small 
differences in BCM (14). Thus, the development of a tracer for BCM determination 
still remains a major unmet need. 
A potential target for measurement of the BCM is the glucagon-like peptide 1 
receptor (GLP-1R). The GLP-1R is abundantly expressed in rat, mouse and human 
pancreatic beta cells but not in α, δ and pp cells (20, 21). The low stability of GLP-1 
(22) requires the use of the more stable agonists exendin-3 and exendin-4. (23, 
24). Preclinical studies with the GLP-1R antagonist 125I-exendin-9-39 and 123I-
labeled exendin-4 showed high uptake in pancreas and in subcutaneous 
insulinoma xenografts (25, 26). However, the highest uptake was observed only 30 
minutes after injection, due to the rapid wash-out of the radioiodine from the target 
cell after degradation of the internalized peptide. Conjugation of a peptidic ligand 
with a chelator (eg. DTPA, DOTA) allows labeling with radiometals. When the 
radiopeptide is internalized by the target cell, the peptide is degraded and the 
radiolabeled metabolite is trapped in the lysosomes (27), leading to accumulation 
in the target cell, a mechanism known as “metabolic trapping” (28). This 
mechanism, together with rapid clearance of the radiopeptide from the blood, leads 
to increasing target-to-background ratios over time allowing for highly sensitive 
detection of target cells by radionuclide imaging. [Lys40(111In-DTPA)]exendin-3 
(111In-exendin-3) showed a higher uptake and retention in subcutaneous 
insulinomas in rats as compared to the 123I-labeled compound (29). Moreover, Wild 
et al. demonstrated high tumor uptake of 111In-labeled exendin-4 in insulinoma-
bearing mice and patients with insulinomas by SPECT (25, 26). These studies 
suggest that exendin labeled with 111In may be useful for the determination of the 
BCM. Recently, Reiner et al. showed that the GLP-1R expression in the pancreatic 
islet could be visualized by intravital fluorescent imaging using exendin-4 
conjugated with a near-infrared fluorophore (30). 
In this study, we have evaluated the feasibility of SPECT after injection of 111In-
exendin-3 to determine the BCM in an alloxan-induced diabetes model in Brown 
 
133 
 
Norway rats. The aim of the study was to determine whether (I) 111In-exendin-3 
accumulates efficiently and specifically in beta cells; (II) the uptake of the tracer 
correlates with the BCM; (III) the difference in tracer uptake between healthy and 
severe diabetic animals is sufficient to determine small changes in BCM (IV); the 
pancreas can be visualized with SPECT after injection of 111In-exendin-3; (V); the 
pancreatic uptake can be quantified by SPECT and (VI) the uptake as quantified by 
SPECT correlates with the BCM. 
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Methods 
 
mRNA extraction and real time PCR 
Poly(A)+ mRNA was isolated from rat tissues using the Dynabeads mRNA 
DIRECT™ kit (Invitrogen, Merelbeke, Belgium), and reversely transcribed as 
previously described (31). Human cDNA were from Gentaur (Brussels, Belgium). 
The real time PCR amplification reaction was done as described (32), using iQ 
SyBR Green Supermix on iCycler MyiQ Single Color (BIO-RAD, Hercules, CA, 
USA) and compared to a standard curve (33). Expression values were corrected 
for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Primers used are summarized in Table 1. 
 
 
Table 1: Primers used for quantitative PCR on rat and human cDNA with the length 
of the amplicon in base-pairs. 
 
Peptides and radiolabeling 
[Lys40(DTPA)]exendin-3 and [Lys40]exendin-3 were purchased from Peptides 
Specialty Laboratories (Heidelberg, Germany). DTPA was conjugated to the ε-
amino group of the Lysine (K40) and the C-terminal carboxyl group was amidated 
(34).  
Radiolabeling was performed by adding 150 MBq 111InCl3 (Covidien, Petten, The 
Netherlands) to 1 µg [Lys40(DTPA)]exendin-3 that was dissolved in 0.1 M MES (2-
(N-morpholino)ethanesulfonic acid) buffer (Sigma Aldrich, St. Louis, MO, USA), pH 
5.5. After incubation at room temperature for 30 min EDTA (Sigma Aldrich, St. 
Louis, MO, USA) was added to a final concentration of 5 mM and 10% Tween80 
(Sigma Aldrich, St. Louis, MO, USA) to a final concentration of 0.1% (34). Quality 
control was performed using reversed-phase high performance liquid 
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chromatography (RP-HPLC) on a C18 reversed-phase column (Zorbax Rx-C18; 4.6 
mm x 25 cm; Agilent Technologies) and Instant Thin Layer Chromatography 
(ITLC). The column was eluted with 10 mM ammonium acetate, pH 5.5 with a 
linear gradient from 3% to 100% acetonitrile in 10 min (flow rate: 1 ml/min). ITLC 
was performed on silica gel ITLC (Pall Corporation Life Sciences, New York, NY, 
USA). Two mobile phases were used: 0.1 M EDTA in 0.1 M NH4Ac, pH 5.5 (Rf 
111In-exendin-3 and colloidal residues = 0, Rf 111In-EDTA = 1) and 0.25 M NH4Ac, 
pH 5.5:methanol (1:1) (Rf = 0: colloidal residues, Rf = 1: 111In-exendin-3 and 111In-
EDTA). The radiochemical purity of 111In-exendin-3 always exceeded 95% as 
determined by HPLC and ITLC.  
 
Biodistribution of 111In-exendin-3 and correlation with the beta cell mass 
Animal experiments were performed after approval of the local ethical committee 
(RUDEC) for animal experiments. Six to eight week old Brown Norway rats (n=4) 
(Harlan, Horst, The Netherlands) were injected intravenously with 370 kBq 111In-
exendin-3 (peptide dose 0.1 µg). A separate group of rats (n=4) was co-injected 
with an excess of unlabeled exendin-3 (25 µg/rat) to determine the non-GLP-1R-
mediated uptake. Rats were euthanized 1 h after injection of the radiolabeled 
exendin and the pancreas and other relevant tissues were dissected, weighed and 
counted in a well type γ-counter (Wallac 1480-Wizard, Perkin-Elmer, Boston, MA, 
USA). 
In order to determine the correlation of the uptake of 111In-exendin-3 and the beta 
cell mass, Brown Norway rats were injected with various concentrations of alloxan 
monohydrate (Sigma Chemicals, St. Louis, MO, USA): 15, 30, 45 or 60 mg/kg body 
weight (n=4 per group). Alloxan was dissolved in ice-cold 10 mM HCl at a 
concentration of 0.1 mg/µl and diluted with ice-cold PBS. Alloxan was protected 
from light during storage and dilution. Rats were injected in the tail vein with 200 µl 
alloxan solution within 5 minutes after dilution in 10 mM HCl, while the control 
group (n=4) was injected with HCl in PBS. Blood glucose concentrations were 
determined one week after injection of alloxan using a glucose meter (Accu-Chek 
Sensor, Roche Diagnostics, Almere, The Netherlands). When hyperglycemia was 
confirmed in treated rats (7 days after alloxan injection), diabetic and control rats 
were injected with 370 kBq 111In-exendin-3. A separate group of control rats was 
co-injected with an excess of unlabeled exendin (25 µg/rat) to determine whether 
the observed uptake was GLP-1R-mediated. Rats were dissected 1 h p.i. and the 
radioactivity concentration in the pancreas was determined. The BCM in the 
pancreata was determined as described below and plotted against the pancreatic 
uptake corrected for non-specific uptake (determined by co-injection of an excess 
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unlabeled exendin-3). The correlation was determined by the Pearson correlation 
coefficient (r) using GraphPad Prism (version 4). 
 
 
SPECT of dissected tissues 
Brown Norway rats were injected intravenously with 60 mg/kg alloxan monohydrate 
(Sigma Chemicals, St. Louis, MO, USA) as described above. When hyperglycemia 
was confirmed, diabetic (n=4) and control (n=4) rats were injected with 15 MBq 
111In-exendin-3. Two control rats were co-injected with an excess of unlabeled 
exendin-3 (25 µg/rat). Rats were euthanized 1 h after injection of the radiolabeled 
exendin and the pancreas, gastro intestinal tract, liver and spleen were dissected 
and fixed in 4% formalin. SPECT images of the dissected pancreata along with the 
gastro-intestinal tract, liver and spleen were acquired on a dedicated small animal 
SPECT scanner (U-SPECT-II, MILabs, Utrecht, The Netherlands). SPECT images 
were acquired with a 1.0 mm pinhole rat collimator with an acquisition time of 4 h. 
The images were reconstructed with OSEM (6 iterations, 16 subsets, voxel size 
0.1875) using the U-SPECT-Rec software (MILabs, Utrecht, The Netherlands).  
 
SPECT of diabetic rats 
Brown Norway rats were injected intravenously with 15, 30, 45 or 60 mg/kg alloxan 
monohydrate (n=5/group) or 10 mM HCl:PBS (2:3) (controls; n=10) as described 
above. One week after the injection of alloxan, when hyperglycaemia was 
confirmed, rats received 15 MBq 111In-exendin-3 intravenously. Five of the control 
rats were co-injected with an excess of unlabeled exendin-3 (25 µg). One hour 
after injection of radiolabeled exendin SPECT/CT scans were acquired using a 
dedicated small animal SPECT/CT scanner (NanoSPECT/CT, Bioscan, Paris, 
France). SPECT images were acquired with a 2.5 mm multi-pinhole rat collimator, 
24 projections of 120 sec were acquired. SPECT images were reconstructed with 
HiSPECT software with the following settings: noise suppression high, standard 
voxel size standard (0.3 mm) and standard reconstruction settings. After SPECT 
imaging the pancreata of one rat per group were harvested and snap-frozen in 
isopentane on dry ice for autoradiography. Cryosections (10 µm) were exposed to 
an imaging plate (Fuji Film BAS-SR 2025, Raytest, Straubenhardt, Germany) for 
72 h. Images were acquired with a radioluminography laser imager (Fuji Film BAS 
1800 II system, Raytest, Straubenhardt, Germany) and analyzed with Aida Image 
Analyzer software (Raytest, Straubenhardt, Germany). The pancreata of the 
remaining rats were fixed in formalin and embedded in paraffin for the 
determination of the beta cell mass as described below.  
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The uptake of 111In-exendin-3 was quantified using Inveon Research Workplace 
(Preclinical Solutions, Siemens Medical Solutions USA, Inc., Knoxville, TN, USA) 
by drawing a volume of interest (8 µl) over the pancreatic region and correcting it 
for the injected activity. The volume of interest was placed in the coronal plane, 
cranial/anterior of the kidneys in the same plane where the high uptake was 
observed in the transition of the stomach to the duodenum (see supplemental Fig. 
1 online). The absolute activity (in Bq) was calculated by multiplying the value with 
the calibration factor determined by quantitative analysis of standards, scanned 
with the same acquisition settings.  
To determine the exact localization of the pancreas in the SPECT images, a Brown 
Norway rat was injected with [99mTc]Demobesin 3 and 111In-exendin-3. 
[99mTc]Demobesin 3 was labeled with 99mTc as previously described (35). Rats 
were injected intravenously with 20 MBq [99mTc]Demobesin 3 (2 µg) diluted in PBS 
containing 0.5% BSA (v/w) and 15 MBq 111In-exendin-3.  
SPECT was acquired for 99mTc and 111In separately, 60 min p.i using a dedicated 
small animal SPECT/CT scanner (NanoSPECT/CT, Bioscan, Paris, France) as 
described above. After SPECT acquisition, the rat was euthanized and the kidneys 
were removed followed by SPECT acquisition. Images were fused and analyzed 
using Inveon Research Workplace. 
 
Determination of the beta cell mass 
Five sections (4 µm) of paraffine-embedded pancreata, 100 µm apart from each 
other were sectioned and stained as follows: the sections were rehydrated using 
xylene for 10 min and washed with xylene, and rehydrated in a graded 
ethanol/water series. Antigen retrieval was performed by a microwave treatment in 
10 mM sodiumcitrate buffer, pH 6.0, for 10 min. Endogenous peroxidase activity 
was blocked by 30 min incubation with 0.6 % H2O2 in 40% methanol / 60% PBS. 
The sections were washed with PBS and incubated with 5% normal rat serum for 
30 min. After removal of the rat serum the sections were incubated with 50 µl anti-
insulin antibody (4 µg/ml in PBS containing 1% BSA w/v) (sc 9168, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA.) for 60 min. After washing with PBS, 50 
µl swine anti-rabbit IgG-peroxidase-conjugate (P217, Dakopatts, Copenhagen, 
Denmark) diluted in PBS containing 1% BSA (1:50) was added and incubated for 
30 min. The bound anti-insulin antibody was visualized using diaminobenzidine 
(PowerVisionTM DAB substrate system, Immunolgic, Duiven, The Netherlands) as a 
chromogen. All slides were counterstained with hematoxylin. Slides were mounted 
with slide mounting fluid (Permount, Fisher Scientific, Waltham, MA, USA). All 
steps were performed at room temperature in the dark. 
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The surface of the beta cells in the sections was estimated by drawing regions of 
interest around insulin stained tissue and total pancreatic tissue on images of the 
pancreatic section that were captured using a digital image processing system for 
bright field microscopy (36) with a magnification of 400x. The total pancreatic pixel 
area was determined by automated image thresholding (37) of the haematoxylin 
stained pancreatic tissue. The total insulin-positive pixel area was determined by 
drawing regions of interest over the insulin-positive tissue and the insulin-positive 
fraction was calculated by dividing the insulin positive pixel area by the total 
pancreatic pixel area (38). The beta cell mass was calculated by multiplying the 
insulin-positive fraction with the total pancreatic weight.  
 
Microautoradioraphy 
One Brown Norway rat was injected intravenously 3 times with 15 MBq 111In-
exendin-3 with an interval of 1 h and the pancreas was harvested 1 h after the last 
injection. The pancreas was fixed in formalin and embedded in paraffin and 4 µm 
section were prepared. The sections were deparaffinized as described above. The 
slides were covered with a homogeneous layer of hypercoat emulsion (Amersham 
LM-1, GE Healthcare UK limited, Buckinghamshire, UK) by dipping the slides in the 
emulsion at 42 ⁰C in the dark. After incubation in the dark for one week the section 
were developed for 4 min in a 6% black and white developer (Agfa studional liquid, 
Agfa, Leverkusen, Germany). The sections were rinsed in water for 20 sec and 
fixed in 24% (w/v) solution of sodium thiosulphate for 4 min. The sections were 
rinsed with water, stained with heamatoxylin for 30 sec, rinsed with water for 10 
min, dehydrated and the slide was mounted with mounting fluid. Consecutive 
sections were stained with an anti-insulin monoclonal antibody as described above 
for colocalization. 
 
Statistical analysis 
All mean values are expressed as mean ± standard deviation (SD). Statistical 
analysis was performed using unpaired two-tailed unpaired t-test using GraphPad 
Prism (version 4). The level of significance was set at p < 0.05. 
Correlation between the BCM and pancreatic uptake was determined by the 
Pearson correlation coefficient (r) using two-tailed analysis of variance with 
GraphPad Prism (version 4). The level of significance was set at p < 0.05.  
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Results 
 
Quantitative PCR 
In order to determine the GLP-1R mRNA expression in human and rat tissues, 
quantitative RT-PCR was performed. In rats, a 13-fold higher GLP-1R mRNA 
expression in the endocrine pancreas compared to the exocrine pancreas was 
found (Fig. 1A). The quantitative PCR on human tissues (Fig. 1B) showed high 
expression of the GLP-1R mRNA in the endocrine pancreas and very low 
expression in the exocrine pancreas with an endocrine-exocrine ratio of 47. These 
results indicate that the GLP-1R expression profile is even more favorable in 
humans than in rats.  
 
 
Figure 1: Quantitative PCR for the GLP-1R in rat (A) and human (B) tissue samples, 
including endocrine and exocrine pancreas. Results are representative of 3 similar 
experiments.  
 
Ex vivo autoradiography 
Autoradiography of pancreatic sections of healthy and alloxan-treated rats 
demonstrated that the tracer specifically accumulated in the islets of Langerhans: 
High activity concentrations of 111In-exendin-3  were observed in hot spots 
throughout the pancreatic section in control rats representing the islets of 
Langerhans (Fig. 2A-B). The uptake was GLP-1R mediated since it could be 
blocked by an excess of unlabeled exendin-3 (Fig. 2A). Very low uptake of the 
 
140 
 
tracer in the exocrine pancreas was observed (Fig. 2A-B). When treated with 
alloxan, tracer uptake in the islets was reduced (Fig. 2A).  
Immunohistochemical staining of the pancreatic sections with an anti-insulin mAb 
showed colocalization of the stained islets and the hot-spots in autoradiography 
(Fig. 2B), demonstrating specific accumulation in the islets. Microautoradiography 
(Fig. 2C) also showed islet specific tracer uptake that colocalized with 
immunohistochemical staining of a consecutive section with an anti-insulin mAb 
(Fig. 2D). 
 
Biodistribution studies 
Biodistribution in Brown Norway rats 1 h p.i. showed tracer uptake in various 
organs (Fig. 3A). 111In-exendin-3 accumulated in the pancreas to a concentration of 
0.29 ± 0.04 %ID/g. Coinjection of an excess unlabeled exendin-3 resulted in a 
marked decrease in pancreatic uptake (0.04 ± 0.01 %ID/g), indicating that the 
uptake of the tracer is GLP-1R mediated, which also holds for the uptake in the 
stomach and the duodenum (0.33 ± 0.03 %ID/g and 0.44 ± 0.08 %ID/g, 
respectively). In addition, very high specific uptake was observed in the lungs, 
known to express high levels of GLP-1R in rodents: 13.45 ± 2.50 %ID/g. Kidney 
uptake was also very high (29.2 ± 2.3 %ID/g) and could not be blocked with an 
excess of unlabeled exendin-3.  
The uptake of 111In-exendin-3 in the pancreas was plotted against the BCM (Fig. 
3B) showing a good correlation between these two parameters (Pearson r=0.89). 
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Figure 2: Macro-autoradiography (A) of pancreatic sections (10 µm) of control and alloxan treated 
Brown Norway rats. Rats were injected with alloxan doses ranging from 15-60 mg/kg. Rats were 
injected with 15 MBq 111In-exendin-3 (0.1 µg) and dissected 1 h p.i.. A consecutive section (4 µm) of 
pancreatic tissue (embedded in paraffin) of a control rat (magnification 4x) was counterstained with an 
anti-insulin mAb (brown) after exposure to the imaging plate (B). A selection is enlarged and the 
immunohistochemically stained islets are connected with the representative radiosignal with arrows. 
Microautoradiography (C) showed specific uptake in the islets and correlated with the 
immunohistochemical staining (D) of a consecutive section with an anti-insulin mAb (right panel). 
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SPECT of dissected tissues 
To visualize the uptake of 111In-exendin-3 in the abdominal organs, SPECT scans 
of dissected organs in the peritoneal cavity of control and alloxan-treated Brown 
Norway rats were acquired (Fig. 4). The uptake of 111In-exendin-3 in the pancreata 
of untreated Brown Norway rats were clearly visualized, whereas the pancreata of 
alloxan-treated rats as well as those from rats coinjected with an excess unlabeled 
exendin were barely visible by ex vivo SPECT (Fig. 4A-C). The resolution of the 
SPECT scanner is 600 µm, so individual islets of Langerhans could not be 
visualized (Fig. 4D). Blocking with an excess of unlabeled exendin-3 resulted in a 
very low pancreatic uptake similar to the uptake in severely diabetic rats. Fig. 4E-F 
show the ex vivo SPECT images of the dissected gastro-intestinal tract, spleen, 
liver and pancreas after injection of 111In-exendin-3. A strong signal was observed 
in the pancreas, whereas other abdominal organs showed only low uptake except 
for the proximal part of the duodenum and the distal part of the stomach that 
showed relatively high uptake. 
 
SPECT and quantitative analysis of SPECT images of diabetic rats 
The SPECT images of dissected tissues enabled accurate interpretation of the 
SPECT images of Brown Norway rats (Fig. 5A). In healthy Brown Norway rats, 
uptake in the pancreas was visible in SPECT scans after injection of 111In-exendin-
3. 
In diabetic rats there was negligible uptake in the pancreatic region and lower 
uptake was observed in rats with reduced BCM. Besides high pancreatic uptake, 
uptake was also observed in the kidneys and lung. Moreover, SPECT images after 
injection of [99mTc]Demobesin 3, specifically accumulating in the pancreas (35), 
correlated with the pancreatic uptake of 111In-exendin-3 (Fig. 5C), confirming that 
the VOI used for quantification of BCM is indeed located in the pancreas. As 
previously described, the pancreas is the organ with the highest uptake of the 
bombesin analog in the peritoneal cavity of rats (39), due to efficient binding to the 
gastrin-releasing peptide recteptor (GRP-R) that is abundantly expressed in the 
pancreas (40, 41). Removal of both kidneys enabled more accurate visualization of 
the pancreas, showing exact colocalization of [99mTc]Demobesin and 111In-exendin-
3 as an additional proof that the VOI used for quantification contained the pancreas 
(Fig. 5D-F). The tracer uptake of 111In-exendin-3 as determined by quantitative 
analysis of the SPECT images correlates linearly with the BCM determined by 
morphometric analysis (Fig. 5B, Pearson r=0.83) 
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Figure 3: Biodistribution (A) of 111In-exendin-3 in control (n=4) and alloxan treated (60 mg/kg) (n=4) 
Brown Norway rats. Values are expressed as percentage injected dose per gram tissue. Blocking was 
performed by co-injection of a 250-fold molar excess of unlabeled exendin-3 (n=2). Rats were 
dissected 1 h p.i. Correlation between the uptake of 111In-exendin-3 in rats that were injected with 
escalating doses of alloxan (0, 15, 30, 45 and 60 mg/kg) and the beta cell mass (B). The uptake on 
the y-axis is expressed as %ID/g and the beta cell mass (in mg) as determined by morphometric 
analysis after immunohistochemical staining with an anti-insulin antibody on the x-axis. The 
correlation was determined with Pearson test with Pearson is r=0.89. 
 
 
Figure 4: Ex vivo SPECT images of pancreata of control (A) and alloxan treated Brown Norway rats 
(B). Blocking (C) was performed with an excess of unlabeled exendin-3 (25 µg) in 2 rats. Ex vivo 
SPECT images of the gastrointestinal tract of Brown Norway rats (D-E) and a “high resolution” scan of 
a pancreas (F) after injection of 111In-exendin-3. 
A B 
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Figure 5: SPECT scans of Brown Norway rats with different amounts of BCM (A) after injection of 
111In-exendin-3. SPECT scans were acquired 1 h post injection. Pancreata are indicated with red 
circles. Correlation between the uptake of 111In-exendin-3 determined by quantitative analysis of the 
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SPECT scans and the beta cell mass (B). The uptake on the y-axis is expressed in Becquerel and 
the beta cell mass (in mg) as determined by morphometric analysis after immunohistochemical 
staining with an anti-insulin antibody on the x-axis. The correlation was determined with Pearson 
test with Pearson r = 0.83. SPECT images of a Brown Norway rat after injection of 
[99mTc]Demobesin-3 and 111In-exendin-3 (C). The pancreatic region seen in the [99mTc]Demobesin 
scan colocalized with the region observed in the 111In-exendin-3 scans (Pancreata are indicated with 
red circles). Removal of both kidney showed a clear colocalization of [99mTc]Demobesin and 111In-
exendin-3  in the pancreatic region (D-E: coronal slices, F: Maximum intensity projection (MIP), red 
arrow: pancreas (S: splenic part, D: duodenal part), white arrow: stomach, green arrow: spleen). 
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Discussion 
 
In this study, we systematically characterized 111In-exendin-3 for the noninvasive 
determination of the pancreatic BCM by SPECT. The key findings of the study are: 
(I) There is specific GLP-1R-mediated uptake of 111In-exendin-3  in the pancreas; 
(II) 111In-exendin-3  localizes specifically in the islets of Langerhans; (III) the 
pancreatic uptake of 111In-exendin-3 determined by ex vivo counting correlated 
linearly with the BCM (Pearson r=0.89); (IV) rats treated with high doses of alloxan, 
representing a model of severe beta cell loss, showed an 80% reduction of tracer 
uptake in the pancreas which allows detection of small differences in BCM; (V) the 
pancreatic tracer uptake decreased with BCM and only minimal uptake was 
observed in rats treated with high doses of alloxan; (VI) most importantly, the 
pancreatic tracer uptake could be visualized by in vivo SPECT and quantitative 
analysis of the SPECT data correlated with the BCM in a linear manner (Pearson 
r=0.83).  
We have previously shown that the peptide dose is a critical factor that determines 
the uptake of 111In-exendin-3 in GLP-1R positive tissues (34). It should be noted 
that the specific and high uptake of the tracer in the pancreas in this rat model is 
only observed at peptide doses not exceeding 0.1 µg per rat, as at higher peptide 
doses the GLP-1R in the pancreas are saturated as shown in the in vivo blocking 
experiments. Therefore, a tracer with a very high specific activity is required for 
SPECT (42). We have therefore improved the specific activity of 111In-exendin-3 up 
to 700 MBq/nmol, which allows administration of an activity dose sufficient for 
SPECT without exceeding the tracer dose of 0.1 µg/rat. 
Previous studies suggested that GLP-1R expression is detected in the exocrine 
pancreas by in vitro autoradiography with 125I-GLP-1 and immunohistochemistry on 
human pancreatic sections (20, 43). Our autoradiographic analysis showed 
scattered focal hotspots throughout the pancreas which colocalized with the islets 
in immunohistochemical staining and only low background activity in the exocrine 
pancreas. This focal uptake decreased with alloxan-induced loss of beta-cell mass 
and was almost completely absent in severe diabetic rats. These results are 
quantitative and do therefore not stand in contrast to the findings of Xu et al. 
showing GLP-1R expression in the pancreatic ducts in human pancreatic tissue by 
immunohistochemistry (43). The results of our ex vivo autoradiography are in line 
with the quantitative PCR analysis on rat tissues: high GLP-1R expression was 
observed in the endocrine pancreas, while low expression was apparent in the 
exocrine pancreas. The differences observed between our results and the 
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previously published data (20, 43) may be explained by differences between 
binding characteristics of 125I-GLP-1 and GLP-1R antibodies in an in vitro assay as 
compared to the binding characteristics of 111In-exendin-3 in vivo. Our data suggest 
that in vivo metabolic trapping leads to a higher target-to-background ratio. 
The quantitative RT-PCR showed that the endocrine-exocrine GLP-1R expression 
ratio is even higher in humans than in rats (endocrine-exocrine ratio 47 in humans 
vs. 13 in rats), opening the way to clinical SPECT studies with 111In-exendin-3. This 
may help to better understand the pathophysiology of T1D and T2D, where the 
fluctuations in BCM could be monitored by 111In-exendin-3, as well as the 
monitoring of new treatments of diabetes aiming to increase BCM.  
In conclusion, in vivo SPECT imaging of the BCM with 111In-exendin-3 is a fast and 
simple quantitative in vivo imaging method, for the first time allowing the non-
invasive detection of small changes in BCM.  
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Supplemental Figure 1: Cross sections of a SPECT scan of a control Brown Norway rat (A) and the 
VOI that was drawn over the pancreatic region (B). The pancreas, kidneys and lung are indicated with 
an arrow, the transition of the stomach to the duodenum with a green circle and the VOI is indicated in 
blue.  
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Chapter 8 
 
 
General discussion and future perspective 
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The beta cell plays a central role in the pathophysiology of diabetes mellitus. 
Hyperglycemia occurs at beta cell dysfunction, beta cell loss or a combination of 
these two phenomena. Although diabetes was discovered thousands of years ago 
and live-saving therapies were developed in the last century, the initial cause of the 
disease is still unknown (1-3). Clinical testing can discriminate between beta cell 
loss and beta cell glucose sensitivity, but cannot differentiate between relative 
changes in beta cell mass versus function (1). Beta cell mass (BCM) determination 
in humans can only be performed by morphometric analysis on pancreatic tissue 
obtained at autopsy. A non invasive method to determine the beta cell mass is still 
a major unmet need and might contribute to further elucidation of the 
pathophysiology of diabetes.  
In this thesis, the development of a method to determine the beta cell mass in vivo 
by radionuclide imaging with a radiotracer that targets the GLP-1R is described. 
The key findings of the studies are: (I) There is specific GLP-1R-mediated uptake 
of 111In-DTPA-exendin-3 in the pancreas; (II) 111In-DTPA-exendin-3 localizes 
specifically in the islets of Langerhans; (III) the pancreatic uptake of 111In-DTPA-
exendin-3 determined by ex vivo counting correlated linearly with the BCM; (IV) 
diabetic rats with severe beta cell loss showed an >80% reduction of tracer uptake 
in the pancreas which allows detection of small differences in BCM; (V) the 
pancreatic tracer uptake decreased with BCM and only minimal uptake was 
observed in rats treated with high doses of alloxan; (VI) most importantly, the 
pancreatic tracer uptake could be visualized by in vivo SPECT and quantitative 
analysis of the SPECT data correlated with the BCM in a linear manner. 
We have shown that the peptide dose is a critical factor that determines the uptake 
of 111In-DTPA-exendin-3 in GLP-1R-expressing tissues (4). It should be noted that 
the specific and high uptake of the tracer in the pancreas in the rat model is only 
observed at peptide doses not exceeding 0.1 µg per rat, as at higher peptide doses 
the GLP-1R in the pancreas are partly saturated. Therefore, a tracer with a very 
high specific activity is required for SPECT (4). We improved the specific activity of 
111In-exendin-3 up to 700 MBq/nmol, which allows administration of an activity dose 
sufficient for SPECT without exceeding the tracer (peptide) dose of 0.1 µg/rat. 
In clinical practice, PET would be preferable over SPECT because of higher spatial 
resolution and sensitivity. Therefore, we examined the feasibility of GLP-1R 
targeting with 68Ga-labeled DOTA-exendin (a PET tracer for GLP-1R targeting). 
Although the in vivo targeting properties are excellent, currently the specific activity 
of this compound is too low to administer activity doses sufficient for in vivo PET 
without exceeding the optimal peptide dose in rodents (4). Thus, an increased 
specific activity for 68Ga-exendin is needed. Recently, a new chelator, TRAP (Tri-
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Azacyclononane-Phosphinic acid), with superior properties for 68Ga-complexation 
in a wide pH range and at low ligand concentrations was developed (5). When 
conjugated to a RGD-multimer extremely high specific activities of the 68Ga-labeled 
RGD-compound (4 TBq/µmol) were observed, without the need of preprocessing 
the 68Ga eluate. Upon injection in mice, this compound exhibited favorable in vivo 
targeting characteristics compared to 18F-galacto-RGD. The specific activity of the 
TRAP-conjugated tracer, in terms of GBq/µmol, was much higher than the specific 
activities of DOTA-exendin-3 and DOTA-MG0 used in our studies (4 TBq/µmol 
versus 110 GBq/µmol and 45 GBq/µmol, respectively). Conjugation of TRAP to 
exendin might result in an increase in specific activity to allow determination of the 
BCM by PET in rodents. Recently, exendin-4 was successfully labeled with 18F and 
showed high uptake in subcutaneous INS-1 tumors (6). Also stabilized GLP-1 
labeled with 18F showed good in vitro and in vivo targeting characteristics (7). 
These 18F-labeled compounds are promising PET-probes for the detection of 
insulinomas and the determination of the BCM. 
In contrast to our results, a recent study showed high uptake of 125I-exendin(9-39) 
in the pancreas of ddY mice (approximately 20% ID/g) (8). This could be due to the 
lower peptide dose injected in the ddY mice: The peptide dose of 125I-exendin(9-39) 
was 60-fold lower than the peptide dose in our study (0.0017 µg vs. 0.1 µg). A 
straight comparison between the two tracers is needed to clarify the cause of the 
paradoxal results in the two studies. Although high pancreatic uptake was 
observed of 125I-exendin(9-39), the feasibility for beta cell imaging remains to be 
determined, because for imaging purposes higher activity doses and thus higher 
peptide doses will be required. Furthermore, the feasibility of exendin(9-39) for in 
vivo targeting of the GLP-1R appears to be limited to rodents. By in vitro 
autoradiography Waser et al. found that 125I-exendin(9-39) had a high affinity for 
the GLP-1R in murine pancreatic tissue (2.6 ± 0.4 nM), whereas the affinity for the 
human GLP-1R is much lower (63 ± 47 nM) (9).  
Previous studies suggested that high GLP-1R levels are expressed in the exocrine 
pancreas by in vitro autoradiography with 125I-GLP-1 and immunohistochemistry on 
human pancreatic sections (10, 11). Our autoradiographic analysis showed 
scattered focal hotspots in the islets of the pancreas and only low uptake in the 
exocrine pancreas. This focal uptake decreased with alloxan-induced loss of beta 
cell mass and was almost completely absent in severely diabetic rats. These 
results are quantitative and are therefore not in contrast to the findings by 
immunohistochemistry showing GLP-1R expression in the pancreatic ducts in 
human pancreatic tissue (11). The results of our autoradiography studies are in line 
with the quantitative PCR analysis on rat tissues: high GLP-1R expression in the 
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endocrine pancreas and low expression in the exocrine pancreas. The differences 
observed between our results and the previously published data (10, 11) may be 
explained by differences between binding characteristics of 125I-GLP-1 and GLP-1R 
antibodies in vitro and those of 111In-DTPA-exendin-3 in vivo. 
The RT-PCR data showed that the endocrine-exocrine GLP-1R expression ratio is 
even higher in humans than in rats (endocrine-exocrine ratio 47 in humans vs. 13 
in rats), opening the way to clinical SPECT studies with 111In-DTPA-exendin-3.  
We provided the proof of principle that the BCM can be determined by SPECT after 
injection of 111In-DTPA-exendin-3 in a rat model of acute beta cell loss. However, 
the alloxan-induced diabetes model does not reflect the pathogenesis of diabetes. 
T1D is characterized by (several courses of) insulitis and gradual beta cell loss. In 
the pathogenesis of T1D several factors, such as inflammation, cytokine 
expression or hyperglycemia could influence GLP-1R expression and/or 111In-
DTPA-exendin-3 uptake. Therefore, it is crucial to extensively characterize the 
tracer and determine the feasibility for the determination of the BCM in T1D. To 
determine the feasibility of the method in T2D might be even more challenging. 
T2D has at least several phenotypes in man (3) and many factors, such as 
hyperglycemia, lipotoxicity, cytokine expression and free fatty acid, influence beta 
cell mass and function and might also alter the GLP-1R expression and/or 111In-
DTPA-exendin-3 uptake. To be able to correctly interpret the results of 111In-DTPA-
exendin-3 scans, the effects of these factors on the GLP-1R expression and on 
111In-DTPA-exendin-3 accumulation should be known.  
In this thesis, we described the development of a method to determine the BCM in 
vivo by SPECT after injection of 111In-DTPA-exendin-3 in an animal model. 
Although the preclinical results are promising, the feasibility of this technique to 
determine the BCM during diabetes in humans is still unclear. Before clinical 
application, the tracer needs to be fully characterized in several animal models for 
T1D and T2D as well as in clinical studies in well-defined population of type 1 and 
2 diabetic patients. When the technique is extensively characterized and the 
outcome of the “exendin-scans” can be correctly interpreted, the technique could 
potentially be used to get more insight in the pathophysiology of diabetes, examine 
the effect of new anti-diabetogenic drugs and could ultimately be used as a tool for 
personalized medicine in diabetes treatment. 
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The aim of the studies described in this thesis was to develop and characterize a 
tracer to determine the beta cell mass (BCM) in vivo. Chapter 1 reviews the 
potential targets and corresponding radiotracers evaluated for their ability to 
determine the BCM in vivo. Several radiotracers, based on antibodies, antibody 
fragments, peptides and small molecules, were developed and characterized in the 
last decades. Although some studies showed promising results in preclinical 
studies, only one tracer, dihydrotetrabenazine (DTBZ), is used in clinical studies up 
to now. An ideal tracer for the determination of the BCM should have high and 
specific uptake in the beta cells and low uptake in the exocrine and other endocrine 
cells. Moreover, low uptake in surrounding non-target tissues is required, for a 
good target-to-background ratio. Furthermore, the uptake of the tracer should 
correlate with the BCM and the difference in uptake between healthy and diabetic 
individuals has to be large to enable detection of small differences in BCM. The 
ideal tracer has not been found yet and the search for new and improved tracers 
and new targets for the development of non-invasive methods to determine the 
beta cell mass is ongoing. 
The radiotracer should have a high specific activity, since low tracer (compound) 
doses need to be administered to prevent receptor saturation and/or (toxic) side 
effect, while high radioactivity doses are required to acquire images with sufficient 
image quality. In Chapter 2 a study is presented in which the effect of the buffer 
used for 111In-labeling of DTPA- and DOTA-conjugated compounds is examined. In 
this study the use of “weakly coordinating” buffers MES and HEPES was compared 
to the use of conventional buffers for 111In labeling: ammonium acetate and sodium 
acetate. The maximum specific activity of two DTPA- or DOTA-conjugated peptides 
(exendin-3 and octreotide) and one antibody (anti-CAIX antibody) was determined 
with the use of 0.1 M MES, HEPES, ammonium acetate or sodium acetate, pH 5.5. 
The specific activity of DTPA-conjugated compounds was 2 to 3-fold higher when 
MES or HEPES were used. The effect was less pronounced when the DOTA-
conjugated compounds were labeled with 111In, probably due to increased 
interference of contaminating metals with DOTA-chelation. Overall, radiolabeling in 
HEPES and MES was more efficient than in acetate buffers in most cases and at 
least as efficient in the case of DOTA-octreotide. Subsequently, the effect of ageing 
of the 111InCl3 stock on the labeling of DTPA-exendin-3 with 111In was examined. 
Lower labeling efficiencies were observed as early as 7 days after production of 
111InCl3 and 3-fold lower specific activities were obtained 11 days after the 
production date (calibration date of the 111InCl3 stock), when the labeling was 
performed with ammonium or sodium acetate. This effect was not observed for 
labeling of DTPA-exendin-3 in MES and HEPES with a maximal decrease in 
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specific activity of 10% and 4% at day 11, respectively. Even the decrease in 
specific activity 14 days after the calibration date of 111InCl3 was not more than 18% 
for 111In-labeling in MES and 5% for HEPES. These results suggest that increasing 
amounts of Cd2+ contamination, due to ageing of the 111InCl3 stock, do not 
influence the labeling of DTPA-conjugated compounds when MES and HEPES are 
used as a buffer for radiolabeling. The suggested effect of cadmium on the 111In-
labeling of DTPA-conjugated compounds was confirmed when increasing amounts 
of Cd2+ were added to the 111In-labeling mixture of DTPA-exendin. In HEPES and 
MES buffer a 100-fold higher amount of cadmium could be added to the labeling 
mixture without reducing the labeling efficiency. Therefore, the improved labeling 
efficiency in MES and HEPES buffer appears to be due to the reduced competitive 
chelation of cadmium. 
Aiming for high specific activities of 68Ga-labeled peptide increases the risk of 
formation of 68Ga-hydroxides (or “colloid”) during the labeling procedure. 68Ga-
hydroxide formation could occur at a pH >3 in the absence of stabilizing agents 
(i.e. DOTA, EDTA). Labeling of compounds with 68Ga at a high specific activity 
increases the risk of 68Ga-hydroxide formation due to the presence of unchelated 
68Ga in a reaction mixture at pH > 3. Upon intravenous injection, 68Ga-hydroxide 
will accumulate in the liver and spleen and will impair image quality. Thus, there is 
a need to reduce the amount of 68Ga-hydroxides  before injection. Three 
purification methods to remove 68Ga-hydroxides from 68Ga-DOTA-exendin-3 
labeling mixtures were examined in Chapter 3. The reaction mixtures were purified 
by gel filtration, solid-phase extraction (SPE) and Reversed-Phase High 
Performance Liquid Chromatography (RP-HPLC) and the in vivo characteristics 
were determined in BALB/c nude mice. 111In-labeled DOTA-exendin-3 was used as 
a control, since 111In-hydroxide formation in 111In-DOTA-exendin-3 labeling 
mixtures at a low specific activity are known to be very low. The accumulation in 
the liver and spleen of SPE and RP-HPLC purified 68Ga-DOTA-exendin-3 
preparations was very low and similar to that of 111In-DOTA-exendin-3, indicating 
complete removal of 68Ga-hydroxide. Gel filtration was less efficient in removing 
68Ga-hydroxide, resulting in elevated accumulation in liver and spleen. Overall, 
SPE is a fast and simple method to remove 68Ga-hydroxides from reaction mixtures 
of 68Ga-labeled tracers. 
After optimization of the labeling and purification of exendin, in vitro and in vivo 
targeting properties were characterized. Chapter 4 describes the comparison of 
three exendin analogs: the agonists exendin-3 and exendin-4 and the antagonist 
exendin(9-39). All peptides were conjugated with DTPA for radiolabeling. In vitro 
studies on GLP-1R expressing INS-1 cells showed high affinity for all 3 exendin 
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analogs. Exendin-3 and exendin-4 showed fast internalization in INS-1 cells in 
vitro, exendin(9-39) showed only minimal internalization. Biodistribution studies in 
BALB/c nude mice with a subcutaneous INS-1 tumor showed high and GLP-1R-
mediated uptake of 111In-labeled DTPA-exendin-3 and DTPA-exendin-4 in the 
tumor and GLP-1R expressing organs (pancreas, stomach, duodenum and lung). 
No uptake in the tumor or GLP-1R positive organs was observed for 111In-labeled 
DTPA-exendin(9-39). These results suggest that internalization is crucial for 
efficient in vivo GLP-1R targeting.  
In the next chapter, the in vitro and in vivo characteristics of 68Ga-labeled DOTA-
minigastrin (DOTA-MG0) were determined (Chapter 5). The in vitro binding 
characteristics of DOTA-MG0, natIn-DOTA-MG0 and natGa-DOTA-MG0 were 
examined in CCK2/gastrin receptor expressing AR42J pancreatic tumor cells. A 
similar receptor affinity was observed for these three compounds, indicating that 
labeling did not affect the affinity of the peptide. Biodistribution studies in BALB/c 
nude mice with a subcutaneous AR42J tumor, showed no significant difference in 
tumor uptake between 68Ga-labeled and 111In-labeled DOTA-MG0. Subcutaneous 
as well as intraperitoneal AR42J tumors could be clearly visualized by dedicated 
small animal PET. 
The in vivo characteristics of 68Ga- and 111In-labeled exendin in BALB/c nude mice 
with a subcutaneous INS-1 tumor were compared in the study described in 
Chapter 6. As previously observed, 111In-labeled exendin showed high uptake in 
the tumor and GLP-1R expressing organs. Remarkably, the uptake of 68Ga-labeled 
exendin in the INS-1 tumor and GLP-1R-expressing tissues was lower compared to 
that of 111In-labeled exendin. The optimal peptide dose for in vivo targeting of the 
GLP-1R in this model was determined and was found to be 0.1 µg. Despite the 
lower tumor uptake of 68Ga-labeled exendin, subcutaneous INS-1 tumors were 
clearly visible in the PET images.  
Due to the low specific activity and maximum peptide dose for in vivo targeting of 
0.1 µg, the determination of the beta cell mass by PET after injection of 68Ga-
labeled exendin was not feasible. Therefore, the ability to determine the beta cell 
mass with exendin was examined by SPECT imaging after injection of 111In-labeled 
DTPA-exendin-3 in a rat model for acute beta cell loss. The results of these studies 
are described in Chapter 7. Biodistribution studies in Brown Norway rats showed 
GLP-1R-mediated uptake in the pancreas. Chemical destruction of the beta cells 
by alloxan resulted in a pancreatic uptake that was >80% lower than in control rats. 
These results indicated beta cell specific uptake of 111In-labeled exendin. These 
results were confirmed by autoradiography: digital autoradiography showed various 
hot spots throughout the pancreas, representing the islets of Langerhans, with low 
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uptake in the exocrine pancreas. The hot spots observed with digital 
autoradiography colocalized with the expression of insulin as determined 
immunohistochemically, indicating that the hotspots were indeed the insulin-
producing beta cells. Gradual destruction of the beta cells by injecting various 
doses of alloxan resulted in reduction of the intensity of the hot spots and the 
number of hot spots was massively decreased in severely diabetic rats. 
Microautoradiography showed specific localization of 111In-labeled exendin in the 
islets of Langerhans that colocalized with insulin staining. Moreover, the uptake of 
111In-DTPA-exendin-3 measured by ex vivo counting, correlated with the BCM as 
determined by morphometric analysis. The pancreas could be visualized in healthy 
rats and the signal was almost absent in severely diabetic rats. Most importantly, 
the uptake could be quantified in the SPECT images and the uptake correlated 
linearly with the beta cell mass, as determined by morphometric analysis.  
In Chapter 8 the results of the studies and future perspectives are discussed. 
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Samenvatting 
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Bij diabetes mellitus kan het lichaam de bloedglucose niet goed op peil houden. 
Normaal gesproken zorgt insuline ervoor dat de bloedglucose op peil blijft. Insuline 
wordt geproduceerd in de beta-cellen, die zich in de eilandjes van Langerhans 
bevinden. De eilandjes van Langerhans liggen verspreid over het pancreas. Bij 
diabetes type 1 worden de beta-cellen vernietigd door een auto-immuun reactie. 
Hierdoor wordt er niet voldoende insuline aangemaakt om het bloedglucose te 
reguleren en patiënten met diabetes type 1 moeten daarom insuline injecteren om 
hun bloedglucose spiegel te controleren. Bij diabetes type 2 zijn de cellen in het 
lichaam die op insuline moeten reageren, zoals de lever en spierweefsel, resistent 
geworden wat verhoogde bloedglucose spiegels tot gevolg heeft. Uiteindelijk 
kunnen de beta-cellen minder insuline gaan produceren of zelfs afsterven, 
waardoor ook patiënten met diabetes type 2 afhankelijk kunnen worden van 
insuline toediening. Tot nu toe is de precieze oorzaak van de ontwikkeling van 
diabetes nog niet bekend. Ook is er weinig bekend over de hoeveelheid beta-
cellen (beta-cel massa) gedurende de ontwikkeling van diabetes. Op dit moment is 
er geen methode om de beta-cel massa (BCM) te bepalen en kan alleen de functie 
van de beta-cellen worden gemeten door bijvoorbeeld bloedglucose en insuline of 
de glucose tolerantie te meten. Er is dus behoefte aan de ontwikkeling van een 
techniek om noninvasief de BCM te meten. In dit proefschrift wordt de ontwikkeling 
en toepassing van een methode beschreven om de beta-cel massa noninvasief te 
bepalen m.b.v. radionuclide imaging. Voor scintigrafische beeldvorming is een 
verbinding (tracer) nodig die specifiek accumuleert in de beta-cellen. In dit 
proefschrift is een tracer ontwikkeld die specifiek bindt aan de glucagon-like 
peptide-1 receptor (GLP-1R), die in hoge mate tot expressie komt op de beta-
cellen. 
In Hoofdstuk 1 wordt een overzicht gegeven van de ontwikkelingen op het gebied 
van radiotracers voor de bepaling van de BCM. Verschillende radioactief gelabelde 
antilichamen, antilichaam-fragmenten, peptiden en chemische verbindingen die 
specifiek binden aan beta-cellen zijn de afgelopen jaren ontwikkeld en 
gekarakteriseerd. Ondanks veelbelovende resultaten van sommige van deze 
tracers in preklinische studies is slechts één van deze tracers getest in klinische 
studies: dihydrotetrabenazine (DTBZ) gelabeld met 11C of 18F.  
De ideale tracer voor BCM imaging accumuleert specifiek in de beta-cellen terwijl 
de opname in de cellen van de exocriene pancreas en andere endocriene cellen 
laag is. Verder zou het verschil in opname in het pancreas van gezonde individuen 
en patiënten met verlaagde BCM zo groot mogelijk moeten zijn, zodat kleine 
verschillen in de BCM kunnen worden gemeten. De opname van de radiotracer in 
omliggende organen moet laag zijn, zodat een goede target-to-background ratio 
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bereikt wordt. Tot nu toe is er nog geen tracer met bovengenoemde 
eigenschappen beschikbaar en gaat de zoektocht naar nieuwe targets en tracers 
voor BCM imaging dus voort. 
Toediening van grote hoeveelheden tracer kunnen leiden tot verzadiging van de 
receptor en dit kan leiden tot een lagere opname van de radiotracer in het 
pancreas. Bovendien kunnen hoge doses tracer bijwerkingen veroorzaken. 
Anderzijds dient voor een goede scintigrafische beeldvorming een voldoende hoge 
dosis radioactiviteit te worden toegediend. Daarom is de specifieke activiteit 
(hoeveelheid radioactiviteit per massaeenheid van de tracer) van een radiotracer 
van groot belang. In Hoofdstuk 2 wordt een studie beschreven waarin het effect 
van de buffers HEPES en MES op de efficiency van de labelingsreactie bepaald is. 
HEPES en MES zijn zwak coördinerende  buffers: dat wil zeggen dat ze in 
beperkte mate complexen vormen met metalen, vergeleken met conventionele 
buffers die gebruikt worden voor 111In-labeling, zoals natriumacetaat en 
ammoniumacetaat. In deze studie werd het effect van deze buffers op de 
labelingsefficiency van 2 peptiden (exendin en octreotide) en een antilichaam (anti-
CAIX antilichaam) geconjugeerd met DTPA of DOTA bepaald. De specifieke 
activiteit van de 111In-gelabelde DTPA-verbindingen was twee tot drie keer hoger 
wanneer de labeling werd uitgevoerd in MES of HEPES. Het effect op de labeling 
met 111In van de DOTA-geconjugeerde verbindingen vertoonde dezelfde trend, 
maar was minder groot.  
In deze studie werd ook het effect van de veroudering van de 111InCl3 
stockoplossing op de labeling onderzocht. DTPA-exendin-3 werd gelabeld op 
verschillende dagen na 111InCl3 productie. In natrium- en ammoniumacetaat was al 
na 7 dagen een afname van de labelingsefficiency te zien en 11 dagen na de 
productie van 111InCl3 (calibratie datum) was de labelingsefficiency 3 keer lager. 
Wanneer HEPES of MES gebruikt werd voor de labeling was er geen afname in 
labelingsefficiency te zien tot 11 dagen na de productie van 111InCl3. Deze 
resultaten geven aan dat toenemende hoeveelheden van het vervalproduct van 
111In, 111Cd, de labeling verstoren in ammonium- en natriumacetaat buffer en dat dit 
effect veel minder is wanneer de labeling in HEPES of MES buffer wordt 
uitgevoerd. 
Wanneer 68Ga-gelabelde peptiden worden geproduceerd met een hoge specifieke 
activiteit is er een groot risico dat tijdens de labelingsprocedure onoplosbaar 68Ga-
hydroxide (colloïd) gevormd wordt. 68Ga-hydroxide kan gevormd worden vanaf pH 
3 in de afwezigheid van chelaterende moleculen, zoals DTPA en EDTA. Wanneer 
een 68Ga-gelabelde tracer 68Ga-hydroxide bevat en intraveneus wordt 
geïnjecteerd, zal het 68Ga-hydroxide accumuleren in de milt en de lever, wat een 
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verminderde beeldkwaliteit tot gevolg heeft. Daarom is het belangrijk om 68Ga-
hydroxide te verwijderen voor injectie. In de studie beschreven in Hoofdstuk 3 is 
de effectiviteit van verschillende zuiveringsmethoden vergeleken voor het 
verwijderen van 68Ga-hydroxide uit het reactiemengsel van 68Ga-DOTA-exendin-3. 
68Ga-DOTA-exendin-3 werd opgezuiverd met gel filtratie, solid-phase extraction 
(SPE) en reversed-phased high performance liquid chromatography (RP-HPLC). 
Onze studies in naakte muizen toonden aan dat het 68Ga-hydroxide het best 
verwijderd kon worden door middel van SPE en RP-HPLC. Omdat SPE een 
snellere methode is, verdient deze methode de voorkeur. 
Nadat de labelingsprocedure en de zuivering van het radioactief gelabelde 
exendin-3 geoptimaliseerd was hebben we de eigenschappen van drie exendin 
analoga vergeleken. In de studie beschreven in Hoofdstuk 4, werden de in vitro en 
in vivo eigenschappen van twee GLP-1R agonisten (exendin-3 en exendin-4) en 
een antagonist (exendin(9-39)) bepaald. In vitro testen toonden aan dat drie 
exendin analoga een vergelijkbare affiniteit voor de GLP-1R hebben. Exendin-3 en 
exendin-4 werden in vitro efficiënt door GLP-1R expresserende INS-1 cellen 
geïnternaliseerd, terwijl exendin(9-39) nauwelijks werd geïnternaliseerd. In naakte 
BALB/c muizen met subcutane INS-1 tumoren toonden 111In-DTPA-exendin-3 en 
111In-DTPA-exendin-4 een hoge opname in de tumor en andere GLP-1R positieve 
organen (pancreas, maag, duodenum en long). Exendin(9-39) accumuleerde niet 
specifiek in de INS-1 tumor en GLP-1R positieve organen. De resultaten van deze 
studie geven aan dat internalisatie een belangrijke voorwaarde is voor in vivo 
targeting van de GLP-1R. 
De studie in Hoofdstuk 5 beschrijft de in vitro en in vivo karakterisatie van 68Ga-
gelabeld minigastrine (DOTA-MG0). De affiniteit van DOTA-MG0, natIn-DOTA-MG0 
en natGa-DOTA-MG0 voor de CCK2/gastrin receptor was vergelijkbaar. Dit geeft 
aan dat de labeling van DOTA-MG0 de affiniteit van het peptide niet beïnvloedt. 
111In-DOTA-MG0 en 68Ga-DOTA-MG0 toonden een hoge en specifieke opname in 
subcutane CCK2/gastrin receptor expresserende AR42J tumoren na i.v. injectie in 
tumor dragende BALB/c muizen. Subcutane en intraperitoneale tumoren konden 
worden afgebeeld met PET na injectie van 68Ga-DOTA-MG0. 
In Hoofdstuk 6 zijn de in vivo targeting eigenschappen van 111In- en 68Ga-
gelabeled exendin-3 bepaald in naakte BALB/c muizen met een subcutane INS-1 
tumor. Opmerkelijk was dat het 68Ga-gelabeld exendin-3 een lagere opname in de 
tumor vertoonde dan het 111In-gelabeld exendin-3. De peptide dosis escalatie 
studie gaf aan dat de opname in de tumor maximaal is als de peptide dosis van het 
exendin-3 niet hoger is dan 0.1 µg per muis. Na injectie van het 68Ga-gelabeld 
exendin-3 konden de subcutane INS-1 tumoren worden afgebeeld met PET.  
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Omdat de specifieke activiteit van 68Ga-gelabeld exendin-3 onvoldoende hoog is 
om voldoende radioactiviteit toe te kunnen dienen zonder de optimale peptide 
dosis van 0.1 µg te overschrijden, is 111In-gelabeld DTPA-exendin-3 gebruikt om te 
bepalen of radioactief exendin gebruikt kan worden voor de noninvasieve bepaling 
van de BCM. De resultaten van deze studie staan beschreven in Hoofdstuk 7. In 
deze studie toonde 111In-DTPA-exendin-3  een hoge opname in het pancreas van 
Brown Norway ratten. In ratten waarbij de beta-cellen met behulp van alloxaan 
werden gedestrueerd werd een afname van de hoeveelheid tracer in pancreas 
gezien van meer dan 80%. Met digitale autoradiografie werden hot-spots gezien in 
het pancreas. Deze hot-spots kwamen overeen met eilandjes van Langerhans. 
Ook met microautoradiografie werd hoge opname van de tracer in de eilandjes van 
Langerhans gezien. De opname van de tracer in het pancreas, vertoonde een 
goede correlatie met de BCM. Het pancreas van gezonde Brown Norway ratten 
kon worden afgebeeld met SPECT. De opname van de 111In-exendin-3 tracer in 
het pancreas zoals bepaald met SPECT correleerde eveneens met de BCM.  
Het onderzoek beschreven in dit proefschrift heeft aangetoond dat radioactief 
gelabeld exendin een veelbelovende tracer is voor noninvasieve bepaling van de 
BCM. De techniek zou gebruikt kunnen worden om meer inzicht te krijgen in het 
ontstaan van diabetes en om het effect van nieuwe medicijnen voor de 
behandeling van diabetes te onderzoeken. Uiteindelijk zou de techniek gebruikt 
kunnen worden voor “personalized medicine” voor de behandeling van diabetes. 
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manuscripten, presentaties, DEC-aanvragen etc. van commentaar voorziet is 
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doen. Bedankt voor de uitstekende begeleiding en ik hoop dat ik nog vele jaren 
met je mag samenwerken en van je expertise gebruik mag maken. 
Gerben, haast onopvallend ben je erg belangrijk voor de afdeling en ook voor mijn 
onderzoek. Blijkbaar valt het je zelf ook niet op, want je was verbaasd toen ik je als 
paranimf vroeg. Je hebt geheel zelfstandig de data voor een van mijn artikelen 
verzameld, ik hoefde het alleen nog maar op te schrijven. Als ik je vroeg of je al 
resultaten had zei je vaak “dat het er wel aardig uit zag”, maar dan bleek altijd dat 
je mooie resultaten had. Bedankt voor al je hulp tijdens mijn promotie. 
De “BetaImage-dames” Desirée, Hanneke en Inge hebben de afgelopen tijd veel 
werk voor mij uit handen genomen. Met de hele “kudde” hebben we heel wat grote 
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experimenten in korte termijn uitgevoerd en ondanks de hoge werkdruk zijn jullie 
altijd gedreven en enthousiast. Ik vind het erg prettig om met jullie samen te 
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